ZA200501133B - Method of treating osteoarthritis - Google Patents
Method of treating osteoarthritis Download PDFInfo
- Publication number
- ZA200501133B ZA200501133B ZA200501133A ZA200501133A ZA200501133B ZA 200501133 B ZA200501133 B ZA 200501133B ZA 200501133 A ZA200501133 A ZA 200501133A ZA 200501133 A ZA200501133 A ZA 200501133A ZA 200501133 B ZA200501133 B ZA 200501133B
- Authority
- ZA
- South Africa
- Prior art keywords
- dimethyl
- pain
- methyl
- substituted
- carboxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 261
- 201000008482 osteoarthritis Diseases 0.000 title claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 212
- 150000003839 salts Chemical class 0.000 claims description 147
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 claims description 117
- 150000001983 dialkylethers Chemical class 0.000 claims description 116
- 239000000203 mixture Substances 0.000 claims description 116
- 159000000007 calcium salts Chemical class 0.000 claims description 106
- -1 dialkyl ether compound Chemical class 0.000 claims description 98
- 241000124008 Mammalia Species 0.000 claims description 92
- 208000006820 Arthralgia Diseases 0.000 claims description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 72
- 206010007710 Cartilage injury Diseases 0.000 claims description 68
- ZJKZKKPIKDNHDM-UHFFFAOYSA-L calcium;6-(5-carboxylato-5-methylhexoxy)-2,2-dimethylhexanoate Chemical compound [Ca+2].[O-]C(=O)C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O ZJKZKKPIKDNHDM-UHFFFAOYSA-L 0.000 claims description 59
- 201000010099 disease Diseases 0.000 claims description 52
- 102000004889 Interleukin-6 Human genes 0.000 claims description 48
- 108090001005 Interleukin-6 Proteins 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 230000002917 arthritic effect Effects 0.000 claims description 43
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 41
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 39
- 206010003246 arthritis Diseases 0.000 claims description 38
- 230000001684 chronic effect Effects 0.000 claims description 36
- 229960002004 valdecoxib Drugs 0.000 claims description 35
- 230000001154 acute effect Effects 0.000 claims description 34
- 230000003349 osteoarthritic effect Effects 0.000 claims description 33
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 239000003937 drug carrier Substances 0.000 claims description 23
- 239000003085 diluting agent Substances 0.000 claims description 22
- 230000001404 mediated effect Effects 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 229940111134 coxibs Drugs 0.000 claims description 13
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 229960000590 celecoxib Drugs 0.000 claims description 12
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 12
- 208000018937 joint inflammation Diseases 0.000 claims description 10
- 229960000371 rofecoxib Drugs 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 6
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 claims description 6
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960004662 parecoxib Drugs 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229960004945 etoricoxib Drugs 0.000 claims description 5
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 229960000994 lumiracoxib Drugs 0.000 claims description 5
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 229960003184 carprofen Drugs 0.000 claims description 4
- 229960003314 deracoxib Drugs 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- 150000003536 tetrazoles Chemical class 0.000 claims description 3
- KOWIZHDULJSRPT-WUKNDPDISA-N (3z)-3-[(4-bromophenyl)-(4-methylsulfonylphenyl)methylidene]oxolan-2-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C=1C=CC(Br)=CC=1)=C/1C(=O)OCC\1 KOWIZHDULJSRPT-WUKNDPDISA-N 0.000 claims description 2
- YCHYFHOSGQABSW-RTBURBONSA-N (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid Chemical compound C1C(C(O)=O)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 YCHYFHOSGQABSW-RTBURBONSA-N 0.000 claims description 2
- HFWZBWTWCKQUCB-RVDMUPIBSA-N 2,6-ditert-butyl-4-[(e)-(2-ethyl-1,1-dioxo-1,2-thiazolidin-5-ylidene)methyl]phenol Chemical compound O=S1(=O)N(CC)CC\C1=C/C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 HFWZBWTWCKQUCB-RVDMUPIBSA-N 0.000 claims description 2
- XNTLXAUHLBBEKP-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound O=C1C(OCCC(C)(O)C)=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=NN1C1=CC=C(F)C(F)=C1 XNTLXAUHLBBEKP-UHFFFAOYSA-N 0.000 claims description 2
- NXMZBNYLCVTRGB-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-3-(4-methylsulfonylphenyl)pyrazolo[1,5-b]pyridazine Chemical compound C1=CC(OCC)=CC=C1C1=NN(N=CC=C2)C2=C1C1=CC=C(S(C)(=O)=O)C=C1 NXMZBNYLCVTRGB-UHFFFAOYSA-N 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- 229960000965 nimesulide Drugs 0.000 claims description 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims description 2
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims 1
- 208000002193 Pain Diseases 0.000 description 242
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 90
- 150000003568 thioethers Chemical class 0.000 description 86
- 150000002576 ketones Chemical class 0.000 description 85
- 125000003710 aryl alkyl group Chemical group 0.000 description 81
- 241000700159 Rattus Species 0.000 description 76
- 210000000548 hind-foot Anatomy 0.000 description 59
- 239000007924 injection Substances 0.000 description 59
- 238000002347 injection Methods 0.000 description 59
- 230000003628 erosive effect Effects 0.000 description 57
- 102100022185 Melanoma-derived growth regulatory protein Human genes 0.000 description 49
- 241001465754 Metazoa Species 0.000 description 46
- 230000003405 preventing effect Effects 0.000 description 43
- 210000000845 cartilage Anatomy 0.000 description 42
- 230000005764 inhibitory process Effects 0.000 description 37
- 239000003981 vehicle Substances 0.000 description 37
- 230000000694 effects Effects 0.000 description 36
- 125000000547 substituted alkyl group Chemical group 0.000 description 35
- 239000000243 solution Substances 0.000 description 33
- 230000008859 change Effects 0.000 description 31
- 230000008407 joint function Effects 0.000 description 31
- 238000009472 formulation Methods 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 27
- 239000003826 tablet Substances 0.000 description 26
- 239000002253 acid Substances 0.000 description 25
- 239000003112 inhibitor Substances 0.000 description 24
- 238000010170 biological method Methods 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 210000003127 knee Anatomy 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 20
- 239000000546 pharmaceutical excipient Substances 0.000 description 20
- 208000004454 Hyperalgesia Diseases 0.000 description 19
- 231100000673 dose–response relationship Toxicity 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 206010065390 Inflammatory pain Diseases 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 210000003414 extremity Anatomy 0.000 description 17
- 230000004054 inflammatory process Effects 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 229940124597 therapeutic agent Drugs 0.000 description 17
- 108010008165 Etanercept Proteins 0.000 description 16
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 208000000094 Chronic Pain Diseases 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 15
- 239000002775 capsule Substances 0.000 description 15
- 210000000629 knee joint Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 208000005298 acute pain Diseases 0.000 description 14
- 206010053552 allodynia Diseases 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 230000001575 pathological effect Effects 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 229920002261 Corn starch Polymers 0.000 description 13
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 13
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 13
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 13
- 239000008120 corn starch Substances 0.000 description 13
- 229940099112 cornstarch Drugs 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 239000012453 solvate Substances 0.000 description 13
- 241000282472 Canis lupus familiaris Species 0.000 description 12
- 206010019233 Headaches Diseases 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 229910052801 chlorine Inorganic materials 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 229910052731 fluorine Inorganic materials 0.000 description 11
- 229960000485 methotrexate Drugs 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 239000012154 double-distilled water Substances 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 210000003041 ligament Anatomy 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- 208000008035 Back Pain Diseases 0.000 description 9
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 125000005466 alkylenyl group Chemical group 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 229940073621 enbrel Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000002683 foot Anatomy 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229960002725 isoflurane Drugs 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000002464 receptor antagonist Substances 0.000 description 9
- 229940044551 receptor antagonist Drugs 0.000 description 9
- 206010005949 Bone cancer Diseases 0.000 description 8
- 208000018084 Bone neoplasm Diseases 0.000 description 8
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 8
- 208000005171 Dysmenorrhea Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000001640 Fibromyalgia Diseases 0.000 description 8
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000010171 animal model Methods 0.000 description 7
- 208000037765 diseases and disorders Diseases 0.000 description 7
- 229960000403 etanercept Drugs 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 102100033902 Endothelin-1 Human genes 0.000 description 6
- 101800004490 Endothelin-1 Proteins 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000008355 cartilage degradation Effects 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000002962 histologic effect Effects 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 210000005065 subchondral bone plate Anatomy 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
- 102000000503 Collagen Type II Human genes 0.000 description 5
- 108010041390 Collagen Type II Proteins 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 102000003815 Interleukin-11 Human genes 0.000 description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- AMNPXXIGUOKIPP-UHFFFAOYSA-N [4-(carbamothioylamino)phenyl]thiourea Chemical compound NC(=S)NC1=CC=C(NC(N)=S)C=C1 AMNPXXIGUOKIPP-UHFFFAOYSA-N 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 229940113118 carrageenan Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 230000036269 ulceration Effects 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- 108090000177 Interleukin-11 Proteins 0.000 description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 4
- 102000004140 Oncostatin M Human genes 0.000 description 4
- 108090000630 Oncostatin M Proteins 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000674 adrenergic antagonist Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- PUXBGTOOZJQSKH-UHFFFAOYSA-N carprofen Chemical compound C1=C(Cl)C=C2C3=CC=C(C(C(O)=O)C)C=C3NC2=C1 PUXBGTOOZJQSKH-UHFFFAOYSA-N 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229940110456 cocoa butter Drugs 0.000 description 4
- 235000019868 cocoa butter Nutrition 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960002009 naproxen Drugs 0.000 description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 3
- YTTWDTVYXAEAJA-UHFFFAOYSA-N 2,2-dimethyl-hexanoic acid Chemical compound CCCCC(C)(C)C(O)=O YTTWDTVYXAEAJA-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 108010017521 Interleukin-11 Receptors Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- 241000407429 Maja Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 101100291239 Rattus norvegicus Mia gene Proteins 0.000 description 3
- 229910020008 S(O) Inorganic materials 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 208000007474 aortic aneurysm Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000003124 biologic agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 230000000051 modifying effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229940061969 rheumatrex Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- 229940087652 vioxx Drugs 0.000 description 3
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
- AXXUJNIHMQQIIP-UHFFFAOYSA-N 2,15-dibromo-3,3,14,14-tetramethylhexadecanedioic acid Chemical compound OC(=O)C(Br)C(C)(C)CCCCCCCCCCC(C)(C)C(Br)C(O)=O AXXUJNIHMQQIIP-UHFFFAOYSA-N 0.000 description 2
- QRMMMWOSHHVOCJ-UHFFFAOYSA-N 2,2-dimethylheptanoic acid Chemical compound CCCCCC(C)(C)C(O)=O QRMMMWOSHHVOCJ-UHFFFAOYSA-N 0.000 description 2
- QEBQEVMZUWUIKD-UHFFFAOYSA-N 4-(3-carboxy-3-methylbutoxy)-2,2-dimethylbutanoic acid Chemical compound OC(=O)C(C)(C)CCOCCC(C)(C)C(O)=O QEBQEVMZUWUIKD-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000283087 Equus Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 2
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102000004553 Interleukin-11 Receptors Human genes 0.000 description 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010082522 Oncostatin M Receptors Proteins 0.000 description 2
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 2
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 2
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 101001076459 Rattus norvegicus Interleukin-6 Proteins 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 208000006045 Spondylarthropathies Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 229940116731 Uricosuric agent Drugs 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002456 anti-arthritic effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000003070 anti-hyperalgesia Effects 0.000 description 2
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000842 anti-protozoal effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000002255 antigout agent Substances 0.000 description 2
- 229960002708 antigout preparations Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003904 antiprotozoal agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 2
- 229940110331 bextra Drugs 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 239000003710 calcium ionophore Substances 0.000 description 2
- NVXIEDHPFHVZTC-UHFFFAOYSA-N calcium;methanol Chemical compound [Ca].OC NVXIEDHPFHVZTC-UHFFFAOYSA-N 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940047495 celebrex Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940051427 deramaxx Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000005837 enolization reaction Methods 0.000 description 2
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 102000046949 human MSC Human genes 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000037231 joint health Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 2
- 229960003058 methotrexate sodium Drugs 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 210000000426 patellar ligament Anatomy 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 102000030769 platelet activating factor receptor Human genes 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000002089 prostaglandin antagonist Substances 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 229940116176 remicade Drugs 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- 229960003329 sulfinpyrazone Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 239000003383 uricosuric agent Substances 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZLSDDICVPOHWTB-UHFFFAOYSA-N 1,11-dihydroxy-2,10-dimethyl-2,10-diphenylundecan-6-one Chemical compound C=1C=CC=CC=1C(CO)(C)CCCC(=O)CCCC(C)(CO)C1=CC=CC=C1 ZLSDDICVPOHWTB-UHFFFAOYSA-N 0.000 description 1
- HLRBENIHKMCTTL-UHFFFAOYSA-N 1,11-dihydroxy-2,2,10,10-tetramethylundecan-6-one Chemical compound OCC(C)(C)CCCC(=O)CCCC(C)(C)CO HLRBENIHKMCTTL-UHFFFAOYSA-N 0.000 description 1
- YUQSKIKOWNWRQV-UHFFFAOYSA-N 1,13-dihydroxy-2,12-dimethyl-2,12-bis(4-methylphenyl)tridecan-7-one Chemical compound C1=CC(C)=CC=C1C(C)(CO)CCCCC(=O)CCCCC(C)(CO)C1=CC=C(C)C=C1 YUQSKIKOWNWRQV-UHFFFAOYSA-N 0.000 description 1
- HGJKCTNNEWONAW-UHFFFAOYSA-N 1,13-dihydroxy-2,12-dimethyl-2,12-bis[4-(2-methylpropyl)phenyl]tridecan-7-one Chemical compound C1=CC(CC(C)C)=CC=C1C(C)(CO)CCCCC(=O)CCCCC(C)(CO)C1=CC=C(CC(C)C)C=C1 HGJKCTNNEWONAW-UHFFFAOYSA-N 0.000 description 1
- FGTDNJHSEFINNG-UHFFFAOYSA-N 1,13-dihydroxy-2,2,12,12-tetramethyltridecan-7-one Chemical compound OCC(C)(C)CCCCC(=O)CCCCC(C)(C)CO FGTDNJHSEFINNG-UHFFFAOYSA-N 0.000 description 1
- ZYXVVXDWQIKBTP-UHFFFAOYSA-N 1-[4-(5,5-dimethyl-6-oxohexoxy)butyl]cyclopentane-1-carbaldehyde Chemical compound O=CC(C)(C)CCCCOCCCCC1(C=O)CCCC1 ZYXVVXDWQIKBTP-UHFFFAOYSA-N 0.000 description 1
- ADVQSOFXAHZIIC-UHFFFAOYSA-N 1-[4-[4-(1-carboxycyclopropyl)butoxy]butyl]cyclopropane-1-carboxylic acid Chemical compound C1CC1(C(O)=O)CCCCOCCCCC1(C(=O)O)CC1 ADVQSOFXAHZIIC-UHFFFAOYSA-N 0.000 description 1
- UBSCUXIZNTXLFW-UHFFFAOYSA-N 11-(10-benzyl-10-carboxy-11-chloroundecoxy)-2,2-diethylundecanoic acid Chemical compound CCC(CC)(C(O)=O)CCCCCCCCCOCCCCCCCCCC(CCl)(C(O)=O)CC1=CC=CC=C1 UBSCUXIZNTXLFW-UHFFFAOYSA-N 0.000 description 1
- ASFNYCBUJKXFTC-UHFFFAOYSA-N 13-(dimethylamino)-2,2,12,12-tetramethyl-7,13-dioxotridecanoic acid Chemical compound CN(C)C(=O)C(C)(C)CCCCC(=O)CCCCC(C)(C)C(O)=O ASFNYCBUJKXFTC-UHFFFAOYSA-N 0.000 description 1
- WJDKTFQIPMJCGR-UHFFFAOYSA-N 2,12-dimethyl-2,12-bis[4-(2-methylpropyl)phenyl]-7-oxotridecanedioic acid Chemical compound C1=CC(CC(C)C)=CC=C1C(C)(C(O)=O)CCCCC(=O)CCCCC(C)(C(O)=O)C1=CC=C(CC(C)C)C=C1 WJDKTFQIPMJCGR-UHFFFAOYSA-N 0.000 description 1
- NHTFPQHLCFYJIJ-UHFFFAOYSA-N 2,2,12,12-tetramethyl-7,13-dioxo-13-(n-phenylanilino)tridecanoic acid Chemical compound C=1C=CC=CC=1N(C(=O)C(C)(C)CCCCC(=O)CCCCC(C)(C)C(O)=O)C1=CC=CC=C1 NHTFPQHLCFYJIJ-UHFFFAOYSA-N 0.000 description 1
- FUSSBLIWQHHZOG-UHFFFAOYSA-N 2,2,12,12-tetramethyltridecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCC(C)(C)C(O)=O FUSSBLIWQHHZOG-UHFFFAOYSA-N 0.000 description 1
- LLFXYXPRAJLGTE-UHFFFAOYSA-N 2,2,15,15-tetramethylhexadecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCCCCC(C)(C)C(O)=O LLFXYXPRAJLGTE-UHFFFAOYSA-N 0.000 description 1
- OAWLZLONZCDJSJ-UHFFFAOYSA-N 2,2,17,17-tetramethyloctadecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCCCCCCC(C)(C)C(O)=O OAWLZLONZCDJSJ-UHFFFAOYSA-N 0.000 description 1
- DJKWDKJYFYUEBQ-UHFFFAOYSA-N 2,2,9,9-tetramethyldecane-1,10-diol Chemical compound OCC(C)(C)CCCCCCC(C)(C)CO DJKWDKJYFYUEBQ-UHFFFAOYSA-N 0.000 description 1
- LYDQREUUWSXQDS-UHFFFAOYSA-N 2,2,9,9-tetramethyldecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCC(C)(C)C(O)=O LYDQREUUWSXQDS-UHFFFAOYSA-N 0.000 description 1
- NAHQIQHWEZQFAU-UHFFFAOYSA-N 2,2-diethyl-5-(5-methoxy-4,4-dimethyl-5-oxopentoxy)pentanoic acid Chemical compound CCC(CC)(C(O)=O)CCCOCCCC(C)(C)C(=O)OC NAHQIQHWEZQFAU-UHFFFAOYSA-N 0.000 description 1
- VUAXHMVRKOTJKP-UHFFFAOYSA-N 2,2-dimethylbutyric acid Chemical compound CCC(C)(C)C(O)=O VUAXHMVRKOTJKP-UHFFFAOYSA-N 0.000 description 1
- IKNDGHRNXGEHTO-UHFFFAOYSA-N 2,2-dimethyloctanoic acid Chemical compound CCCCCCC(C)(C)C(O)=O IKNDGHRNXGEHTO-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- RIUBYPPHIXWKKB-UHFFFAOYSA-N 2-(3-chloropropyl)-5-(5-formyl-7-hydroxy-5-methylheptoxy)-2-methylpentanoic acid Chemical compound OCCC(C)(C=O)CCCCOCCCC(C)(C(O)=O)CCCCl RIUBYPPHIXWKKB-UHFFFAOYSA-N 0.000 description 1
- YQLYBTRODIEZQI-UHFFFAOYSA-N 2-(bromomethyl)-9-[4-carboxy-4-(chloromethyl)-5-hydroxypentoxy]-2-(iodomethyl)nonanoic acid Chemical compound OCC(CCl)(C(O)=O)CCCOCCCCCCCC(CBr)(CI)C(O)=O YQLYBTRODIEZQI-UHFFFAOYSA-N 0.000 description 1
- XEDWMSUMRFDIOJ-UHFFFAOYSA-N 2-[4-[8-carboxy-9-methoxy-8-(methoxymethyl)nonoxy]butyl]-2-pentylheptanoic acid Chemical compound CCCCCC(CCCCC)(C(O)=O)CCCCOCCCCCCCC(COC)(COC)C(O)=O XEDWMSUMRFDIOJ-UHFFFAOYSA-N 0.000 description 1
- VRSUAEIFUULQBH-UHFFFAOYSA-N 2-[6-[5,5-dimethyl-6-(oxan-2-yloxy)hexyl]sulfanyl-2,2-dimethylhexoxy]oxane Chemical compound C1CCCOC1OCC(C)(C)CCCCSCCCCC(C)(C)COC1CCCCO1 VRSUAEIFUULQBH-UHFFFAOYSA-N 0.000 description 1
- YAPBXDDPSIAEHH-UHFFFAOYSA-N 2-ethyl-2-[2-(5-ethyl-5-methoxycarbonylheptoxy)ethyl]-3-methylbutanoic acid Chemical compound COC(=O)C(CC)(CC)CCCCOCCC(CC)(C(C)C)C(O)=O YAPBXDDPSIAEHH-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- CCPAROICJDHUHE-UHFFFAOYSA-N 3,14-diethyl-3,14-dimethylhexadecanedioic acid Chemical compound OC(=O)CC(C)(CC)CCCCCCCCCCC(C)(CC)CC(O)=O CCPAROICJDHUHE-UHFFFAOYSA-N 0.000 description 1
- SRJWQXGYTPCQBI-UHFFFAOYSA-N 3,3,12,12-tetramethyltetradecanedioic acid Chemical compound OC(=O)CC(C)(C)CCCCCCCCC(C)(C)CC(O)=O SRJWQXGYTPCQBI-UHFFFAOYSA-N 0.000 description 1
- MYCWUMRBKGTYGG-UHFFFAOYSA-N 3,3,14,14-tetracyclohexylhexadecanedioic acid Chemical compound C1CCCCC1C(C1CCCCC1)(CC(=O)O)CCCCCCCCCCC(CC(O)=O)(C1CCCCC1)C1CCCCC1 MYCWUMRBKGTYGG-UHFFFAOYSA-N 0.000 description 1
- MNXRNHVTBJYOMC-UHFFFAOYSA-N 3,3,14,14-tetrakis(4-chlorophenyl)hexadecanedioic acid Chemical compound C=1C=C(Cl)C=CC=1C(C=1C=CC(Cl)=CC=1)(CC(=O)O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 MNXRNHVTBJYOMC-UHFFFAOYSA-N 0.000 description 1
- WRAJNZCUSWQWRS-UHFFFAOYSA-N 3,3,14,14-tetrakis(4-hydroxyphenyl)hexadecanedioic acid Chemical compound C=1C=C(O)C=CC=1C(C=1C=CC(O)=CC=1)(CC(=O)O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 WRAJNZCUSWQWRS-UHFFFAOYSA-N 0.000 description 1
- BCDDMJAZZDQSQD-UHFFFAOYSA-N 3,3,14,14-tetrakis(4-methoxyphenyl)hexadecanedioic acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)(CC(O)=O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BCDDMJAZZDQSQD-UHFFFAOYSA-N 0.000 description 1
- HYVCJBOGBXWNLU-UHFFFAOYSA-N 3,3,14,14-tetrakis(4-methylphenyl)hexadecanedioic acid Chemical compound C1=CC(C)=CC=C1C(C=1C=CC(C)=CC=1)(CC(O)=O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 HYVCJBOGBXWNLU-UHFFFAOYSA-N 0.000 description 1
- XJOQLLOLGFBHDP-UHFFFAOYSA-N 3,3,14,14-tetrakis(hydroxymethyl)hexadecanedioic acid Chemical compound OC(=O)CC(CO)(CO)CCCCCCCCCCC(CO)(CO)CC(O)=O XJOQLLOLGFBHDP-UHFFFAOYSA-N 0.000 description 1
- DTGWPBXWEDHULN-UHFFFAOYSA-N 3,3,14,14-tetrakis(prop-2-enyl)hexadecanedioic acid Chemical compound OC(=O)CC(CC=C)(CC=C)CCCCCCCCCCC(CC=C)(CC=C)CC(O)=O DTGWPBXWEDHULN-UHFFFAOYSA-N 0.000 description 1
- GORDJQZOFOVSQR-UHFFFAOYSA-N 3,3,14,14-tetramethylhexadec-8-enedioic acid Chemical compound OC(=O)CC(C)(C)CCCCC=CCCCCC(C)(C)CC(O)=O GORDJQZOFOVSQR-UHFFFAOYSA-N 0.000 description 1
- LWFCJLGMDXFDJL-UHFFFAOYSA-N 3,3,14,14-tetramethylhexadecanediamide Chemical compound NC(=O)CC(C)(C)CCCCCCCCCCC(C)(C)CC(N)=O LWFCJLGMDXFDJL-UHFFFAOYSA-N 0.000 description 1
- ZHNHHDJUKFLIMS-UHFFFAOYSA-N 3,3,14,14-tetraphenylhexadecanedioic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(CC(=O)O)CCCCCCCCCCC(CC(O)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 ZHNHHDJUKFLIMS-UHFFFAOYSA-N 0.000 description 1
- ALPCCMYAJZAWAO-UHFFFAOYSA-N 3,3,16,16-tetramethyloctadecanedioic acid Chemical compound OC(=O)CC(C)(C)CCCCCCCCCCCCC(C)(C)CC(O)=O ALPCCMYAJZAWAO-UHFFFAOYSA-N 0.000 description 1
- RQKGSIGQBVSOAD-UHFFFAOYSA-N 3,3,18,18-tetramethylicosanedioic acid Chemical compound OC(=O)CC(C)(C)CCCCCCCCCCCCCCC(C)(C)CC(O)=O RQKGSIGQBVSOAD-UHFFFAOYSA-N 0.000 description 1
- KEPKSKRXODHWGP-UHFFFAOYSA-N 3-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound CCCC(C(C)(C)C(O)=O)OCCCCC(C)(C)C(O)=O KEPKSKRXODHWGP-UHFFFAOYSA-N 0.000 description 1
- HGXXYAGULYAJKN-UHFFFAOYSA-N 3-[3-[3-(2-carboxy-2-methylpropyl)benzoyl]phenyl]-2,2-dimethylpropanoic acid Chemical compound OC(=O)C(C)(C)CC1=CC=CC(C(=O)C=2C=C(CC(C)(C)C(O)=O)C=CC=2)=C1 HGXXYAGULYAJKN-UHFFFAOYSA-N 0.000 description 1
- FTBNTXVJGPCPPJ-UHFFFAOYSA-N 5-(3-carboxy-3-methylbutoxy)-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCOCCC(C)(C)C(O)=O FTBNTXVJGPCPPJ-UHFFFAOYSA-N 0.000 description 1
- NIYWONCEAOSHIM-UHFFFAOYSA-N 5-(4-carboxy-4-methylpentoxy)-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCOCCCC(C)(C)C(O)=O NIYWONCEAOSHIM-UHFFFAOYSA-N 0.000 description 1
- JWUQKQJBJGXVQR-UHFFFAOYSA-N 5-(5-hydroxy-4-methyl-4-phenylpentyl)sulfanyl-2-methyl-2-phenylpentan-1-ol Chemical compound C=1C=CC=CC=1C(CO)(C)CCCSCCCC(C)(CO)C1=CC=CC=C1 JWUQKQJBJGXVQR-UHFFFAOYSA-N 0.000 description 1
- JSOCMLGSQVOMQK-UHFFFAOYSA-N 5-(5-hydroxy-4-methyl-4-phenylpentyl)sulfinyl-2-methyl-2-phenylpentan-1-ol Chemical compound C=1C=CC=CC=1C(CO)(C)CCCS(=O)CCCC(C)(CO)C1=CC=CC=C1 JSOCMLGSQVOMQK-UHFFFAOYSA-N 0.000 description 1
- ROHIGTBTCFMSNZ-UHFFFAOYSA-N 5-[(4-carboxy-4-methylpentyl)sulfanylmethylsulfanyl]-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCSCSCCCC(C)(C)C(O)=O ROHIGTBTCFMSNZ-UHFFFAOYSA-N 0.000 description 1
- ZBEHQYBIKITXIF-UHFFFAOYSA-N 5-[2-(4-carboxy-4-methylpentyl)sulfanylethylsulfanyl]-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCSCCSCCCC(C)(C)C(O)=O ZBEHQYBIKITXIF-UHFFFAOYSA-N 0.000 description 1
- MGNOFERDBFZQEP-UHFFFAOYSA-N 5-[2-(5-hydroxy-4,4-dimethylpentoxy)ethoxy]-2,2-dimethylpentan-1-ol Chemical compound OCC(C)(C)CCCOCCOCCCC(C)(C)CO MGNOFERDBFZQEP-UHFFFAOYSA-N 0.000 description 1
- SGAOHSSCGUPUAO-UHFFFAOYSA-N 5-[3-ethyl-11-[6-ethyl-6-(2h-tetrazol-5-yl)octoxy]undecan-3-yl]-2h-tetrazole Chemical compound N=1N=NNC=1C(CC)(CC)CCCCCCCCOCCCCCC(CC)(CC)C1=NN=NN1 SGAOHSSCGUPUAO-UHFFFAOYSA-N 0.000 description 1
- ZLZUXDUGPRKMRG-UHFFFAOYSA-N 5-[4-(4-carboxy-3,3-dimethylbutyl)sulfanylbutylsulfanyl]-3,3-dimethylpentanoic acid Chemical compound OC(=O)CC(C)(C)CCSCCCCSCCC(C)(C)CC(O)=O ZLZUXDUGPRKMRG-UHFFFAOYSA-N 0.000 description 1
- NPRXDJJJMKMIAK-UHFFFAOYSA-N 6,11-dioxo-3,3,14,14-tetraphenylhexadecanedioic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(CC(=O)O)CCC(=O)CCCCC(=O)CCC(CC(O)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 NPRXDJJJMKMIAK-UHFFFAOYSA-N 0.000 description 1
- AZEOCZDDNNNLII-UHFFFAOYSA-N 6-(5-butyl-5-methoxycarbonylnonoxy)-2-ethyl-2-methylhexanoic acid Chemical compound CCCCC(CCCC)(C(=O)OC)CCCCOCCCCC(C)(CC)C(O)=O AZEOCZDDNNNLII-UHFFFAOYSA-N 0.000 description 1
- QNIHXFBGHLJFBJ-UHFFFAOYSA-N 6-(5-carboxy-5-ethylheptoxy)-2,2-diethylhexanoic acid Chemical compound CCC(CC)(C(O)=O)CCCCOCCCCC(CC)(CC)C(O)=O QNIHXFBGHLJFBJ-UHFFFAOYSA-N 0.000 description 1
- CQMGKZDPSUYHTH-UHFFFAOYSA-N 6-(5-carboxy-5-phenylhexyl)sulfanyl-2-methyl-2-phenylhexanoic acid Chemical compound C=1C=CC=CC=1C(C)(C(O)=O)CCCCSCCCCC(C)(C(O)=O)C1=CC=CC=C1 CQMGKZDPSUYHTH-UHFFFAOYSA-N 0.000 description 1
- FTJKEUBBWSIOEH-UHFFFAOYSA-N 6-(5-hydroxy-5-methylhexoxy)-2-methylhexan-2-ol Chemical compound CC(C)(O)CCCCOCCCCC(C)(C)O FTJKEUBBWSIOEH-UHFFFAOYSA-N 0.000 description 1
- XWZKWLJMXQMPKY-UHFFFAOYSA-N 6-(6-ethyl-6-formyloctoxy)-2,2-dimethylhexanoic acid Chemical compound CCC(CC)(C=O)CCCCCOCCCCC(C)(C)C(O)=O XWZKWLJMXQMPKY-UHFFFAOYSA-N 0.000 description 1
- ULDZFCNXQRYRSI-UHFFFAOYSA-N 6-(6-hydroxy-5,5-dimethylhexoxy)-2,2-dimethylhexan-1-ol Chemical compound OCC(C)(C)CCCCOCCCCC(C)(C)CO ULDZFCNXQRYRSI-UHFFFAOYSA-N 0.000 description 1
- AXKNHRFGQOGVFD-UHFFFAOYSA-N 6-(6-hydroxy-5,5-dimethylhexyl)sulfanyl-2,2-dimethylhexan-1-ol Chemical compound OCC(C)(C)CCCCSCCCCC(C)(C)CO AXKNHRFGQOGVFD-UHFFFAOYSA-N 0.000 description 1
- OFBPTQHRYOEMOZ-UHFFFAOYSA-N 6-(6-hydroxy-5,5-dimethylhexyl)sulfinyl-2,2-dimethylhexan-1-ol Chemical compound OCC(C)(C)CCCCS(=O)CCCCC(C)(C)CO OFBPTQHRYOEMOZ-UHFFFAOYSA-N 0.000 description 1
- CABKSVMDTCABIY-UHFFFAOYSA-N 6-(6-hydroxy-5-methyl-5-phenylhexyl)sulfanyl-2-methyl-2-phenylhexan-1-ol Chemical compound C=1C=CC=CC=1C(CO)(C)CCCCSCCCCC(C)(CO)C1=CC=CC=C1 CABKSVMDTCABIY-UHFFFAOYSA-N 0.000 description 1
- OUDQFSIFGNXYLD-UHFFFAOYSA-N 6-(6-hydroxy-5-methyl-5-phenylhexyl)sulfinyl-2-methyl-2-phenylhexan-1-ol Chemical compound C=1C=CC=CC=1C(CO)(C)CCCCS(=O)CCCCC(C)(CO)C1=CC=CC=C1 OUDQFSIFGNXYLD-UHFFFAOYSA-N 0.000 description 1
- CHBCZBPNDMEOEL-UHFFFAOYSA-N 7-(4-carboxy-4-methylpentoxy)-2,2-dimethylheptanoic acid Chemical compound OC(=O)C(C)(C)CCCCCOCCCC(C)(C)C(O)=O CHBCZBPNDMEOEL-UHFFFAOYSA-N 0.000 description 1
- FRJUMZKUZWELAL-UHFFFAOYSA-N 7-(5-carboxy-5-ethyl-6-methylheptoxy)-2-ethyl-2-(2-methylpropyl)heptanoic acid Chemical compound CC(C)CC(C(O)=O)(CC)CCCCCOCCCCC(CC)(C(C)C)C(O)=O FRJUMZKUZWELAL-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- SCYSJZSCOPJXEE-UHFFFAOYSA-N 8-(4-carboxy-4-methylpentoxy)-2,2-diethyloctanoic acid Chemical compound CCC(CC)(C(O)=O)CCCCCCOCCCC(C)(C)C(O)=O SCYSJZSCOPJXEE-UHFFFAOYSA-N 0.000 description 1
- HZKWZWPUKXZEEW-UHFFFAOYSA-N 9-hydroxy-3-(6-hydroxy-5,5-dimethylhexyl)-8,8-dimethylnonan-2-one Chemical compound OCC(C)(C)CCCCC(C(=O)C)CCCCC(C)(C)CO HZKWZWPUKXZEEW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229940124810 Alzheimer's drug Drugs 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000283705 Capra hircus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000033131 Congenital factor II deficiency Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102100029109 Endothelin-3 Human genes 0.000 description 1
- 108010072844 Endothelin-3 Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- QQHJDPROMQRDLA-UHFFFAOYSA-N Hexadecane-1,16-dioic acid Natural products OC(=O)CCCCCCCCCCCCCCC(O)=O QQHJDPROMQRDLA-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000007646 Hypoprothrombinemias Diseases 0.000 description 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940122048 Leucotriene receptor antagonist Drugs 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- HYSMCRNFENOHJH-UHFFFAOYSA-N MEDICA 16 Chemical compound OC(=O)CC(C)(C)CCCCCCCCCCC(C)(C)CC(O)=O HYSMCRNFENOHJH-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 101100221725 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-17 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 101150050331 PGIC gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 241000219161 Theobroma Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010003059 aggrecanase Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- ZRYCZAWRXHAAPZ-UHFFFAOYSA-N alpha,alpha-dimethyl valeric acid Chemical compound CCCC(C)(C)C(O)=O ZRYCZAWRXHAAPZ-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- ZGOVYTPSWMLYOF-QEADGSHQSA-N chembl1790180 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@H](CCC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)[C@H](C)O)=O)NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZGOVYTPSWMLYOF-QEADGSHQSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- PXNICCQYLXPRIW-UHFFFAOYSA-N dibenzyl [5-[4-bis(phenylmethoxy)phosphoryloxy-4-methylpentoxy]-2-methylpentan-2-yl] phosphate Chemical compound C=1C=CC=CC=1COP(=O)(OCC=1C=CC=CC=1)OC(C)(C)CCCOCCCC(C)(C)OP(=O)(OCC=1C=CC=CC=1)OCC1=CC=CC=C1 PXNICCQYLXPRIW-UHFFFAOYSA-N 0.000 description 1
- QXUGBFZAJYXWAO-UHFFFAOYSA-N dibenzyl [6-[5-bis(phenylmethoxy)phosphoryloxy-5-methylhexoxy]-2-methylhexan-2-yl] phosphate Chemical compound C=1C=CC=CC=1COP(=O)(OCC=1C=CC=CC=1)OC(C)(C)CCCCOCCCCC(C)(C)OP(=O)(OCC=1C=CC=CC=1)OCC1=CC=CC=C1 QXUGBFZAJYXWAO-UHFFFAOYSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- LLCNSWNSEHNQFE-UHFFFAOYSA-N diethyl 2,15-dibromo-3,3,14,14-tetramethylhexadecanedioate Chemical compound CCOC(=O)C(Br)C(C)(C)CCCCCCCCCCC(C)(C)C(Br)C(=O)OCC LLCNSWNSEHNQFE-UHFFFAOYSA-N 0.000 description 1
- YMIGBZCDNMUJIH-UHFFFAOYSA-N diethyl 2,2,12,12-tetramethyl-7-oxotridecanedioate Chemical compound CCOC(=O)C(C)(C)CCCCC(=O)CCCCC(C)(C)C(=O)OCC YMIGBZCDNMUJIH-UHFFFAOYSA-N 0.000 description 1
- MAVBJYZRJVMJSF-UHFFFAOYSA-N diethyl 3,3,14,14-tetramethylhexadecanedioate Chemical compound CCOC(=O)CC(C)(C)CCCCCCCCCCC(C)(C)CC(=O)OCC MAVBJYZRJVMJSF-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- MSTYEGBNWBXKEH-UHFFFAOYSA-N dimethyl 2,15-dibromo-3,3,14,14-tetramethylhexadecanedioate Chemical compound COC(=O)C(Br)C(C)(C)CCCCCCCCCCC(C)(C)C(Br)C(=O)OC MSTYEGBNWBXKEH-UHFFFAOYSA-N 0.000 description 1
- ZEQBTPAAGXVVFA-UHFFFAOYSA-N dimethyl 2,15-dichloro-3,3,14,14-tetramethylhexadecanedioate Chemical compound COC(=O)C(Cl)C(C)(C)CCCCCCCCCCC(C)(C)C(Cl)C(=O)OC ZEQBTPAAGXVVFA-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- KJDNTLXQVUSDEG-UHFFFAOYSA-L disodium [2-methyl-5-(4-methyl-4-phosphonooxypentoxy)pentan-2-yl] phosphate Chemical compound [Na+].CC(CCCOCCCC(C)(OP(=O)(O)O)C)(C)OP([O-])([O-])=O.[Na+] KJDNTLXQVUSDEG-UHFFFAOYSA-L 0.000 description 1
- UNOLHKIYEHQTNF-UHFFFAOYSA-L disodium [2-methyl-6-(5-methyl-5-phosphonooxyhexoxy)hexan-2-yl] phosphate Chemical compound [Na+].CC(CCCCOCCCCC(C)(OP(=O)(O)O)C)(C)OP([O-])([O-])=O.[Na+] UNOLHKIYEHQTNF-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- HIQMPLFRKJIMLD-UHFFFAOYSA-N ethyl 11-(6-hexoxy-5,5-dimethyl-6-oxohexoxy)-2,2-dimethylundecanoate Chemical compound CCCCCCOC(=O)C(C)(C)CCCCOCCCCCCCCCC(C)(C)C(=O)OCC HIQMPLFRKJIMLD-UHFFFAOYSA-N 0.000 description 1
- CJEQNDYMODCRLG-UHFFFAOYSA-N ethyl 2,2-dimethyl-5-sulfanylpentanoate Chemical compound CCOC(=O)C(C)(C)CCCS CJEQNDYMODCRLG-UHFFFAOYSA-N 0.000 description 1
- CYGYYRHOCJKRIH-UHFFFAOYSA-N ethyl 5-(5-ethoxy-4,4-dimethyl-5-oxopentoxy)-2,2-dimethylpentanoate Chemical compound CCOC(=O)C(C)(C)CCCOCCCC(C)(C)C(=O)OCC CYGYYRHOCJKRIH-UHFFFAOYSA-N 0.000 description 1
- RDPATGHAVQEVBJ-UHFFFAOYSA-N ethyl 6-(6-ethoxy-5,5-dimethyl-6-oxohexoxy)-2,2-dimethylhexanoate Chemical compound CCOC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(=O)OCC RDPATGHAVQEVBJ-UHFFFAOYSA-N 0.000 description 1
- UVWSLXZTGTXBCT-UHFFFAOYSA-N ethyl 6-[6-ethoxy-5,5-bis(hydroxymethyl)-6-oxohexoxy]-2,2-bis(hydroxymethyl)hexanoate Chemical compound CCOC(=O)C(CO)(CO)CCCCOCCCCC(CO)(CO)C(=O)OCC UVWSLXZTGTXBCT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229940018991 hyalgan Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229940096405 magnesium cation Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- VYKFUWZZYAUUJN-UHFFFAOYSA-N methyl 8-(8-methoxy-7,7-dimethyl-8-oxooctoxy)-2,2-dimethyloctanoate Chemical compound COC(=O)C(C)(C)CCCCCCOCCCCCCC(C)(C)C(=O)OC VYKFUWZZYAUUJN-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940101972 mirapex Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000019261 negative regulation of glycolysis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 229960002934 propentofylline Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 201000007183 prothrombin deficiency Diseases 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229940113775 requip Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229940099315 rimadyl Drugs 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 229940036220 synvisc Drugs 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940000238 tasmar Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BXMYVNSHJNBFIO-UHFFFAOYSA-N tetraethyl 2,2,11,11-tetramethyldodecane-1,1,12,12-tetracarboxylate Chemical compound CCOC(=O)C(C(=O)OCC)C(C)(C)CCCCCCCCC(C)(C)C(C(=O)OCC)C(=O)OCC BXMYVNSHJNBFIO-UHFFFAOYSA-N 0.000 description 1
- GCHZOPYORPQCIX-UHFFFAOYSA-N tetraethyl 2,2,13,13-tetramethyltetradecane-1,1,14,14-tetracarboxylate Chemical compound CCOC(=O)C(C(=O)OCC)C(C)(C)CCCCCCCCCCC(C)(C)C(C(=O)OCC)C(=O)OCC GCHZOPYORPQCIX-UHFFFAOYSA-N 0.000 description 1
- GIQMITBANDPQQH-UHFFFAOYSA-N tetraethyl 2,2,17,17-tetramethyloctadecane-1,1,18,18-tetracarboxylate Chemical compound CCOC(=O)C(C(=O)OCC)C(C)(C)CCCCCCCCCCCCCCC(C)(C)C(C(=O)OCC)C(=O)OCC GIQMITBANDPQQH-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
METHOD OF TREATING OSTEOARTHRITIS
: This invention relates to methods, compositions, and combinations using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component for preventing or treating osteoarthritis (“OA”), preventing or inhibiting cartilage damage, preventing or treating rheumatoid arthritis (“RA”), improving joint function, alleviating pain, including joint pain, and the like, in a patient in need thereof.
More than 100 million people worldwide are afflicted with some form of arthritis, a disabling, even crippling, disease or disorder of the joints or spine (ankylosing spondylitis). Depending on the type of the disease or disorder, a patient afflicted with an arthritis may or may not also be afflicted with additional conditions such as psoriasis (psoriatic arthritis), autoimmune conditions (e.g., systemic lupus erythematosus), gout, muscle disorders (e.g., fibromyalgia), a joint infection (infectious arthritis), scleroderma, or one or more of the following conditions: urethritis, prostatitis, cervicitis, cystitis, eye problems, or skin problems (Reiter’s syndrome).
For example in the United States alone, more than 42 million people currently have some form of arthritis, including 300,000 children (e.g., juvenile rheumatoid arthritis), and the total number is expected to grow to 60 million people by the year 2020. Among the various forms of arthritis in the U.S., OA is the most prevalent, afflicting 21 million people. An OA patient suffering from cartilage damage primarily experiences pain and joint stiffness leading to joint deformities and diminishment or loss of joint function.
In patients suffering from RA, the clinical outcome relates to progressive destruction of cartilage and bone. In joints affected with RA, the chronically inflamed and hyperplastic synovial tissue invades adjacent cartilage and bone, leading to a loss of joint function and disability.
Aspirin and conventional nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, diclofenac, and naproxen, are the typical agents used to treat
RA related inflammation or RA- or OA-related pain. NSAIDs inhibit prostaglandin release by blocking cyclooxygenase-1 (COX-1) and/or cyclooxygenase-2 (COX-2) mediated conversion of cell membrane lipids from arachidonic acid. However, the therapeutic use of conventional NSAIDs is limited due to drug- and mechanism-associated side effects, including life threatening gastric ulceration and renal toxicity. Further, these drugs only treat secondary symptoms associated with cartilage damage, rheumatoid arthritis, or osteoarthritis such as pain. They do not prevent or treat the underlying pathophysiological condition, which is damage to the cartilage or bone. The need for new and improved therapies for these diseases thus continues.
We have now discovered that compounds which are substituted dialkyl ethers, substituted aryl-alkyl ethers, substituted dialkyl thioethers, substituted dialkyl ketones, or substituted-alkyl compounds, or a pharmaceutically acceptable salt thereof, including a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt, are useful for preventing and inhibiting cartilage damage, preventing and treating rheumatoid arthritis, improving joint function, alleviating pain, including joint pain, preventing and treating osteoarthritis, and the like. All that is required to practice a method of this invention is to administer to a subject in need of treatment an effective amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, or a combination comprising said compound and another therapeutically active agent such as a COX-2 inhibitor.
This invention relates to methods, compositions, and combinations using or having substituted dialkyl ethers, substituted dialkyl thioethers, substituted dialkyl ketones, or substituted-alkyl compounds for preventing or treating osteoarthritis (“OA”), preventing or inhibiting cartilage damage, preventing or treating rheumatoid arthritis (“RA”), improving joint function, alleviating pain, including joint pain, and the like in a patient in need thereof.
One aspect of this invention is a method of inhibiting cartilage damage in a mammal, comprising administering to the mammal a therapeutically effective amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of preventing cartilage damage in a mammal, comprising administering to the mammal a therapeutically effective amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of preventing osteoarthritis in a mammal, comprising administering to the mammal an osteoarthritis preventing "effective amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of treating osteoarthritis in a mammal, comprising administering to the mammal an osteoarthritis treating effective amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of preventing rheumatoid arthritis in a mammal, comprising administering to the mammal a rheumatoid arthritis preventing effective amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of treating rheumatoid . arthritis in a mammal, comprising administering to the mammal a rheumatoid arthritis treating effective amount of a substituted dialkyl ether, substituted aryl- alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted- alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of treating joint inflammation in a mammal, comprising administering to the mammal a therapeutically effective amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
In one aspect of this invention, the joint inflammation is rheumatoid arthritic joint inflammation.
Another aspect of this invention is a method of improving joint function in a mammal, comprising administering to the mammal a joint function improving effective amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of alleviating pain in a mammal, comprising administering to the mammal a pain alleviating effective amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl! ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of treating systemic lupus erythematous in a mammal, comprising administering to the mammal a therapeutically effective amount of a substituted dialkyl ether, substituted aryl- alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted- alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of treating mixed connective tissue disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a substituted dialkyl ether, substituted aryl- alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted- alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of treating an I1.-6 mediated disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a substituted dialkyl ether, substituted aryl-alky] ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of treating an IL-6 receptor mediated disease in 2 mammal, comprising administering to the mammal a therapeutically effective amount of a substituted dialkyl ether, substituted aryl- alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted- alkyl compound, or a pharmaceutically acceptable salt thereof. . In another aspect of this invention, the IL-6 or IL-6 receptor mediated disease is sepsis.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether is a compound of Formula I
Y! Y?
RICH O—(CHa—f gt
R? rR’ I or a pharmaceutically acceptable salt thereof, wherein: n and m independently are integers of from 2 to 9;
R', R% R?, and R* independently are C;-Cs alkyl, C,-Cs alkenyl, or C»-Cs alkynyl; or
R' and R? together with the carbon atom to which they are attached, or R® and R* together with the carbon atom to which they are attached, or R! and R? together with the carbon atom to which they are attached and R® and R* together with the carbon atom to which they are attached, can complete a carbocyclic ring having from 3 to 6 carbons; ’
Y! and Y? independently are COOH, CHO, tetrazole, or COOR?, wherein
R’ is C;-Cs alkyl, C,-C alkenyl, or C2-Cg alkynyl; and wherein the alkyl, alkenyl, and alkynyl! groups may be substituted with one or two groups selected from halo, hydroxy, C;-Cg alkoxy, and phenyl; wherein halo includes chloro, bromo, and iodo, C,-C¢ alkoxy is a C;-Cs - alkyl group linked through oxygen.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, or a pharmaceutically acceptable salt thereof.
Another aspect is any one of the above invention methods wherein the | substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt hydrate.
Another aspect is any one of the above invention methods wherein what is administered is the substituted dialkyl ether that is Crystal Form 1 of a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
Another aspect is any one of the above invention methods wherein what is administered is the substituted dialkyl ether that is Crystal Form 2 of a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt ethyl alcohol solvate.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt methanol solvate.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt 1-propyl alcohol solvate.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt 2-propyl alcohol solvate.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt 1-butyl alcohol solvate.
Another aspect of this invention is a method of inhibiting cartilage damage in a mammal, comprising administering to the mammal a cartilage damage inhibiting effective amount of a compound named 6-(5-carboxy-5-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
Another aspect of this invention is a method of preventing cartilage damage in a mammal, comprising administering to the mammal a cartilage damage preventing effective amount of a compound named 6-(3-carboxy-5- methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
Another aspect of this invention is a method of preventing osteoarthritis in a mammal, comprising administering to the mammal an osteoarthritis preventing effective amount of a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt.
Another aspect of this invention is a method of treating osteoarthritis in a mammal, comprising administering to the mammal an osteoarthritis treating effective amount of a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt.
Another aspect of this invention is a method of preventing rheumatoid arthritis in a mammal, comprising administering to the mammal an osteoarthritis preventing effective amount of a compound named 6-(5-carboxy-5-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
Another aspect of this invention is a method of treating rheumatoid arthritis in a mammal, comprising administering to the mammal an osteoarthritis treating effective amount of a compound named 6-(5-carboxy-5-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
Another aspect of this invention is a method of alleviating pain in a mammal, comprising administering to the mammal a pain alleviating effective amount of a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt.
In another aspect, a compound of Formula I that may be utilized in an invention method is selected from: 7,7" -oxybis(2,2-dimethylheptanoic acid); 5,5'-oxybis(2,2-dimethylpentanoic acid);
4.4" -oxybis{2,2-dimethylbutanoic acid); 8,8’-0xybis(2,2-dimethyloctanoic acid);
Ethyl 2,2-dimethyl-5-(4-methyl-4-ethoxycarbonylpentyloxy)pentanoate;
Ethyl 2,2-dimethyl-6-(5-methyl-5-ethoxycarbonylhexyloxy)hexanoate;
Methyl 2,2-dimethyl-8-(7-methyl-7-methoxycarbonyloctyloxy)octanoate; and 7-(4-methyl-4-hydroxycarbonylpentyloxy)-2,2-dimethylheptanoic acid; or a pharmaceutically acceptable salt thereof.
In another aspect, a compound of Formula I that may be utilized in an invention method is selected from: 5-(3-Carboxy-3-methyl-butoxy)-2,2-dimethyl-pentanoic acid; 2,2-Diethyl-5-(4-methoxycarbonyl-4-methyl-pentyloxy)-pentanoic acid; 6-(3-Carboxy-3-ethyl-4-methyl-pentyloxy)-2,2-diethyl-hexanoic acid methyl ester; 2-(3-Chloro-propyl)-5-(5-formyl-7-hydroxy-5-methyl-heptyloxy)-2- methyl-pentanoic acid; 6-(5-Carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid; 6-(5-Carboxy-5-ethyl-heptyloxy)-2,2-diethyl-hexanoic acid, bis sodium salt; 6-(5-Butyl-5-methoxycarbonyl-nonyloxy)-2-ethyl-2-methyl-hexanoic acid; 6-(5-Ethoxycarbonyl-6-hydroxy-5-hydroxymethyl-hexyloxy)-2,2-bis- hydroxymethyl-hexanoic acid ethyl ester; 2,2-Dipropyl-6-[5-propyl-5-(1H-tetrazol-5-yl)-octyloxy}-hexanal; 1-{4-[4-(1-Carboxycyclopropan-1-yl)-butyloxy]-butyl }- cyclopropanecarboxylic acid; 1-[4-(5,5-Dimethyl-6-oxo-hexyloxy)-butyl]-cyclopentanecarbaldehyde; 2-Benzyl-6-(5,5-dimethyl-6-0x0-hexyloxy)-2-methyl-hexanal; 6-(6-Ethyl-6-formyl-octyloxy)-2,2-dimethyl-hexanoic acid; 7-(5-Carboxy-5-ethyl-6-methyl-heptyloxy)-2-ethyl-2-isobutyl-heptanoic acid; 2-[2-(6-Carboxy-6-hexyl-dodecyloxy)-ethyl]-2-hex yl-octanoic acid;
8-(3-Carboxy-3-iscbutyl-5-methyl-hexyloxy)-2,2-dipropyl-octanoic acid, bis potassium salt; 8-(4-Carboxy-4-methyl-pentyloxy)-2,2-diethyl-octanoic acid; 2-Bromomethyl-9-(4-carboxy-4-chloromethyl-5-hydroxy-pentyloxy)-2- iodomethyl-nonanoic acid; 9-(5-Carboxy-5-pentyl-decyloxy)-2,2-bis-methoxymethyl-nonanoic acid, 1:1 salt with triethylamine; 10-~(5,5-Dimethyl-6-o0xo0-hexyloxy)-2,2-dimethyl-decanoic acid; 11-(5-Hexyloxycarbonyl-5-methyl-hexyloxy)-2,2-dimethyl-undecanoic acid ethyl ester; 5-{3-Ethyl-11-[6-Ethyl-6-(1H-tetrazol-5-yl)-octan-1-yloxy]-undecan-3- yl}-tetrazole; and 11-(10-Benzyl-10-carboxy-11-chloro-undecyloxy)-2,2-diethyl-undecanoic acid; or a pharmaceutically acceptable salt thereof.
Another aspect is any one of the above invention methods wherein the substituted-alkyl compound is a compound of Formula II
O CH, CH;0
Ro—E—|— (cpr —E—or I
CH; CH, or a pharmaceutically acceptable salt thereof, 20 . whereinnis 6,7, 8,9, or 10; and
R and R' are selected from the group consisting of hydrogen and C;-Cy alkyl.
In another aspect, a compound of Formula II that may be utilized in an invention method is selected from: 2,2,9,9-tetramethyldecanedioic acid; and 2,2,12,12-tetramethyltridecanedioic acid; or a pharmaceutically acceptable salt thereof.
Another aspect is any one of the above invention methods wherein the substituted-alkyl compound is a compound of Formula III
CH; CH,
Root, — | —(CHy—|—cri OR ii
CH, CH, or a pharmaceutically acceptable salt thereof, wherein nis 6,7, 8, 9, or 10;
R and R! are selected from the group consisting of hydrogen, (C1-Ci2 alkyl)-C(=0)-, HO,C(CHz)-CH;-C(=0)-, phenyl-CH,-
C(H)(NH,)-C(=0)-, and (HO),-P(=0)-; and m is an integer of from 1 to 3; wherein alkyl is straight or branched.
In another aspect, a compound of Formula III that may be utilized in an invention method is selected from: 2,2,9,9-tetramethyl-1,10-decanediol; or a pharmaceutically acceptable salt thereof.
Another aspect is any one of the above invention methods wherein the substituted aryl-alkyl ether is a compound of Formula IV 0)
Ll!
Lod end he Iv
Lo EN or a pharmaceutically acceptable salt thereof, wherein
R! is C;-Cyp alkyl, C3-C; cycloalkyl, phenyl-(C;-Cs alkyl)-, phenyl, thienyl, furanyl, thiazolyl, pyridinyl, or RR*N-;
R? and R* are the same or different C,-C, alkyl, or R* and R* are combined to each other either directly, or as interrupted by a heteroatom selected from N, O, and S, with the nitrogen atom to which they are both bonded to form a 5- or 6-membered ring, wherein the 5- or 6- membered ring is piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;
R2 is a bond or -(CHp)m~;
L! and L? are the same or different C;-Cy alkyl, or L! and L? are combined to each other to form -(CHp),-; p is an integer of from 2 to 6; and when R! is C3-C; cycloalkyl, phenyl<(Cy-Cs alkyl}-, phenyl, thienyl, furanyl, thiazolyl, pyridinyl, or R’R*N-, L! and L% may further by : hydrogen; wherein the C3-C; cycloalkyl, phenyl-(Cy-Cs alkyl)-, phenyl, thienyl, furanyl, thiazolyl, pyridinyl, piperidinyl, morpholinyl, pyrrolidinyl, and piperazinyl groups may optionally have from 1 to 3 substituents independently selected from Cy-Cj alkyl, (C1-Cy alkyl)-O-, F, Cl, Br, I, OH, and a methylenedioxy group of formula -0-(CH,),-O-, wherein the oxygen atoms of the methylenedioxy group are bonded to contiguous carbon atoms to form a ring of . from 5 to 7 members; and
Each m independently is an integer of from 1 to 3. :
In another aspect, a compound of Formula IV that may be utilized in an invention method is selected from: 5-[4-(1-methylcyclohexylmethyloxy)benzyl]thiazolidine-2,4-dione; a compound of any one of Examples 1 to 8, 10, and 11 of U.S. 4,287,200; any one of Compound Nos. 1 to 54 of Example 10 of U.S. 4,287,200; and any one of Compound Nos. 1 to 7 of Example 12 of U.S. 4,287,200; or a pharmaceutically acceptable salt thereof.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound is a compound of
Formula V
X R' R'X #o0c——|—q—|——coon AY
Y Rr? R? Y or a pharmaceutically acceptable salt thereof, or an in vivo hydrolyzable functional derivative selected from an ester, amide, or anhydride with (C;-Cs alkyl)-COOH; wherein
R' and R? each independently represent an unsubstituted or substituted hydrocarbyl selected from C,-Cg alkyl optionally substituted by phenyl, OH, (C;-Cs alkyl)-C-, F, Ci, or Br, C3-Cs alkenyl, C2-Cs alkynyl, C5-C; cycloalkyl, phenyl optionally substituted by OH, (C,-Ce alkyl)-O-, C;-Cs alkyl, F, Cl, or Br, or heterocyclyl;
X and Y each independently represent hydrogen, C;-C¢ alkyl, F, Cl, Br,
COOH, (C4-Cg alkyl)-O-C(=0)-, or (C;-Cg alkyl)-N(H)-C(=0)-, 3 and further one of X and Y can also be (C;-Cg alkyl)-O-, HO, or
NC-;
Q represents a diradical consisting of an alkylenyl diradical of from 8 to 14 carbon atoms or a heteroalkylenyl diradical of from 8 to 14 members having carbon atoms and a heteroatom selected from S,
S(0), S(O), N(H), N(C,-Cg alkyl), N(CH,-phenyl), and O, wherein the alkylenyl or heteroalkylenyl may optionally be substituted by oxo (=0), F, Cl, Br, OH, or (C;-Cg¢ alkyl)-O-, and wherein any from 1 to 4 contiguous atoms in the alkylenyl or heteroalkylenyl may comprise a C3-Cy cycloalkyl and wherein any from 2 to 4 contiguous atoms in the alkylenyl or heteroalkylenyl may comprise a phenyl.
In another aspect, a compound of Formula V that may be utilized in an invention method is selected from: 2,3,3,14,14,15-hexamethyl-hexadecane-1,16-dioic acid; 2,15-di-carbamoyl-3,3,14,14-tetramethyl-hexadecane-1,16-dioic acid; 3,14-diethyl-3,14-dimethyl-hexadecane-1,16-dioic acid; 3,3,14,14tetra-(2-propenyl)-hexadecane-1,16-dioic acid; 3,3,14,14-tetra-cyclohexyl-hexadecane-1,16-dioic acid; 2,15-dibromo-3,3,14,14-tetraphenyl-hexadecane-1,16-dioic acid; 1,2-cyclopropylidine-bis-(3,3-dimethyl-7-yl-heptanoic acid); 9.9-pentamethylene-3,3-15,15-tetramethyl-heptadecane-1,17-dioic acid; 1,2-cyclohexylidene-bis-(3,3-dimethyl-7-yl-heptanoic acid); 1,2-phenylene-(3,3-dimethyl-7-yl-heptanoic acid); 3,3,15,15-tetramethyl-9-thia-heptadecane-1,17-dioic acid; 9-oxa-3,3,15,15-tetramethyl-heptadecane-1,17-dioic acid; 9-aza-3,3,15,15-tetramethyl-heptadecane-1,17-dioic acid; : 3,3,14,14-tetramethyl-6,11-dithiahexadecane-1,16-dioic acid;
2,15-difluoro-3,3,14,14-tetramethyl-hexadecane-1,16-dioic acid; 2,2,15,15-tetrafluoro-3,3,14, 14-tetramethyl-hexadecane-1,16-dioic acid; 2.2,15,15-tetrachloro-3,3,14,14-tetramethyl-hexadecane-1,16-dioic acid; 3,3,14,14-tetrahydroxymethyl-hexadecane-1,16-dioic acid; 2,15-dichloro-3,14-di(chloromethyl)-3,14-dimethyl-hexadecane-1,16-dioic acid; 2,15-dichloro-3,3,14,14-tetra(chloromethyl)-hexadecane-1,16-dioic acid; 3,3,14,14-tetra-(4-hydroxyphenyl)-hexadecane-1,16-dioic acid; 3,3,14,14-tetra-(4-chlorophenyl)-hexadecane-1,16-dioic acid; 3,3,14,14-tetra-(4-methyl-phenyl)-hexadecane-1,16-dioic acid; and 3,3,14,14-tetra-(4-methoxy-phenyl)-hexadecane-1,16-dioic acid; or a pharmaceutically acceptable salt thereof.
In another aspect, a compound of Formula V that may be utilized in an invention method is selected from: 1,1,14,14-tetra(ethox ycarbonyl)-2,2,13,13-tetramethyl-tetradecane; 1,1,16,16-tetra(ethoxycarbonyl)-2,2,15,15-tetramethyl-hexadecane; 1,1,12,12-tetra(ethoxycarbonyl)-2,2,11,11-tetramethyl-dodecane; 3,3,14,14-tetramethyl-hexadecane-1,16-dioic acid; 3,3,16,16-tetramethyl-octadecane-1,18-dioic acid; 3,3,12,12-tetramethyl-tetradecane-1,14-dioic acid; 1,14-di-(ethoxycarbonyl)-1,14-dicyano-2,213,13-tetramethyl-tetradecane; 2,15-dicyano-3,3,14,14-tetramethyl-hexadecane-1,16-dioic acid; 2,15-dibromo-3,3,14,14-tetramethyl-hexadecane-1,16-dioic acid; 2,3,3,14,14,15-hexamethyl-hexadecane-1,16-dioic acid, 1,14-diethoxycarbonyl-2,2,13,13-tetramethyl-tetradecane; 1,14-di-(ethoxycarbonyl)-1,14-dibromo-2,2,13,13-tetramethyl-tetradecane; 1,14-bis-carbamoyl-2,2,13,13-tetramethyl-tetradecane; 2,15-dichloro-3,3,14,14-tetramethylhexadecane-1,16-dioic acid; 2,15-dibromo-3,3,14,14-tetramethylhexadecane-1,16-dioic acid; 2,15-dihydroxy-3,3,14,14-tetramethylhexadecane-1,16-dioic acid; 1,14-di-(carbomethoxy)-1,14-dibromo-2,2,13,13-tetramethyltetradecane; 1,14-di-(carbomethoxy)-1,14-dichloro-2,2,13,13-tetramethyltetradecane; 2,15-dimethoxy-3,3,14,14-tetramethylhexadecane-1,16-dioic acid;
1,1,18,18-tetra(carboethoxy)-2,2,17,17-tetramethyloctadecane; 3,3,18,18-tetramethyleicosane-1,20-dioic acid; 3,3,14,14-tetramethyl-8-hexadecene-1,16-dioic acid; 3,3,14,14-tetraphenyl-6,1 1-diketohexadecane-1,16-dioic acid; 3,3,14,14-tetraphenylhexadecane-1,16-dioic acid; 1,4-phenylene-bis-[(1,1-dimethyl-but-4-yl)-dipropionic acid dimethyl ester]; 1,4-phenylene-bis-[(1,1-dimethyl-but-4-yl)-dipropionic acid]; 1,4-phenylene-bis(3,3-dimethyl-6-yl-5-hexenoic acid methyl ester); 1,3-phenylene-bis(3,3-dimethyl-6-yl-5-hexenoic acid methyl ester); 1,4-phenylene-bis(3,3-dimethyl-6-yl-hexanoic acid methyl ester); 1,3-phenylene-bis(3,3-dimethyl-6-yl-hexanoic acid methyl ester); 1,4-phenylene-bis(3,3-dimethyl-6-yl-hexanoic acid); 1,3-phenylene-bis(3,3-dimethyl-6-yl-hexanoic acid); 1,4-(cyclohexylidene-bis-(3,3-dimethyl-6-yl-hexanoic acid methyl ester); 1,3-(cyclohexylidene-bis-(3,3-dimethyl-6-yl-hexanoic acid methyl ester); 1,4-(cyclohexylidene-bis-(3,3-dimethyl-6-yl-hexanoic acid); 1,3-(cyclohexylidene-bis-(3,3-dimethyl-6-yl-hexanoic acid); 1,4-phenylene-bis(3,3-dimethyl-7-yl-5-heptenoic acid); 1,3-phenylene-bis(3 ,3-dimethyl-7-yl-5-heptenoic acid); 1,4-phenylene-bis(3,3-dimethyl-7-yl-heptanoic acid); 1,3-phenylene-bis(3,3-dimethyl-7-yl-heptanoic acid); 1,4-(cyclohexylidene-bis-(3,3-dimethyl-7-yl-heptanoic acid); 1,3-(cyclohexylidene-bis-(3,3-dimethyl-7-yl-heptanoic acid); and 1,4-(cyclohexylidene-bis-(3,3-dimethyi-5-0x0-7-yl-heptanoic acid); or a pharmaceutically acceptable salt thereof.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound is a compound of
Formula VI
X R' R' X nooc—|——o——{—coon V1
Y R”? RY or a pharmaceutically acceptable salt thereof, or an in vivo hydrolyzable functional derivative selected from an ester, amide, or anhydride with (C;-Cs alkyl)-COOH; wherein
R! and R? each independently represent an unsubstituted or substituted C;-
Cs alkyl optionally substituted by OH, (C;-Cs alkyl)-O-, F, Cl, Br, or phenyl, wherein the phenyl optionally substituted one or more times by OH, (C;-Cg alkyl)-O-, C;-Cs alkyl, F, Cl, or Br, C;-Ce alkenyl, C-Cs alkynyl, C3-C; cycloalkyl, phenyl optionally substituted by OH, (C;-Cs alkyl)-O-, C;-Cs alkyl, F, Cl, or Br, or heterocycle;
X and Y each independently represent hydrogen, C;-Cs alkyl, (C1-Cs alkyl)-O-, HO, NC-, F, Cl, Br, COOH, (C;-Cs alkyl)-O-C(=0)-, or (C1-Cs alky)-N(H)-C(=0)-;
Q represents a diradical consisting of an alkylenyl diradical of from 8 to 14 carbon atoms or a heteroalkylenyl diradical of from 8 to 14 members having carbon atoms and a heteroatom selected from S,
S(0), S(0)2, N(H), N(C;-Cg alkyl), N(CHz-phenyl), and O, wherein the alkylenyl or heteroalkylenyl may optionally be substituted by oxo (=0), F, Cl, Br, OH, or (C;-Cs alkyl)-O-, and wherein any from 1 to 4 contiguous atoms in the alkylenyl or heteroalkylenyl may comprise a C3-C; cycloalkyl and wherein any from 2 to 4 contiguous atoms in the alkylenyl or heteroalkylenyl may comprise a phenyl.
In another aspect, a compound of Formula VI that may be utilized in an invention method is selected from: 2,15-difluoro-3,3,14,14-tetramethyl-1,16-hexadecanedioic acid; 2,15-dichloro-3,3,14,14-tetramethyl-hexadecane-1,16-dioic acid diisopropyl ester; and
2.2,15,15-tetrachioro-3,3,14, 14-tetrametnyl- hexadecane-1,16-dioic acid; or a pharmaceutically acceptable salt thereof.
Another aspect is any one of the above invention methods wherein the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound is a compound of
Formula VII
R’ R’ R! R’®
HOOC—&— CH, —&—Q—C—CHy—~C—COOH VII (CE UE or a pharmaceutically acceptable salt thereof, or in vivo hydrolysable functional derivatives of the carboxylic groups thereof selected from C;-Cg alkyl ester, unsubstituted amide, C;-Cs alkyl amide, bis(C;-Cs alkyl) amide, anhydride with a C;-Cg carboxylic acid, and lactone formed by a dehydrative ring closure between a COOH group and any OH group of R® or RS, wherein:
R!, R?, R? and R* each independently represents a hydrogen, an unsubstituted or substituted hydrocarbyl radical selected from C;-
Cs alkyl, C,-Cs alkenyl, C,-Cg alkynyl, C5-C7 cycloalkyl, phenyl, and phenyl-(C,-C; alkylenyl), or a heterocyclyl radical;
R® and RS independently represent hydrogen, hydroxyl, C,-Cs alkyl, chloro, bromo, cyano, nitro, C;-Cg alkoxy, or CFs;
Q represents a diradical consisting of an unsubstituted or substituted linear chain of 2 to 14 carbon atoms, one or more of which may be replaced by heteroatoms selected from O, S, S(O), S(O),, N(H),
N(C;-Cs alkyl), and N(CHzphenyl); wherein substituents are selected from oxo (=O), F, Cl, Br, OH, or (C;-Cs alkyl)-O-, and wherein any from 1 to 4 contiguous atoms in the in the linear chain may comprise a C;3-C; cycloalkyl and wherein any from 2 to 4 contiguous atoms in the linear chain may comprise a phenyl.
In another aspect, a compound of Formula VII that may be utilized in an invention method is the compound wherein RR? R3, R* R%, and R® are not each hydrogen. :
In another aspect, a compound of Formula VII that may be utilized in an invention method is selected from: 4.,4,11,11-tetramethyltetradecanedioic acid; diethyl 4,4,13,13-tetramethylhexadeca-2,5,11,14-tetraenedionate; 4 4,13,13-tetramethylhexadecanedioic acid; 4.4,15,15-tetramethyloctadecanedioic acid; 2,2,15,15-tetramethylhexadecanedioic acid; and 2,2,17,17-tetramethyloctadecanedioic acid.
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 10/205,939; United States Patent Nos. 6,410,802; 6,459,003; and 6,506,799; in United States Patent Application Publication No. US 2003/0065195; and in PCT International Patent Application Publication No. WO 00/59855, or a pharmaceutically acceptable salt thereof.
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 10/205,939; United States Patent Nos. 6,410,802; 6,459,003; and 6,506,799; in United States Patent Application Publication No. US 2003/0065195; and in PCT International Patent Application Publication No. WO 00/59855, or a pharmaceutically acceptable salt thereof selected from: 6-(6-Hydroxy-5,5-dimethyl-hexyloxy)-2,2-dimethyl-hexan-1-ol; phosphoric acid mono-(1,1-dimethyl-5-(5-methyl-5-phosphonooxy- hexyloxy)-pentyl) ester sodium salt; phosphoric acid dibenzyl ester 5-(5-(bis-benzyloxy-phosphoryloxy)-5- methyl-hexyloxy)-1,1-dimethyl-pentyl ester; phosphoric acid mono-(1,1-dimethyl-4-(4-methyl-4-phosphonooxy- pentyloxy)-butyl) ester sodium salt; phosphoric acid dibenzyl ester 4-(4-(bis-benzyloxy-phosphoryloxy)-4- methyl-pentyloxy)-1,1-dimethyl-butyl ester; and 6-(5-hydroxy-5-methyl-hexyloxy)-2-methyl-hexan-2-ol;
or a pharmaceutically acceptable salt thereof. :
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 09/976,867; United States Patent Application Publication No. US 2003/0018013; and in PCT International Patent Application Publication No. WO 02/30863, or a pharmaceutically acceptable salt thereof.
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 09/976,867; United States Patent Application Publication No. US 2003/0018013; and in PCT International Patent Application Publication No. WO 02/30863, or a pharmaceutically acceptable salt thereof, selected from: 5-[2-(5-Hydroxy-4,4-dimethyl-pentyloxy)-ethoxyl]-2,2-dimethyl-pentan-1- ol; and 3-{3-[3 -(2-Carboxy-2-methy)-propyl)-phenoxy] -phenyl}-2,2-dimethyl- propionic acid; or a pharmaceutically acceptable salt thereof.
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 09/976,938; United States Patent Application Publication No. US 2003/0078239 and PCT International Patent Application Publication No. WO 02/30860, or a pharmaceutically acceptable salt thereof.
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 09/976,938; United States Patent Application Publication No. US 2003/0078239 and PCT International Patent Application Publication No. WO 02/30860, or a pharmaceutically acceptable salt thereof selected from: 1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one; 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid diethyl ester; 1,11-Dihydroxy-2,2,10,10-tetramethyl-undecan-6-one; 2,12-Dimethyl-7-0x0-2,12-di-p-tolyl-tridecanedioic acid; 1,13-Dihydroxy-2,12-dimethyl-2,12-di-p-tolyl-tridecan-7-one; 2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid;
1,13-Dihydroxy-2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-tridecan-7- one; 2,10-Dimethyl-6-ox0-2,10-diphenyl-undecanedioic acid; 1,11-Dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one; 9-Hydroxy-3-(6-hydroxy-5,5-dimethyl-hexyl)-8,8-dimethylnonan-2-one;
Bis[3-(3-hydroxy-2,2-dimethylpropyl)phenylJmethanone; 3-{3-[3-(2-Carboxy-2-methyl-propyl)-benzoyl]-phenyl }-2,2-dimethyl- propanoic acid; 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-methylamide; 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-phenylamide; and 7-0%x0-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid; or a pharmaceutically acceptable salt thereof.
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 09/976,898; United States Patent Application Publication No. US 2002/0077316; and in PCT International Patent Application Publication No. WO 02/30884, or a pharmaceutically acceptable salt thereof.
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 09/976,898; United States Patent Application Publication No. US 2002/0077316; and in PCT International Patent Application Publication No. WO 02/30884, or a pharmaceutically acceptable salt thereof selected from: 5-[2-(4-Carboxy-4-methyl-pentylsulfanyl)-ethylsulfanyl]-2,2-dimethyl- pentanoic acid;
Bis-(5,5-dimethyl-6-tetrahydropyranyloxy-hexyl)-sulfide; 6-(5,5-Dimethyl-6-hydroxy-hexyl-sulfanyl)-2,2-dimethyl-hexan-1-ol;
Ethyl 5-mercapto-2,2-dimethylpentanoate; 2,2,12,12-Tetramethyl-6,8-dithiatridecane-1,13-dioic acid; 6-(6-Hydroxy-5-methyl-5-phenylhexylsulfanyl)-2-methyl-2-phenylhexan- 1-ol; 6-(5-Carboxy-5-phenylhexylsulfanyl)-2-methyl-2-phenyl-hexanoic acid;
Di-(6-hydroxy-5,5-dimethylpentyl)sulfide;
5-(5-Hydroxy-4-methyl-4-phenylpentylsulfanyl)-2-methyl-2- phenylpentan-1-ol; and 2,2,12,12-Tetramethyl-5,9-dithiatridecanedioic acids disodium salt; or a pharmaceutically acceptable salt thereof.
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 09/976,899; United States Patent Application Publication No. US : 2003/0022865; and in PCT International Patent Application Publication No. WO 02/30882, or a pharmaceutically acceptable salt thereof.
In another aspect, a compound that may be utilized in an invention method is any single compound or genus of compounds of United States Patent
Application No. 09/976,899; United States Patent Application Publication No. US 2003/0022865; and in PCT International Patent Application Publication No. WO 02/30882, or a pharmaceutically acceptable salt thereof selected from: 6-(5,5-Dimethyl-6-hydroxy-hexane-1-sulfinyl)-2,2-dimethyl-hexan-1-ol; 6-(6-Hydroxy-5-methyl-5-phenylhexylsulfinyl)-2-methyl-2-phenylhexan- 1-ol; 5-(5-Hydroxy-4,4-dimethyl-pentyl-1-sulfinyl)-2,2-dimethyl-pentan-1-ol; and 5-(5-Hydroxy-4-methyl-4-phenylpentylsulfinyl)-2-methyl-2-phenylpentan- 1-ol; or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a method of inhibiting cartilage damage in a mammal, comprising administering to the mammal a therapeutically effective amount of a means for inhibiting cartilage damage in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is a method of preventing cartilage damage in a mammal, comprising administering to the mammal a therapeutically effective amount of a means for preventing cartilage damage in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is a method of preventing osteoarthritis in a mammal, comprising administering to the mammal an osteoarthritis preventing effective amount of a means for preventing osteoarthritis in 2 mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient one.
Another aspect of this invention is a method of treating osteoarthritis in a mammal, comprising administering to the mammal an osteoarthritis treating effective amount of a means for treating osteoarthritis in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is a method of preventing rheumatoid arthritis in a mammal, comprising administering to the mammal a rheumatoid arthritis preventing effective amount of a means for preventing rheumatoid arthritis in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient
Another aspect of this invention is a method of treating rheumatoid arthritis in a mammal, comprising administering to the mammal a rheumatoid arthritis treating effective amount of a means for treating rheumatoid arthritis in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is a method of improving joint function in a mammal, comprising administering to the mammal a joint function improving effective amount of a means for improving joint function in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is a method of treating systemic lupus erythematous in a mammal, comprising administering to the mammal a therapeutically effective amount of a means for treating systemic lupus erythematous in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is a method of treating mixed connective tissue disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a means for treating mixed connective tissue disease in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is a method of treating an IL-6 mediated disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a means for treating an IL-6 mediated disease in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is a method of treating an IL-6 receptor mediated disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a means for treating an IL-6 receptor mediated disease in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is a method of treating sepsis in a mammal, comprising administering to the mammal a therapeutically effective amount of a means for treating sepsis in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient. : Another aspect of this invention is a method of alleviating pain in a mammal, comprising administering to the mammal a pain alleviating effective amount of a means for alleviating pain in a mammal in admixture with a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is osteoarthritic pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is rheumatoid arthritic pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is joint pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is osteoarthritic joint pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is rheumatoid arthritic joint pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is acute pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is acute joint pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is chronic pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is chronic joint pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is inflammatory pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is inflammatory joint pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is a mechanical pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is a mechanical joint pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is mediated by IL-6, IL-65sR, or IL-6 receptor.
Another aspect is any one of the above methods of alleviating pain other than joint pain, osteoarthritic pain, rheumatoid arthritic pain, and inflammatory joint pain, wherein the pain is pain mediated by IL-6, IL-6sR, or IL-6 receptor.
Another aspect of this invention is any one of the above methods of alleviating pain, wherein the pain is mediated by a protein or protein and its receptor selected from: oncostatin-M, oncostatin-M and oncostatin-M receptor, leukemia inhibitor factor (“LIF”), LIF and leukemia inhibitor factor receptor (“LIFR”), interleukin-11 (“IL-11"), and I-11 and interleukin-11 receptor (“IL- 11R").
Another aspect is any one of the above methods of alleviating pain other than joint pain, osteoarthritic pain, rheumatoid arthritic pain, and inflammatory joint pain, wherein the pain is pain mediated by endothelin-1.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is bone cancer pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is neuropathic pain.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is static allodynia.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is dynamic allodynia.
Another aspect is any one of the above methods of alleviating pain, wherein the pain is headache pain.
Another aspect of this invention is a pharmaceutical composition, comprising an amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, effective for use in any one of the above methods, and a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is use of a pharmaceutical composition, comprising an amount of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, effective for use in any one of the above methods, and a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is use of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament effective for use in any one of the above methods or uses.
Another aspect of this invention is a combination, comprising a selective
COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is the combination, comprising a selective
COX-2 inhibitor selected from: celecoxib, valdecoxib, and parecoxib, and a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
Another aspect of this invention is a combination, comprising methotrexate and a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is a combination, comprising a therapeutic biological agent and a substituted dialkyl ether, substituted aryl-alkyl ether,
substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof.
Another aspect of this invention is any invention method wherein the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound is replaced with an invention combination comprising the substituted dialkyl ether, substituted aryl- alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted- alkyl compound and another therapeutically active compound or therapeutic biological agent.
Another aspect of this invention is a pharmaceutical composition, comprising an amount of an invention combination effective for use in any one of the above methods, and a pharmaceutically acceptable carrier, diluent, or excipient.
Another aspect of this invention is use of a pharmaceutical composition, comprising an amount of an invention combination effective for use in any one of the above methods, and a pharmaceutically acceptable carrier, diluent, or excipient.
FORMULATION EXAMPLE 1
Tablet Formulation: ‘Ingredient ~~ Amount(mg) "Substituted dialkyl ether, substituted aryl-alkyl ether, 25 substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound useful in the invention method
Lactose 50
Cornstarch (for mix) 10
Cornstarch (paste) 10
Magnesium stearate (1%) 5
Total 100
The substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound useful in the invention method, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed powders.
The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1% magnesium stearate and pressed into a tablet. Such tablets can be administered to a human from one to four times a day for inhibiting cartilage damage, improving joint function, treating rheumatoid arthritis, or treating osteoarthritis.
FORMULATION EXAMPLE 2
Coated Tablets:
The tablets of Formulation Example 1 are coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth, and colorant.
FORMULATION EXAMPLE 3
Injection vials:
The pH of a solution of 500 g of 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt, and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 L of double-distilled water using2 M hydrochloric acid.
The solution is sterile filtered, and the filtrate is filled into injection vials, lyophilized under sterile conditions, and aseptically sealed. Each injection vial contains 25 mg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 4
Suppositories:
A mixture of 25 g of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt, 100 g of soya lecithin, and 1400 g of cocoa butter is fused, poured into molds, and allowed to cool. Each suppository contains 25 mg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 5
A solution is prepared from 1 g of 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt, 9.38 g of NaH;PO4-12H50, 28.48 g of
NagHPO4-12H20, and 0.1 g benzalkonjum chloride in 940 mL of double-distilled water. The pH of the solution is adjusted to pH 6.8 using 2 M hydrochloric acid.
The solution is diluted to 1.0 L with double-distilled water, and sterilized by irradiation. A 25 mL volume of the solution contains 25 mg of 6-(5-carboxy-5- methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 6
Ointment: 500 mg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt is mixed with 99.5 g of petroleum jelly under aseptic conditions. A 5 g portion of the ointment contains 25 mg of 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 7
Capsules: 2 kg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt are filled into hard gelatin capsules in a customary manner such that each capsule contains 25 mg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt.
FORMULATION EXAMPLE 8
Ampoules:
A solution of 2.5 kg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt is dissolved in 60 L of double-distilled water. The solution is sterile filtered, and the filtrate is filled into ampoules. The ampoules are lyophilized under sterile conditions and aseptically sealed. Each ampoule contains 25 mg of 6-(S-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 9
Tablet Formulation: “Ingredient ____ Amount(mg) “6-(5carboxy-5-methyl-hexyloxy)-2,2-dimethyl- 25 hexanoic acid, calcium salt
Valdecoxib 20
Lactose 50
Comstarch (for mix) 10
Cornstarch (paste) 10
Magnesium stearate (1%) 5
Total T1200 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, valdecoxib, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1% magnesium stearate and pressed into a tablet. Such tablets can be administered to a human from one to four times a day for treatment of one of the above-listed diseases, including rheumatoid arthritis.
FORMULATION EXAMPLE 10
Coated Tablets:
The tablets of Formulation Example 9 are coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth, and colorant.
FORMULATION EXAMPLE 11
Injection vials:
The pH of a solution of 250 g of valdecoxib, 500 g of 6-(5-carboxy-5- methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 L of double-distilled water using 2 M hydrochloric acid. The solution is sterile filtered, and the filtrate is filled into injection vials, lyophilized under sterile conditions, and aseptically sealed. Each injection vial contains 12.5 mg of valdecoxib and 25 mg of 6-(5-carboxy-5- methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 12
Suppositories:
A mixture of 50 g of valdecoxib, 25 g of 6-(5-carboxy-5-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, 100 g of soya lecithin, and 1400 g of cocoa butter is fused, poured into molds, and allowed to cool. Each suppository contains 50 mg of valdecoxib and 25 mg of 6-(5-carboxy-5-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 13
A solution is prepared from 0.5 g of valdecoxib, 1 g of 6-(5-carboxy-5- methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, 9.38 g of
NaHyPO4-12H70, 28.48 g of NagHPO4-12H70, and 0.1 g benzalkonium chloride in 940 mL of double-distilled water. The pH of the solution is adjusted to pH 6.8 using 2 M hydrochloric acid. The solution is diluted to 1.0 L with double- distilled water, and sterilized by irradiation. A 25 mL volume of the solution contains 12.5 mg of valdecoxib and 25 mg of 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 14
Ointment: 100 mg of valdecoxib, 500 mg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt is mixed with 99.4 g of petroleum jelly under aseptic conditions. A 5 g portion of the ointment contains 5 mg of valdecoxib and 25 mg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
" RORMULATION EXAMPLE 15
Capsules: 2 kg of valdecoxib and 20 kg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt are filled into hard gelatin capsules in a customary manner such that each capsule contains 25 mg of valdecoxib and 250 mg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 16
Ampoules:
A solution of 2.5 kg of valdecoxib and 2.5 kg of 6-(5-carboxy-5-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt is dissolved in 60 L. of double-distilled water. The solution is sterile filtered, and the filtrate is filled into ampoules. The ampoules are lyophilized under sterile conditions and aseptically sealed. Each ampoule contains 25 mg each of valdecoxib and 6-(5-carboxy-5- methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
FORMULATION EXAMPLE 17
Tablet Formulation of 6-(5-carboxy-5-methyl-hexyloxy)-2.2-dimethyl-hexanoic acid, calcium salt: “Ingredient ________________ Amount(mg) “6 (5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- 25 hexanoic acid, calcium salt
Lactose 50
Cornstarch (for mix) 10
Cornstarch (paste) 10
Magnesium stearate (1%) 5
Total 100 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, lactose, and cornstarch (for mix) are blended to uniformity. The cornstarch (for paste) is suspended in 200 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried at 80°C. The dry granules are lubricated with the 1% magnesium stearate and pressed into a tablet.
Injection vial formulation of valdecoxib: , The pH of a solution of 500 g of valdecoxib and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 L of double-distilled water using 2 M hydrochloric acid. The solution is sterile filtered, and the filtrate is filled into injection vials, lyophilized under sterile conditions, and aseptically sealed. Each injection vial contains 25 mg of valdecoxib.
Such tablets containing 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt can be administered to a human from one to four times a day for treatment of the above-listed diseases, and the injection solutions containing valdecoxib can be administered to a human 1 or 2 times per day, wherein the administration by injection is optionally simultaneous with administration of the tablets or at different times, for the treatment of one of the . above-listed diseases, including rheumatoid arthritis.
FORMULATION EXAMPLE 18
Coated Tablets containing 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt:
The tablets of Formulation Example 17 are coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth, and colorant.
Capsules containing valdecoxib: 2 kg of valdecoxib are filled into hard gelatin capsules in a customary manner such that each capsule contains 25 mg of valdecoxib.
Such coated tablets containing 6-(5-carboxy-5-methyl-hexyloxy)-2,2- , dimethyl-hexanoic acid, calcium salt can be administered to 2 human from one to four times a day for treatment of the above-listed diseases, and the capsules containing valdecoxib can be administered to a human 1 or 2 times per day, wherein the administration of the capsules is optionally simultaneous with administration of the tablets or at different times, for the treatment of one of the above-listed diseases.
Other aspects of invention methods, compositions, and combinations are contemplated by the inventors, as illustrated below in the Detailed Description of the Invention.
Figure 1 (“FIG. 1”) is a dose response line graph that shows the change in rat hind paw weight distribution, expressed in grams, on Day 14 in rats with knee joint arthritis, which was induced on Day 0 by injection of a physiologic saline solution of 1 mg of monosodium iodoacetate (“MIA”) through the infrapatellar ligament of the right knee, following oral administration of 10, 30, or 100 mg/kg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt (“CI-1027”). The rat hind paw weight distribution data were measured at Time 0, 2, 4, and 6 hours post compound administration.
Figure 2 (“FIG. 2”) is a time course line graph that shows the change in rat hind paw weight distribution, expressed in grams, on Days 7, 14, and 28 in rats with knee joint arthritis, which was induced on Day 0 by injection of a physiologic saline solution of 1 mg of monosodium iodoacetate (“MIA”) through the infrapatellar ligament of the right knee, following chronic oral administration b.i.d. of 30 mg/kg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt versus vehicle, wherein the compound was administered from 0.5 hour pre-injection of MIA and then approximately every 12 hours through the end of Day 28.
Figure 3 (“FIG. 3") is a time course, dose response line graph that shows the change in rat hind paw weight distribution, expressed in grams, on Days 7, 14, and 28 in rats with knee joint arthritis, which was induced on Day 0 by injection of a physiologic saline solution of 1 mg of monosodium iodoacetate (“MIA”) through the infrapatellar ligament of the right knee, following chronic oral administration b.i.d. of 3, 10, or 30 mg/kg of 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt versus vehicle, wherein the compound was administered from 0.5 hour pre-injection of MIA and then approximately every 12 hours through the end of Day 28.
Figure 4 (“FIG. 4”) is a dose response bar graph that shows effects on (i) cartilage erosion severity, expressed as Grade 0 (no erosion), Grade I (erosion extending into the superficial or middle cartilage layers and further characterized by size small, medium, and large), or Grade II (deep layer erosion; no cartilage remaining in spots, subchondral bone exposed in spots, and further characterized by size small, medium, and large) and (ii) cartilage size, expressed as percent erosion distribution, relative to vehicle-injected control animals, on Day 28 in rats with knee joint arthritis, which was induced on Day 0 by injection of a physiologic saline solution of 1 mg of monosodium iodoacetate (“MIA”) through the infrapatellar ligament of the right knee, following chronic oral administration b.i.d. of 3, 10, or 30 mg/kg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt versus vehicle, wherein the compound was administered from 0.5 hour pre-injection of MIA and then approximately every 12 hours through the end of Day 28.
Figure 5 (“FIG. 5) is a dose response bar graph that shows effects on total cartilage erosion area, expressed in square millimeters, regardless of cartilage erosion severity grade, relative to vehicle-injected control animals, on Day 28 in rats with knee joint arthritis, which was induced on Day 0 by injection of a physiologic saline solution of 1 mg of monosodium iodoacetate (“MIA”) through the infrapatellar ligament of the right knee, following chronic oral administration b.i.d. of 3, 10, or 30 mg/kg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt versus vehicle, wherein the compound was administered from 0.5 hour pre-injection of MIA and then approximately every 12 hours through the end of Day 28.
Figure 6 (“FIG. 6”) is a time course, dose response line graph that shows the change in rat hind paw weight distribution, expressed in grams, following oral administration at Time -1 hour of 10, 30, or 100 mg/kg of 6-(5-carboxy-S-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, followed by intra-articular injection through the patellar ligament into the joint space at Time 0 hour of a combination of 100 ng IL-6 and 300 ng of IL-6sR dissolved in 50 UL of PBS, compared to a vehicle treated control group. The rat hind paw weight distribution data were measured at Time 0, 1, 3, and 6 hours post injection or 1, 2, 4, and 7 hours post compound administration, respectively.
Figure 7 (“FIG. 7”) is a time course, dose response line graph that shows the change in rat hind paw weight distribution, expressed in grams, following oral administration at Time -1 hour of 10 or 30 mg/kg of 6-(5-carboxy-5-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, followed by intra-articular injection through the patellar ligament into the joint space at Time 0 hour of a combination of 100 ng IL-6 and 300 ng of IL-6sR dissolved in 50 pL of PBS, compared to a vehicle treated control group. The rat hind paw weight distribution data were measured at Time 0, 1, 3, and 6 hours post injection or 1, 2, 4, and 7 hours post compound administration, respectively.
Figure 8 (“FIG. 8”) is a time course, dose response line graph that shows change in mouse ankle joint and paw swelling, expressed in millimeters (“mm”), following oral administration of vehicle or 30, 100, or 200 mg/kg of 6-(5-carboxy-
S-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, dissolved in oral vehicle beginning on Day -1 and continuing through Day 11 and an intraperitoneal injection of a mixture of monoclonal anti-collagen antibodies on Day 0.
As summarized above, this application relates to methods, compositions, and combinations using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component : for preventing or treating osteoarthritis (“OA”), preventing or inhibiting cartilage damage, preventing or treating rheumatoid arthritis (“RA”), improving joint function, or alleviating pain, including joint pain, in a patient in need thereof.
Substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in an invention method, composition, or combination include any aspect or embodiment of the therapeutic compounds described in United States Patent numbers 3,773,946; 3,930,024; 4,287,200; 4,689,344; 4,711,896; 5,648,387; 5,750,569;
5,756,544; 5,783,600; 6,410,802; 6,459,003; and 6,506,799; United States Patent
Application Numbers 09/976,867; 09/976,938; 09/976,898; 09/976,899; and 10/205,939; United States Patent Application Publication Numbers US 2002/0077316; US 2003/0018013; US 2003/0022865; US 2003/0065195; and US 2003/0078239; and PCT International Application Publication numbers WO 96/30328; WO 98/30530; WO 00/59855; WO 01/55078; WO 02/30860; WO 02/30863; WO 02/30882; and WO 02/30884, which are each hereby incorporated herein by reference.
Substituted dialkyl ethers of Formula I, and pharmaceutically acceptable salts thereof, including the compound named 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, calcium salt, are described in United States Patent
No. 5,648,387 and its divisionals Nos. 5,750,569; 5,756,544; and 5,783,600, and in PCT International Application Publication nos. WO 96/30328; WO 01/55078.
Substituted-alkyl compounds of Formula II, and pharmaceutically acceptable salts thereof, are described in United States Patent No. 3,773,946.
Substituted-alkyl compounds of Formula III, and pharmaceutically acceptable salts thereof, are described in United States Patent No. 3,930,024.
Substituted aryl-alkyl ethers of Formula IV, and pharmaceutically acceptable salts thereof, are described in United States Patent No. 4,287,200.
Substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds of Formula
V, and pharmaceutically acceptable salts thereof, are described in United States
Patent No. 4,689,344.
Substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds of Formula
VI, and pharmaceutically acceptable salts thereof, are described in United States
Patent No. 4,711,896.
Substituted dialkyl ether, substituted aryl-alky] ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds of Formula
VII, and pharmaceutically acceptable salts thereof, are described in PCT
International Patent Application Publication No. WO 98/30530.
Substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds, and .
pharmaceutically acceptable saits thereof, are described in United States Patent
Application No. 10/205,939; United States Patent Nos. 6,410,802; 6,459,003; and 6,506,799; in United States Patent Application Publication No. US 2003/0065195; and in PCT International Patent Application Publication No. WO 00/59855.
Substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds, and pharmaceutically acceptable salts thereof, are described in United States Patent
Application No. 09/976,867; United States Patent Application Publication No. US 2003/0018013; and in PCT International Patent Application Publication No. WO 02/30863.
Substituted dialkyl thioethers are described in United States Patent
Application No. 09/976,898; and 09/976,899; United States Patent Application
Publication Nos. US 2002/0077316; and US 2003/0022865; and in PCT
International Patent Application Publication Nos. WO 02/30882 and WO 02/30884.
Substituted dialkyl ketones are described in United States Patent
Application No. 09/976,938; United States Patent Application Publication No. US 2003/0078239 and PCT International Patent Application Publication No. WO 02/30860.
It should be appreciated that the compounds utilized in an invention method, composition, or combination are capable of further forming pharmaceutically acceptable salts, including, but not limited to, acid addition : and/or base salts. The acid addition salts are formed from basic compounds, whereas the base addition salts are formed from acidic compounds. All of these forms are within the scope of the compounds useful in an invention method, composition, or combination.
Pharmaceutically acceptable acid addition salts of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound include nontoxic salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well nontoxic salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl- substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like. Also contemplated are nontoxic salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example,
Berge S.M. et al., “Pharmaceutical Salts,” J. of Pharma. Sci., 1977;66:1).
An acid addition salt of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound is prepared by contacting the free base form of the compound with a sufficient amount of a desired acid to produce a nontoxic salt in the conventional manner. The free base form of the compound may be regenerated by contacting the acid addition salt so formed with a base, and isolating the free base form of the compound in the conventional manner. The free base forms of compounds differ from their respective acid addition salt forms somewhat in certain physical properties such as solubility, crystal structure, hygroscopicity, and the like, but otherwise free base forms of the compounds and their respective acid addition salt forms may be equally utilized in an invention method, composition, or combination.
A pharmaceutically acceptable base addition salt of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound may be prepared by contacting the free acid form of the compound with a metal cation such as an alkali or alkaline earth metal cation, or an amine, especially an organic amine. Examples of suitable metal cations include sodium cation (Nat), potassium cation (K+), magnesium cation (Mg2+), calcium cation (Ca2+), and the like. Examples of suitable amines are N,N’-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge, supra., 1977).
A base addition salt of a substituted dialkyi ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound may be prepared by contacting the free acid form of the compound with a sufficient amount of a desired base to produce the salt in the conventional manner. The free acid form of the compound may be regenerated by contacting the salt form so formed with an acid, and isolating the free acid of the compound in the conventional manner. The free acid forms of the compounds differ from their respective salt forms somewhat in certain physical properties such as solubility, crystal structure, hygroscopicity, and the like, but otherwise the salts may be utilized equally in an invention method, composition, or combination.
The compounds useful in an invention method, composition, or combination may exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms. An invention method, composition, or combination may utilize any solvated form, including hydrated form, of the compound, as well as mixtures thereof.
The compounds useful in an invention method, composition, or combination may possess one or more chiral centers, and each center may exist in : the R or S configuration. An invention method, composition, or combination may utilize any diastereomeric, enantiomeric, or epimeric form of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt ) thereof, as well as mixtures thereof.
Certain compounds useful in an invention method, composition, or combination may exist as two or more tautomeric forms. Tautomeric forms of the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds may interchange, for example, via enolization/de-enolization, 1,2-hydride, 1,3-hydride, or 1,4-hydride shifts, and the like. An invention method, composition, or combination may utilize any tautomeric form of the compound, as well as mixtures thereof.
Some compounds useful in an invention method, composition, or combination have alkenyl groups, which may exist as entgegen or zusammen conformations, in which case all geometric forms thereof, both entgegen and zusammen, cis and trans, and mixtures thereof, may be utilized in an invention method, composition, or combination.
Some compounds useful in an invention method, composition, or combination have cycloalkyl groups, which may be substituted at more than one carbon atom, in which case all geometric forms thereof, both cis and trans, and mixtures thereof, may be used in an invention method, composition, or combination.
Some compounds useful in an invention method, composition, or combination may exist as amorphous or crystalline solids, in which case all physical forms thereof, including clathrates thereof and mixtures thereof, may be used in an invention method, composition, or combination.
Invention methods, compositions, or combinations also utilize isotopically-labelled compounds useful in an invention method, composition, or combination, which are identical to those recited above, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds utilized in an invention method, composition, or combination include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as ’H,%H, Be, Hc,
BN, 130, 170, 3p, 2p, 35 S, 8g and 3%, respectively. Compounds and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms may be utilized in an invention method, composition, or combination. Certain isotopically labelled compounds utilized in an invention method, composition, or combination, for example those into which radioactive isotopes such as *H and 'C are incorporated, are useful in drug and/or substrate tissue distribution assays.
Tritiated, i.e., ’H and carbon-14, i.e., C, isotopes are known for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be utilized in some circumstances.
Isotopically labelled compounds of those described above in an invention method, composition, or combination can generally be prepared by carrying out the procedures incorporated by reference above and below, or procedures disclosed in the Schemes and/or in the Examples and Preparations, if any, disclosed herein, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent. ’
As mentioned above, an aspect of the invention is a method that prevents or inhibits cartilage tissue damage. The ability of the compounds useful in an invention method, composition, or combination to prevent or inhibit cartilage damage may be evidenced by the beneficial effects of the active compounds on synovial changes and lesions on tibial plateaus, and reduced damage to femoral condyles and tibial plateaus. Additional evidence may include the active compounds’ beneficial effects on proteoglycan content of a joint.
The compounds useful in an invention method, composition, or combination can also be used in combination with existing therapeutic agents for the treatment of osteoarthritis or rheumatoid arthritis, or the alleviation of pain.
Suitable agents to be used in combination include standard non-steroidal anti- inflammatory agents (hereinafter NSAID’s) such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, COX-2 inhibitors such as celecoxib (tradename CELEBREX® by G. D. Searle & Co., Skokie,
Illinois), valdecoxib (tradename BEXTRA® by Pharmacia & Upjohn Company,
North Peapack, New Jersey), etoricoxib (tradename ARCOXIA® by Merck &
Co., Inc., Whitehouse Station, New Jersey), lumiracoxib (tradename PREXIGE® by Novartis AG, Basel, Switzerland), parecoxib, and rofecoxib (tradename
VIOXX® by Merck & Co., Inc., Whitehouse Station, New Jersey), deracoxib (tradename DERAMAXX® by Novartis AG, Basel, Switzerland), and carprofen analgesics and intraarticular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc.
Another aspect of the invention relates to a method of, and a pharmaceutical composition for, treating inflammatory processes and diseases comprising administering an active compound, composition, or combination to a mammal, including a human, cat, livestock or dog, wherein said inflammatory processes and diseases are defined as above and said compound is used in combination with one or more other therapeutically active agents under the following conditions:
A.) where a joint has become seriously inflamed as well as infected at the same time by bacteria, fungi, protozoa and/or virus, said inhibitory combination is administered in combination with one or more antibiotic, antifungal, antiprotozoal and/or antiviral therapeutic agents;
B.) where a multi-fold treatment of pain and inflammation is desired, said inhibitory combination is administered in combination with inhibitors of other mediators of inflammation, comprising one or more members independently selected from the group consisting essentially of: (1) NSAIDs; (2) H; -receptor antagonists; (3) kinin-B; - and B; -receptor antagonists; (4) prostaglandin inhibitors selected from the group consisting of PGD-,
PGF- PGI; - and PGE-receptor antagonists; (5) thromboxane A; (TXA;-) inhibitors; (6) 5-, 12- and 15-lipoxygenase inhibitors; (7) leukotriene LTC, -, LTD4/LTE, - and LTB, inhibitors; (8) PAF-receptor antagonists; (9) gold in the form of an aurothio group together with one or more hydrophilic groups; (10) immunosuppressive agents selected from the group consisting of cyclosporine, azathioprine and methotrexate; (11) anti-inflammatory glucocorticoids; (12) penicillamine; (13) hydroxychloroquine; (14) anti-gout agents including colchicine; xanthine oxidase inhibitors including allopurinol; and uricosuric agents selected from probenecid, sulfinpyrazone and benzbromarone;
C. where older mammals are being treated for disease conditions, syndromes and symptoms found in geriatric mammals, said inhibitory combination is administered in combination with one or more members independently selected from the group consisting essentially of:
(1) cognitive therapeutics to counteract memory ioss and impairment; (2) anti-hypertensives and other cardiovascular drugs intended to offset the consequences of atherosclerosis, hypertension, myocardial ischemia, angina, congestive heart failure and myocardial infarction, selected from the group consisting of: a. diuretics; b. vasodilators; c. B-adrenergic receptor antagonists; d. angiotensin-II converting enzyme inhibitors (ACE-inhibitors), alone or optionally together with neutral endopeptidase inhibitors; e. angiotensin II receptor antagonists; f. renin inhibitors; g. calcium channel blockers; ) h. sympatholytic agents; i. 0p-adrenergic agonists;
Jj. a-adrenergic receptor antagonists; and k. HMG-CoA -reductase inhibitors (anti-hypercholesterolemics); (3) antineoplastic agents selected from: a. antimitotic drugs selected from: i. vinca alkaloids selected from:
[1] vinblastine and
[2] vincristine; (4) growth hormone secretagogues; (5) strong analgesics; (6) local and systemic anesthetics; and (7) H; -receptor antagonists, proton pump inhibitors and other gastroprotective agents.
The compounds useful in an invention method, composition, or combination may be administered in combination with inhibitors of other mediators of inflammation, comprising one or more members selected from the group consisting essentially of the classes of such inhibitors and examples thereof which include, matrix metalloproteinase inhibitors, aggrecanase inhibitors, TACE inhibitors, leucotriene receptor antagonists, IL-1 processing and release inhibitors,
ILra, H, -receptor antagonists; kinin-B; - and B; -receptor antagonists; prostaglandin inhibitors such as PGD-, PGF- PGI, - and PGE-receptor antagonists; thromboxane A; (TXA2-) inhibitors; 5- and 12-lipoxygenase inhibitors; leukotriene LTCy4 -, LTD4/LTE, - and LTB, -inhibitors; PAF-receptor antagonists; MEK inhibitors; IKK inhibitors; MKX inhibitors; gold in the form of an aurothio group together with various hydrophilic groups; immunosuppressive agents, e.g., cyclosporine, azathioprine and methotrexate; anti-inflammatory glucocorticoids; penicillamine; hydroxychloroquine; anti-gout agents, e.g., colchicine, xanthine oxidase inhibitors, e.g., allopurinol and uricosuric agents, e.g., probenecid, sulfinpyrazone and benzbromarone.
The compounds useful in an invention method, composition, or combination may also be used in combination with anticancer agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine and antimetabolites such as methotrexate.
The compounds useful in an invention method, composition, or combination may also be used in combination with anti-hypertensives and other cardiovascular drugs intended to offset the consequences of atherosclerosis, including hypertension, myocardial ischemia including angina, congestive heart failure and myocardial infarction, selected from vasodilators such as hydralazine, f-adrenergic receptor antagonists such as propranolol, calcium channel blockers such as nifedipine, o;-adrenergic agonists such as clonidine, a-adrenergic receptor antagonists such as prazosin and HMG-CoA-reductase inhibitors (anti- hypercholesterolemics) such as lovastatin or atorvastatin.
The compounds useful in an invention method, composition, or combination may also be administered in combination with one or more antibiotic, antifungal, antiprotozoal, antiviral or similar therapeutic agents.
The compounds useful in an invention method, composition, or combination may also be used in combination with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as L-dopa, requip, mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, nicotine agonists, dopamine agonists and inhibitors of neuronal nitric oxide synthase) and anti-Alzheimer’s drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.
The compounds useful in an invention method, composition, or combination may also be used in combination with osteoporosis agents such as roloxifene, lasofoxifene, droloxifene or fosomax and immunosuppressant agents such as FK-506 and rapamycin.
Other mammalian diseases and disorders which are treatable by administration of an invention combination alone, or contained in a pharmaceutical composition as defined below, include: fever (including rheumatic fever and fever associated with influenza and other viral infections), common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn’s disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, Alzheimer’s disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer (such as solid tumor cancer including colon cancer, breast cancer, lung cancer and prostrate cancer; hematopoietic malignancies including leukemias and lymphomas;
Hodgkin's disease; aplastic anemia, skin cancer and familiar adenomatous polyposis), tissue ulceration, peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis, recurrent gastrointestinal lesion, gastrointestinal bleeding, coagulation, anemia, synovitis, gout, ankylosing spondylitis, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plague rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), periarteritis nodosa, congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuralgia, neuro-degenerative disorders (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson’s disease, migraine, depression, peripheral neuropathy, pain (including low back and neck pain, headache and toothache), gingivitis, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, conjunctivitis, abnormal wound healing, muscle or joint sprains or strains, tendonitis, skin disorders (such as psoriasis, eczema, scleroderma and dermatitis), myasthenia gravis, polymyositis, myositis, bursitis, burns, diabetes (including types I and TI diabetes, diabetic retinopathy, neuropathy and nephropathy), tumor invasion, tumor growth, tumor metastasis, corneal scarring, scleritis, immunodeficiency diseases (such as AIDS in humans and FLV, FIV in cats), sepsis, premature labor, hypoprothrombinemia, hemophilia, thyroiditis, sarcoidosis, Behcet's syndrome, hypersensitivity, kidney disease, Rickettsial infections (such as Lyme disease, Erlichiosis), Protozoan diseases (such as malaria, giardia, coccidia), reproductive disorders (for example in livestock), epilepsy, convulsions, and septic shock.
The substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds : disclosed herein are useful in human and veterinary medicines for preventing and treating osteoarthritis, preventing and treating rheumatoid arthritis, improving joint function, alleviating pain, including, but not limited to, OA pain, RA pain, joint pain, inflammatory pain, acute pain, chronic pain, bone cancer pain, pain mediated by IL-6, IL-6sR, or a combination of IL-6 and IL-6sR, pain mediated by endothelin-1, static allodynia, dynamic allodynia, mechanical pain, headache pain, and the like, and preventing and inhibiting cartilage damage in a mammal, and for treating any other disease or disorder wherein cartilage damage is a symptom or is involved in the underlying pathology of the condition being treated.
The terms and phrases used herein are as defined below or as they otherwise occur in the specification.
The phrase “substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound” is synonymous with the phrase “active compound,” which refers to a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound that is useful in an invention method, composition, or combination, or a pharmaceutically acceptable salt thereof, or any other form thereof that is described herein. A substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound is any compound, including a cyclic ether, as described above, including oxo-substituted ether compounds wherein the ether oxygen atom comprises a functional group of the formula (A):
Oo % PN (A) and oxo-substituted thioether compounds, which are substituted dialkyl sulfoxides or substituted dialkyl sulfones.
It should be appreciated that any compound described herein as an active compound may be used in any invention method, composition, or combination.
It should be appreciated that the substituted dialkyl ether named 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid may be represented by the structure drawn below: 0] Oo eo SS
H,C CH, H,C CH,
The substituted dialkyl ether named 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt, may be represented by the structure drawn below: 0] oO 2-
AAAS A | Ca?
H,C CH; H,C CH;
The substituted dialkyl ether named 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt is known by other names, including “6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, monocalcium salt,” “6-~ (5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, mono-calcium salt, “ 6,6’-0xybis(2,2-dimethylhexanoic acid),” “CI-1027” and gemcabene calcium. CI- 1027 has been in clinical development for the treatment of dyslipidemia. CI-1027 is a substituted dialkyl ether as defined herein that is a monocalcium salt.
It should be appreciated that the substituted dialkyl ether named 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt may exist in a number of different physical forms, including Crystal Form 1 and Crystal
Form 2. Crystal Form 1 and Crystal Form 2 of the substituted dialkyl ether named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt have been disclosed in PCT International Patent Application Publication No. WO 01/55078. The use of each of these crystal forms is within the scope of this invention method.
Crystal Form 1 has an x-ray powder diffraction pattern substantially comprising: # 2Theta d(A) Peak P% Area Area% FWHM "1 6.760 130648 5106 100.0 1497 1000 0.234 2 8.183 10.7953 1743 34.1 435 29.1 0.200 3 8.560 10.3207 1866 36.5 543 36.3 0.233 4 9.239 9.5638 234 4.6 29 1.9 0.096 5 9.760 9.0546 972 19.0 220 14.7 0.181 6 10.569 8.3634 156 3.1 12 0.8 0.061 - 7 11.141 7.9353 178 3.5 29 1.9 0.130 8 13.760 6.4304 266 5.2 46 3.1 0.138 9 15.599 5.6761 338 6.6 63 4.2 0.148 16.740 5.2917 433 8.5 64 4.3 0.118 11 17.420 5.0866 1890 37.0 689 46.0 0.291 12 20.639 4.3000 523 10.2 128 8.5 0.196 13 21391 4.1505 188 37 20 13 0.085 14 22.139 4.0119 445 8.7 74 4.9 0.132 31.559 2.8326 270 5.3 24 1.6 0.070
Crystal Form 2 has an x-ray powder diffraction pattern substantially comprising: # 2Theta d(A) Peak P% Area Area% FWHM “1 7.259 12.1686 9283 100.0 2482 100.0 0214 2 8.739 10.1100 4191 45.1 603 243 0.115 3 9.386 8.9628 967 10.4 161 6.5 0.133 4 11.659 7.5838 430 4.6 49 1.9 0.089 13955 6.3408 305 33 58 23 0.151 6 14220 6.2233 326 3.5 73 2.9 0.178 7 15.387 5.7537 278 3.0 19 0.7 0.053 8 16461 5.3806 986 10.6 187 7.5 0.152 9 17361 5.1039 1490 16.1 348 14.0 0.187 18.063 4.9069 1284 13.8 323 13.0 0.201 11 19.302 4.5947 871 9.4 166 6.7 0.152 12 19.862 4.4664 686 7.4 142 5.7 0.166 13 20200 4.3923 457 4.9 103 4.1 0.179 14 21.178 4.1918 656 7.1 97 3.9 0.117 21.641 4.1031 167 1.8 6 0.2 0.029 16 22.300 3.9833 794 8.6 192 7.7 0.193 17 23.218 3.8278 247 2.7 23 0.9 0.071 18 24.100 3.6897 183 2.0 34 13 0.145 19 25481 3.4928 487 5.2 141 5.7 0.231 28.800 3.0974 134 14 14 0.6 0.083 21 29.297 3.0459 259 2.8 28 1.1 0.084 22 30.700 2.9099 287 3.1 20 0.8 0.055
It should be appreciated that the substituted dialkyl ether named 6-(5- 5 carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, may further exist as a hydrate, known by the name 6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-hexanoic acid, monocalcium salt hydrate in PCT International Patent
Application Publication No. WO 01/55078. The use of this or another hydrate form is within the scope of this invention method.
It should be appreciated that the substituted dialkyl ether named 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, may further exist'as a C{-C,; alcohol solvate, including an ethyl alcohol, methanol, 1- propyl alcohol, 2-propyl alcohol, or 1-butyl alcohol solvate, known by the names 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, mono-calcium salt ethyl alcohol solvate, 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, mono-calcium salt methanol solvate, 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, monocalcium salt 1-propyl alcohol solvate, 6-(5-carboxy- 5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, monocalcium salt 2-propyl alcohol solvate, 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, monocalcium salt 1-butyl alcohol solvate, respectively, in PCT International
Patent Application Publication No. WO 01/55078. The use of these and other alcohol solvate forms is within the scope of this invention method.
The phrase “therapeutic biological agent” includes CP-870, etanercept (a tumor necrosis factor alpha (“TNF-alpha”) receptor immunoglobulin molecule; trade names ENBREL® and ENBREL ENTANERCEPT® by Immunex
Corporation, Seattle, Washington), infliximab (an anti-TNF-alpha chimeric IgG 1K monoclonal antibody; tradename REMICADE® by Centocor, Inc., Malvern,
Pennsylvania), methotrexate (tradename RHEUMATREX® by American
Cyanamid Company, Wayne, New Jersey), and adalimumab (a human monoclonal anti-TNF-alpha antibody; tradename HUMIRA® by Abbott
Laboratories, Abbott Park, Illinois).
The term “Etanercept” means a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (“p75”) tumor necrosis factor receptor (“TNFR”) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the Cy2 domain, the C3 domain and hinge region, but not the Cyz1 domain of IgG1. Etanercept is produced by recombinant
DNA technology in a Chinese hamster ovary (“CHO”) mammalian cell expression system. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons. Etanercept is an inhibitor of tumor necrosis factor alpha (“TNFalpha”).
Etanercept is marketed in the United States under the tradename
ENBREL® and ENBREL ENTANERCEPT® for the treatment of rheumatoid arthritis and psoriatic arthritis. ENBREL® and ENBREL ENTANERCEPT® are registered by Immunex Corporation, Seattle, Washington. ENBREL® is supplied as a sterile, white, preservative-free, lyophilized powder for parenteral administration after reconstitution with 1 mL of the supplied Sterile Bacteriostatic
Water for Injection, USP (containing 0.9% benzyl alcohol). Following reconstitution, the solution of ENBREL® is clear and colorless, with a pH of ‘ 7.4 + 0.3. Each single-use vial of ENBREL® contains 25 mg etanercept, 40 mg mannitol, 10 mg sucrose, and 1.2 mg tromethamine.
The term “infliximab” includes the product marketed in the United States under the tradename REMICADE® for the treatment of rheumatoid arthritis.
REMICADER® is registered by Centocor, Inc., Malvern, Pennsylvania.
The term “methotrexate” includes a compound named N-[4-[[(2,4- diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, or a pharmaceutically acceptable salt thereof. Methotrexate is used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. For example, Methotrexate Sodium Tablets for oral administration are available in a packaging system designated as the RHEUMATREX® Methotrexate Sodium
Dose Pack for therapy with a weekly dosing schedule of 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg of methotrexate and the following pharmaceutically acceptable excipients, diluents, or carriers: lactose, magnesium stearate, and pregelatinized starch. RHEUMATREX® is registered by American Cyanamid
Company, Wayne, New Jersey. The tablets may also contain cornstarch.
Methotrexate is also administered by injection intramuscularly, intravenously, intra-arterially, or intrathecally.
It should be appreciated that COX-2 is also known as prostaglandin synthase-2, prostaglandin PGH, synthase, and prostaglandin-H; synthase-2.
A selective inhibitor of COX-2 means compounds that inhibit COX-2 selectively versus COX-1 such that a ratio of ICs for a compound with COX-1 divided by a ratio of ICsq for the compound with COX-2 is greater than, or equal to, 5, where the ratios are determined in one or more assays. All that is required to determine whether a compound is a selective COX-2 inhibitor is to assay a compound in one of a number of well know assays in the art.
It should be appreciated that two forms of cyclooxygenase (“COX”) are now known, namely a constitutive isoform usually named cyclooxygenase-1 (“COX-17) and an inducible isoform usually named cyclooxygenase-2 (“COX- 27), the latter of which expression is upregulated at sites of inflammation. COX-1 appears to play a physiological role and to be responsible for gastrointestinal and renal protection. On the other hand, COX-2 appears to play a pathological role and is believed to be the predominant isoform present in inflammation conditions.
The therapeutic use of conventional COX inhibitors, which are typically nonselective inhibitors of both COX-1 and COX-2, is limited due to drug associated side effects, including life threatening ulceration and renal toxicity.
Compounds that selectively inhibit COX-2 would exert anti-inflammatory effects without the adverse side effects associated with COX-1 inhibition.
For the purposes of this invention, a selective inhibitor of COX-2 includes a compound, or a pharmaceutically acceptable salt thereof, selected from:
LAS-34475;
UR-8880; }
ABT-963;
Valdecoxib;
BMS-347070;
Celecoxib;
Tilacoxib;
The compound of formula (B)
F
H,N—S=0 2: AY
CS-502 [Chemical Abstracts Service Registry Number (“CAS Reg. No.”) 176429-82-6];
(6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6- dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid (“CT-3");
CV-247, 2(5H)-Furanone, 5,5-dimethyl-3-(1-methylethoxy)-4-[4- (methylsulfonyl)phenyl]- (“DFP”); }
Carprofen (trade name RIMADYL® by Pfizer, Inc., New York, New
York);
Deracoxib (tradename DERAMAXX® by Novartis AG, Basel,
Switzerland);
Etoricoxib (tradename ARCOXIA® by MERCK & CO., Inc., Whitehouse
Station, New Jersey);
GW-406381;
Tiracoxib;
Meloxicam;
Nimesulide; 2-(Acetyloxy)benzoic acid, 3-[(nitrooxy)methyl]phenyl ester (“NCX- 4016™);
Lumiracoxib (tradename PREXIGE® by Novartis AG, Basel,
Switzerland);
Parecoxib (trade name application pending for DYNASTAT® by G. D.
Searle & Co., Skokie, Hlinois);
P54 (CAS Reg. No. 130996-28-0);
Rofecoxib (tradename VIOXX® by MERCK & CO., Inc., Whitehouse
Station, New Jersey);
RevIMiD; 2,6-Bis(1,1-dimethylethyl)-4-[(E)-(2-ethyl-1,1-dioxo-5- isothiazolidinylidene)methyl]phenol (“S-2474"); 5(R)-Thio-6-sulfonamide-3(2H)-benzofuranone (“SVT-2016"); and
N-[3-(Formylamino)-4-oxo0-6-phenox y-4H-1-benzopyran-7-yll- methanesulfonamide (“T-614""); or a pharmaceutically acceptable salt thereof.
The term “celecoxib” means the compound named 4-(5-(4-methylphenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl)-benzenesulfonamide. Celecoxib is a selective cyclooxygenase-2 (“COX-2") inhibitor currently approved by the FDA for the treatment of osteoarthritis, rheumatoid arthritis, and Polyposis-familial adenomatus. Celecoxib is marketed under the tradename “CELEBREX®”.
Celecoxib is currently in clinical trials for the treatment of bladder cancer, chemopreventative-lung cancer, and post-operative pain, and is registered for the treatment of dysmenorrhea. Celecoxib has the structure drawn below: 0 CF
Ni N
HN =
HC
The term “valdecoxib” means the compound named 4-(5-methyl-3-phenyl- 4-isoxazolyl)-benzenesulfonamide, which is described in U.S. patent nos. 5,633,272; 5,859,257; and 5,985,902, which are hereby incorporated by reference herein. Valdecoxib has been approved by the FDA for treating osteoarthritis, rheumatoid arthritis, dysmenorrhea, and general pain, and is marketed under the tradename “BEXTRA®”. Valdecoxib is in clinical trials for the treatment of migraine. Valdecoxib has the structure drawn below:
H,C
Cn 4 o
NO
7”
HN" \ > 0 :
It should also be appreciated that carprofen and deracoxib are each indicated for the treatment of arthritis in an animal, especially a dog.
It should be appreciated that the terms “uses”, “utilizes”, and “employs”, and their derivatives thereof, are used interchangeably when describing an aspect of an invention method, composition, or combination. .
The terms “including,” “having,” and “containing” are open ended unless otherwise indicated.
The phrase “admixed” or “in admixture” means the ingredients so mixed comprise either a heterogeneous or homogeneous mixture. In some circumstances a homogeneous mixture is preferred. In other circumstances, a heterogeneous mixture is preferred.
The term “ED4o”” means the dose of a drug, including an active compound, or a pharmaceutically acceptable salt thereof, that is sufficient to inhibit cartilage damage or treat a disease or disorder listed above, in at least 40% of the patients being treated.
The term “drug”, which is synonymous with the phrases “therapeutic agent”, “active cornponent”, “active compound”, and “active ingredient”, includes a nontoxic therapeutic agent such as an active compound, celecoxib, or a pharmaceutically acceptable salt thereof, valdecoxib, or a pharmaceutically acceptable salt thereof, and may further include one or two of the other therapeutic agents described above.
The term “nontoxic” means the efficacious dose is 10 times or greater than the dose at which a toxic effect is observed in 10% or more of a patient population.
The term “patient” means a mammal, and the two terms are used interchangeably herein.
For the purposes of this invention, the term “mammal” includes humans, companion animals such as cats and dogs, livestock animals such as horses, cows, pigs, goats, and sheep, and laboratory animals such as guinea pigs, rabbits, rats, mice, hamsters, and monkeys, and transgenic variants thereof. A human patient is preferred. Also preferred are companion animals, particularly dogs, cats, and horses. Also preferred are laboratory animals, particularly rabbits, rats, mice, and monkeys, and transgenic variants thereof,
The phrase “companion animals” includes dogs, cats, rabbits, hamsters, monkeys, horses, and other household or barnyard pets.
The phrase “livestock animals” as used herein refers to domesticated quadrupeds, which includes those being raised for meat and various byproducts, e.g., a bovine animal including cattle and other members of the genus Bos, a porcine animal including domestic swine and other members of the genus Sus, an ovine animal including sheep and other members of the genus Ovis, domestic goats and other members of the genus Capra; domesticated quadrupeds being raised for specialized tasks such as use as a beast of burden, e.g., an equine animal including domestic horses and other members of the family Equidae, genus
Equus, or for searching and sentinel duty, e.g., a canine animal including domestic dogs and other members of the genus Canis; and domesticated quadrupeds being raised primarily for recreational purposes, e.g., members of Equus and Canis, as well as a feline animal including domestic cats and other members of the family
Felidae, genus Felis.
For the purposes of this invention, the term “arthritis” includes osteoarthritis, rheumatoid arthritis, degenerative joint disease, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus, juvenile arthritis, and psoriatic arthritis. The substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in an invention method, composition, or combination may also be useful for treating degenerative joint disease, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus, juvenile arthritis, and psoriatic arthritis.
The phrase “cartilage damage” means a disorder of articular cartilage and subchondral bone characterized by hypertrophy of tissues in and around an involved joint, which may or may not be accompanied by deterioration of articular cartilage surface. As used herein, the phrase cartilage damage relates to damage to joint cartilage.
Tt should be appreciated that cartilage is a multicellular tissue found at joint linings and in other parts of the body, including the nose, for example.
Cartilage tissue provides frictionless surfaces for joint movement, and structure and support for soft tissue features of the body such as the nostrils of the nose.
When cartilage tissue is damaged by disease or trauma, breakdown products are formed and the physiological function of the tissue is impaired. There principally are three types of cartilage in a body, including articular cartilage.
The phrase “inhibiting cartilage damage” means the therapeutic effect of a compound, or a combination as described above, that eliminates, alleviates, inhibits or prevents the onset of, inhibits the progress of, prevents further progress of, or reverses progression of, in part or in whole, any one or more pathological hallmarks or symptoms of cartilage damage observed for any of the diseases and disorders which have cartilage damage as a component of the disease or disorder pathology. A patient at risk for developing cartilage damage may be prophylactically treated just as a patient having cartilage damage may be medically treated.
It should be appreciated that a pathological hallmark of a disease or disorder relates to a structural change in a body that is a direct or indirect result of the body being afflicted with the disease or disorder. Such structural changes may be identified by clinical observation, examination of biopsied tissue, pathological examination or by imaging techniques such as X-ray or magnetic resonance imaging, of the affected structure. Nlustrative examples of a pathological hallmark include histopathological damage to cartilage, thickening or thinning of bone, hypertrophy of muscle, fibrosis, a tear in a ligament or tendon, and the like.
The term “osteoarthritis” includes diseases of the joint principally characterized by the pathological hallmark of joint cartilage damage, and optionally the symptom of joint pain. Osteoarthritis patients typically do not suffer from inflammation of the joint, although they may experience transient inflammatory flares from time to time.
The term “rheumatoid arthritis” includes rheumatic diseases of the joint principally characterized by the symptom of joint inflammation, and optionally joint pain. Rheumatoid arthritis patients may eventually also experience damage to joint cartilage.
The term “treating” means administration of one or more of the compounds or combinations according to the invention method as defined above that eliminates, alleviates, inhibits or prevents the onset of, inhibits the progress of, prevents further progress of, or reverses progression of, in part or in whole, any one or more of the pathological hallmarks or symptoms of any one of the diseases and disorders being treated, including, but not limited to, the pathological hallmark of cartilage damage and the symptoms of pain and inflammation. A patient at risk for developing a disease or disorder may be prophylactically treated just as a patient having the disease or disorder may be medically treated.
The term “preventing” means prophylactic administration, according to the invention method as defined above, of one or more of the active compounds or combinations of the invention, to an asymptomatic patient at risk for the disease or disorder being prevented to inhibit the onset of an associated pathological hallmark or symptom, including, but not limited to, the pathological hallmark of cartilage damage and the symptoms of pair and inflammation. Further, once onset of a pathological hallmark or symptom has begun, preventing means to prevent further progression or reverse progression, in part or in whole, of the pathological hallmark or symptom.
As mentioned above, an active compound may be administered prophylactically to prevent or inhibit the onset of osteoarthritis, rheumatoid arthritis, loss of joint function, cartilage damage, or any pain in an asymptomatic patient (mammal). It should be appreciated that an asymptomatic patient at risk for the disease or disorder being prevented may be identified by analysis of genetic risk factors (inherited or spontaneous mutation diseases and disorders), family medical history, occupation, participation in athletic activities, general medical screening, and the like.
The term “improving” means administration of one or more of the compounds or combinations according to the invention method as defined above that eliminates or prevents the loss, inhibits further loss, or improves, in part or in whole, of any one or more of the clinical measures of a function in a patient suffering from any one of the diseases and disorders being improved, including, but not limited rheumatoid arthritis and osteoarthritis.
The phrase “joint function” relates to any one or more of the clinical assessments of joint function, including stiffness, range of movement, flexibility, and movement-related symptoms (e.g., altered gait, pain, warmth, or inflammation), in a patient suffering from any one of the diseases and disorders being improved, including, but not limited the diseases of rheumatoid arthritis and osteoarthritis. The Western Ontario and McMaster Universities Osteoarthritis
Index (“WOMAC”) may be used by a clinician to assess joint function.
The phrase “pain alleviating” means the effect of one or more of the compounds or combinations according to the invention method as defined above that eliminates, or inhibits or prevents onset of, suppresses, reduces, prevents, or otherwise inhibits, pain in a patient, including, but not limited to, the suppression, reduction, prevention, inhibition or elimination of pain symptoms due to cartilage damage, acute pain, chronic pain, mechanical pain, static allodynia, dynamic allodynia, bone cancer pain, headache, osteoarthritic pain, inflammatory pain, and pain associated with autoimmune disorders or fibromyalgia.
The phrase “joint pain” means any pain in a joint.
The phrase “osteoarthritic pain” means joint pain in an osteoarthritic joint.
The phrase “rheumatoid arthritic pain’ means joint pain in a rheumatoid arthritic joint.
The phrase “inflammatory pain” means pain due to edema or swelling of any inflamed tissue, including inflammatory joint pain. Inflammatory joint pain includes rheumatoid arthritic pain.
The phrase “mechanical pain” means a pain related to an injury or damage to a structure of a body, including osteoarthritic pain, surgical pain, burn pain, bone cancer pain, and the like.
The phrase “acute pain” means any pain, including, but not limited to, joint pain, osteoarthritic pain, rheumatoid arthritic pain, inflammatory pain, pain from a bum, pain from a cut, surgical pain, pain from fibromyalgia, bone cancer pain, menstrual pain, back pain, headache, static allodynia, and dynamic allodynia, that lasts from 1 minute to 91 days, 1 minute to 31 days, 1 minute to 7 days, 1 minute to 5 days, 1 minute to 3 days, 1 minute to 2 days, 1 hour to 91 days, 1 hour to 31 days, 1 hour to 7 days, 1 hour to 5 days, 1 hour to 3 days, 1 hour to 2 days, 1 hour to 24 hours, 1 hour to 12 hours, or 1 hour to 6 hours, per occurrence if left untreated. Acute pain includes, but is not limited to, joint pain, osteoarthritic pain, rheumatoid arthritic pain, inflammatory pain, pain from a burn, pain from a cut, surgical pain, pain from fibromyalgia, bone cancer pain, menstrual pain, back pain, headache, static allodynia, dynamic allodynia, acute joint pain, acute osteoarthritic pain, acute rheumatoid arthritic pain, acute inflammatory pain, acute headache, acute menstrual pain, acute back pain, and acute pain from fibromyalgia. Acute pain may be selected from acute joint pain, acute osteoarthritic pain, acute rheumatoid arthritic pain, acute inflammatory pain, acute headache, acute menstrual pain, and acute back pain. Acute pain may be selected from acute joint pain, acute osteoarthritic pain, acute rheumatoid arthritic pain, and acute inflammatory pain. Acute pain may be selected from acute joint pain, acute osteoarthritic pain, and acute rheumatoid arthritic pain. Acute pain may be selected from acute joint pain and acute osteoarthritic pain.
It should be appreciated that alleviating acute pain means having an appreciable pain alleviating effect within 91, 31, 7, 5, 3, or 2 days, or 24, 12, 6, 3, 2,1, 0.5, 0.25, 0.20. 0.17, or 0.10 hours after administering the first dose of an active compound or combination comprising the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound and another active ingredient.
The phrase “chronic pain” means any pain, including, but not limited to, joint pain, osteoarthritic pain, rheumatoid arthritic pain, inflammatory pain, pain from a burn, pain from a cut, surgical pain, pain from fibromyalgia, bone cancer pain, menstrual pain, back pain, headache, static allodynia, dynamic allodynia, chronic joint pain, chronic osteoarthritic pain, chronic rheumatoid arthritic pain, chronic inflammatory pain, chronic headache, chronic back pain, and chronic pain from fibromyalgia that lasts longer than 91 days, 6 months, 1 year, 5 years, or 10 years per occurrence if left untreated. Chronic pain may be selected from chronic joint pain, chronic osteoarthritic pain, chronic rheumatoid arthritic pain, chronic inflammatory pain, chronic headache, chronic back pain, and chronic pain from fibromyalgia. Chronic pain may be selected from chronic joint pain, chronic osteoarthritic pain, chronic rheumatoid arthritic pain, chronic inflammatory pain, chronic headache, and chronic back pain. Chronic pain may be selected from chronic joint pain, chronic osteoarthritic pain, chronic rheumatoid arthritic pain, and chronic inflammatory pain. Chronic pain may be selected from chronic joint pain, chronic osteoarthritic pain, and chronic rheumatoid arthritic pain. Chronic pain may be selected from chronic joint pain and chronic osteoarthritic pain.
It should be appreciated that alleviating chronic pain means having an appreciable pain alleviating effect within 91, 60, 31, 28, 21, 14, 7, 3, or 2 days or 24,12,6,3,2,1,0.5, 0.25, 0.20. 0.17, or 0.10 hours after administering the first dose of an active compound or other active ingredient.
The phrase “wherein the pain is mediated by IL-6, IL-6sR, or IL-6 receptor” refers to pain in a patient that is alleviated by administering to the patient an inhibitor of the cytokine interleukin-6 (“IL-6”), its cell-bound receptor interleukin-6 receptor (“IL-6 receptor”), or interleukin-6 soluble receptor (“IL- 6sR”), which is an unbound cleavage fragment of IL-6 receptor that can bind to
IL-6. An inhibitor of pain mediated by IL-6, IL-6sR, or IL-6 receptor may also be identified by practicing the method of Biological Method 5 below. An IL-6, IL- 6sR, or IL-6 receptor inhibitor includes inhibitors of IL-6, IL-6sR, or IL-6 expression or biological activity and promoters of IL-6, IL-6sR, or IL-6 clearance, respectively.
It should be appreciated that pain substantially (>10%) resulting from a deficit of oxygen in an organ (e.g., brain, heart, or liver) is not embraced by any pain disclosed herein.
The phrases “therapeutically effective amount” and “effective amount” are synonymous and mean an amount of a compound or a combination as described above sufficient to alleviate, eliminate, inhibit or prevent the onset, or inhibit the progress, prevent further progress, or reverse progression, in part or in whole, of any one or more pathological hallmarks or symptoms of the disease or disorder that is appreciated or suspected or expected in the particular patient being treated.
It should be appreciated that a therapeutically effective or effective amount means an amount sufficient to have a desired effect in a patient to whom that amount has been administered. For illustrative example, where cartilage damage is being inhibited, a therapeutically effective amount includes a cartilage damage inhibiting effective amount. Where osteoarthritis is being treated, a therapeutically effective amount includes an osteoarthritis treating effective amount. Where pain is being alleviated, a therapeutically effective amount includes a pain alleviating effective amount. Where osteoarthritic or rheumatoid arthritic pain is being alleviated, a therapeutically effective amount includes an osteoarthritic or rheumatoid arthritic pain alleviating effective amount, respectively.
It should be appreciated that endothelin-1 is a member of a family of 21- residue peptides. The endothelin peptides are produced by a vast array of cell types in response to diverse stimuli, and are mediated through specific ET, and
ETjg receptors. Receptors of the ET 4 type exhibit higher affinity for endothelin-1 than endothelin-3, and can be selectively blocked by antagonists known in the art.
An active compound having an anti-inflammatory, an analgesic, anti- arthritic, or a cartilage damage inhibiting effect, or any combination of these effects, may be readily identified by one of ordinary skill in the pharmaceutical or medical arts by assaying the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound in any number of well known assays for measuring determining the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound's effects on cartilage damage, arthritis, inflammation, or pain. These assays include in vitro assays that utilize cartilage samples and in vivo assays in whole animals that measure cartilage degradation, inhibition of inflammation, or pain alleviation.
For example with regard to assaying cartilage damage in vitro, an amount of an active compound or control vehicle may be administered with a cartilage damaging agent to cartilage, and the cartilage damage inhibiting effects in both tests studied by gross examination or histopathologic examination of the cartilage, or by measurement of biological markers of cartilage damage such as, for example, proteoglycan content or hydroxyproline content. Further, in vivo assays to assay cartilage damage may be performed as follows: an amount of an active compound or control vehicle may be administered with a cartilage damaging agent to an animal, and the effects of the substituted dialkyl ether, substituted aryl- alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted- alkyl compound being assayed on cartilage in the animal may be evaluated by gross examination or histopathologic examination of the cartilage, by observation of the effects in an acute model on functional limitations of the affected joint that result from cartilage damage, or by measurement of biological markers of cartilage damage such as, for example, proteoglycan content or hydroxyproline content.
Several methods of identifying an active compound with cartilage damage inhibiting properties are described below. The amount to be administered in an assay is dependent upon the particular assay employed, but in any event is not higher than the well known maximum amount of a compound that the particular assay can effectively accommodate.
Similarly, substituted dialkyl ether, substituted aryl-alky] ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds having pain-alleviating properties may be identified using any one of a number of in vivo animal models of pain. A number of in vivo animal models of joint pain are known in the art, and a model of endothelin-1 mediated pain is described by
Piovezan, Anna P., et al., British Journal of Pharmacology, 2000;129:961-968, which is incorporated herein by reference.
Still similarly, substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds having anti-inflammatory properties may be identified using any one of a number of in vivo animal models of inflammation. For example, for an example of inflammation models, see United States Patent number 6,329,429, which is incorporated herein by reference.
Still similarly, substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds having anti-arthritic properties may be identified using any one of a number of in vivo animal models of arthritis. For example, for an example of arthritis models, see also United States Patent number 6,329,429.
In a clinical setting, a physician may assess a patients need for, or response to, treatment of osteoarthritis, rheumatoid arthritis, impaired joint function, pain, including osteoarthritic pain, rheumatoid arthritic pain, acute pain, joint pain, chronic pain, inflammatory pain, pain mediated by IL-6, IL-6sR, or IL-6 receptor, or mechanical pain by administering a standard assessment questionnaire such as
WOMAC or the Patient Global Impression of Change (“PGIC”).
Further with respect to the assessment of a patients need for, or response to, treatment of the aforementioned pain states and bone cancer pain, pain mediated by endothelin-1, static allodynia, and dynamic allodynia, the physician may apply a pain assessment scale such as the Visual Analog Scale (“VAS”), wherein a patient is asked to indicate a point on a 100 millimeter line, having a left anchor of no pain and a right anchor of worst possible pain, corresponding to their degree of pain or the Likert score, wherein a patient is asked to categorize their pain on a numerical scale of from 0 (no pain) to 10 (worst possible pain).
Compounds useful in an invention method, composition, or combination may be formulated alone or with one or more other therapeutic agents which are to form the intended combination, including wherein said different drugs have varying half-lives, by creating controlled-release forms of said drugs with different release times which achieves relatively uniform dosing; or, in the case of non-human patients, a medicated feed dosage form in which said drugs used in the combination are present together in admixture in the feed composition. There is further provided herein a method of co-administration in which the combination of drugs is achieved by the simultaneous, or non-simultaneous, sequential or concurrent, administration of said drugs to be given in combination; including co- administration by means of different dosage forms and routes of administration; or the use of combinations in accordance with different but regular and continuous dosing schedules whereby desired plasma levels of said drugs involved are maintained in the patient being treated, which may be achieved even though the individual drugs making up said combination are not being administered to said patient simultaneously.
In determining what constitutes a therapeutically effective amount of an active compound, or a pharmaceutically acceptable salt thereof, or a combination of the same with a selective COX-2 inhibitor, for alleviating pain, preventing or treating osteoarthritis, preventing or treating rheumatoid arthritis, improving joint function, or preventing or inhibiting cartilage damage according to the invention method, a number of factors will generally be considered by the medical practitioner or veterinarian in view of the experience of the medical practitioner or veterinarian, published clinical studies, the subject's (ie, mammal’s) age, sex, weight and general condition, as well as the type and extent of the disease, disorder or condition being treated, and the use of other medications, if any, by the subject. Such amounts will generally be from about 0.1 mg/kg to about 300 mg/kg of subject body weight. Typical doses will be from about 10 to about 5000 mg/day for an adult subject of normal weight. In a clinical setting, regulatory agencies such as, for example, the FDA in the United States may require a particular therapeutically effective amount.
As such, the administered dose may fall within the ranges or amounts recited above, or may vary outside, ie, either below or above, those ranges depending upon the requirements of the individual subject, the severity of the condition being treated, and the particular therapeutic formulation being employed. Determination of a proper dose for a particular situation is within the skill of the medical or veterinary arts. Generally, treatment may be initiated using smaller dosages of an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, or a combination of the same with another therapeutic agent, that are less than optimum for a particular subject.
Thereafter, the dosage can be increased by small increments until the optimum effect under the circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
The invention method may be conducted by administering an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, or a combination of the same with another therapeutic agent, either alone or formulated in a composition suitable for pharmaceutical administration.
Pharmaceutical compositions, described here briefly and more fully below, of an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, are produced by formulating the active compound in dosage unit form with a pharmaceutical carrier. Some examples of dosage unit forms are tablets, capsules, pills, powders, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses. .
Some examples of suitable pharmaceutical carriers, including pharmaceutical diluents, are gelatin capsules; sugars such as lactose and sucrose; starches such as corn starch and potato starch; cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate; gelatin; talc; stearic acid; magnesium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; propylene glycol, glycerin; sorbitol; polyethylene glycol; water; agar; alginic acid; isotonic saline, and phosphate buffer solutions; as well as other compatible substances normally used in pharmaceutical formulations.
The compositions to be employed in the invention can also contain other components such as coloring agents, flavoring agents, and/or preservatives. These materials, if present, are usually used in relatively small amounts. The compositions can, if desired, also contain other therapeutic agents commonly employed to treat osteoarthritis. Further, the compositions can, if desired, also contain other therapeutic agents commonly employed to treat secondary symptoms such as, for example, inflammation or pain that may or may not accompany cartilage damage. For example, the compositions may contain aspirin, naproxen, or similar anti-inflammatory analgesic agents.
The percentage of the active ingredients in the foregoing compositions can be varied within wide limits, but for practical purposes may be present in a concentration of at least 10% in a solid composition and at least 2% in a primary liquid composition, both up to about 95%.
Typical routes of administration of an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, or a combination of the same with another therapeutic agent, are oral or parenteral. For example, a useful intravenous dose is between 5 and 50 mg, and a useful oral dosage is between 20 and 800 mg. The dosage is within the dosing range used in treatment of diseases resulting in cartilage damage, loss of joint function, or pain such as rheumatoid arthritis and osteoarthritis, or as would be determined by the physician - 15 according to the needs of the patient as described above.
The substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound useful in the invention method, or a pharmaceutically acceptable salt thereof, or a combination of the same with another therapeutic agent as described above, may be administered in any form, including unit dosage form. A unit dosage form of the an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, to be used in this invention may also comprise other compounds useful in the therapy of diseases resulting in cartilage damage or loss of joint function.
The advantages of the instant invention include the relatively nontoxic nature of the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, their ease of preparation, the fact that the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds are well-tolerated, and the ease of IV and oral administration of the drugs.
Another important advantage is that the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method represent a new mechanistic treatment of arthritic pain and cartilage damage. This will be important to patients given the efficacy and/or safety limitations of current pharmacological treatments for OA, OA pain, RA pain, cartilage damage, and the like as described above. For example, it was found that 6-(5-carboxy-5-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt does not inhibit prostaglandin-F2a (“PGF2a’) expression from calcium ionophore-stimulated rat basophilic leukemia cells or leukotriene B4 (“LTB4”) expression from calcium ionophore-stimulated rat basophilic leukemia cells, and thus will not exhibit the gastrointestinal liabilities (e.g., gastric ulceration and bleeding, dyspepsia, etc.) of cyclooxygenase inhibitors such as naproxen or indomethacin or 5-lipoxygenase inhibitors.
Another important advantage is that the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method do not elevate blood pressure, which has been observed in some patients for the arthritic pain alleviating agent VIOXX®. For example, it was found that 6-(5-carboxy-5- methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt has no effect or perhaps even slightly (1-5 mmHg) decreases blood pressure in normal healthy humans.
Another important advantage is that the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method provide disease modifying activity for osteoarthritis and other diseases and disorders having cartilage damage as a component of their pathology. There is currently no recognized drug on the market that is approved for this treatment effect. Even further, this cartilage damage inhibiting effect and the OA and RA symptom (pain) treating effect are now found in one pharmacological agent, and the instant substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound may be administered once per day. If patients can take one drug instead of two and only one pill per day instead of two or more, patient compliance, and thus patient benefit, goes up.
Further, the instant invention may, if desired, allow the amount of an anti- inflammatory agent and/or pain relieving agent currently used in the treatment of patients suffering from cartilage damage and inflammation and/or pain to be reduced or even eliminated. It is known that anti-inflammatory and analgesic agents may produce undesirable side effects such as gastro-intestinal bleeding and ulceration. These side effects may be avoided, reduced or eliminated by using the instant invention to inhibit cartilage damage.
Intermediates for the synthesis of an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, useful in the invention method, and pharmaceutically acceptable salts thereof, may be prepared by one of ordinary skill in the art of organic chemistry by adapting various synthetic procedures that are well-known in the art of organic chemistry. These synthetic procedures may be found in the literature in, for example, Reagents for
Organic Synthesis, by Fieser and Fieser, John Wiley & Sons, Inc, New York, 2000; Comprehensive Organic Transformations, by Richard C. Larock, VCH
Publishers, Inc, New York, 1989; the series Compendium of Organic Synthetic
Methods, 1989 by Wiley-Interscience; the text Advanced Organic Chemistry, 4th edition, by Jerry March, Wiley-Interscience, New York,1992; or the Handbook of
Heterocyclic Chemistry by Alan R. Katritzky, Pergamon Press Ltd, London, 1985, to name a few. Alternatively, a skilled artisan may find methods useful for preparing the intermediates in the chemical literature by searching widely available databases such as, for example, those available from the Chemical
Abstracts Service, Columbus, Ohio, or MDL Information Systems GmbH (formerly Beilstein Information Systems GmbH), Frankfurt, Germany.
Preparations of the compounds useful in an invention method, composition, or combination may use starting materials, reagents, solvents, and catalysts that may be purchased from commercial sources or they may be readily prepared by adapting procedures in the references or resources cited above.
Commercial sources of starting materials, reagents, solvents, and catalysts useful in preparing substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds include, for example, The Aldrich Chemical Company, and other subsidiaries of
Sigma-Aldrich Corporation, St. Louis, Missouri, BACHEM, BACHEM AG,
Switzerland, or Lancaster Synthesis Ltd, United Kingdom.
Syntheses of some compounds useful in an invention method, composition, or combination may utilize starting materials, intermediates, or reaction products that contain a reactive functional group. During chemical reactions, a reactive functional group may be protected using protecting groups that render the reactive group substantially inert to the reaction conditions employed. A protecting group is introduced onto a starting material prior to carrying out the reaction step for which a protecting group is needed. Once the protecting group is no longer needed, the protecting group can be removed. It is well within the ordinary skill in the art to introduce protecting groups during a synthesis of an active compound, or a pharmaceutically acceptable salt thereof, and then later remove them. Procedures for introducing and removing protecting groups are known and referenced such as, for example, in Protective Groups in
Organic Synthesis, 2nd ed., Greene T.W. and Wuts P.G., John Wiley & Sons,
New York: New York, 1991, which is hereby incorporated by reference. Thus, for example, protecting groups such as the following may be utilized to protect amino, hydroxyl, and other groups: carboxylic acyl groups such as, for example, formyl, acetyl, and trifluoroacetyl; alkoxycarbonyl groups such as, for example, ethoxycarbonyl, tert-butoxycarbonyl (BOC), B,B,p-trichloroethoxycarbonyl (TCEC), and B-iodoethoxycarbonyl; aralkyloxycarbonyl groups such as, for example, benzyloxycarbonyl (CBZ), para-methoxybenzyloxycarbonyl, and 9-fluorenyimethyloxycarbonyl (FMOC); trialkylsilyl groups such as, for example, trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBDMS); and other groups such as, for example, triphenylmethyl (trityl), tetrahydropyranyl, vinyloxycarbonyl, : ortho-nitrophenylsulfenyl, diphenylphosphinyl, para-toluenesulfonyl (Ts), mesyl, trifluoromethanesulfonyl, and benzyl. Examples of procedures for removal of protecting groups include hydrogenolysis of CBZ groups using, for example, hydrogen gas at 50 psi in the presence of a hydrogenation catalyst such as 10% palladium on carbon, acidolysis of BOC groups using, for example, hydrogen chloride in dichloromethane, trifluoroacetic acid (TFA) in dichloromethane, and the like, reaction of silyl groups with fluoride ions, and reductive cleavage of
TCEC groups with zinc metal.
Preparations of an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, are incorporated by reference to the patents and patent application publications incorporated by reference above.
It should be appreciated that in the below studies, a dose in mg/kg means the weight in milligrams of test compound per weight of test animal body weight in kilograms.
It should be appreciated that in Biological Methods 1, 2, 4, and 5 below, hind paw weight bearing differentials between the paw of the limb having the control joint (in animals administered test compound vehicle only) and the paw of the limb having the contralateral test joint (in control or inducement animals administered test compound vehicle only and in treatment animals administered test compound dissolved in test compound vehicle) were determined using an incapacitance tester, model 2KG (Linton Instrumentation, Norfolk, United
Kingdom). The incapacitance tester has a chamber on top with an outwardly sloping front wall that supports a rat’s front limbs, and two weight sensing pads, one for each hind paw, that facilitates this determination. The hind paw weight bearing differentials were expressed in grams and calculated as follows: (the average weight in grams placed on the control limb minus the average weight in grams placed on the contralateral test limb for each of the inducement or treatment animals) minus (the average weight in grams placed on the control limb minus the average weight in grams placed on the contralateral test limb for each of the control animals). All results were statistically analyzed by comparing the average results for an induction or treatment group with the average result for its control group at the same time point using analysis of covariance (“ANCOVA”) followed by the Hoehberg’s procedure and those with statistical significance had p < 0.05 unless otherwise noted.
It should be appreciated that it is not necessary to use ANCOVA followed by Hochberg’s procedure to statistically analyze data in a method of this invention. Alternative statistical analyses are known that may be used such as
ANCOVA without Hochberg’s procedure, analysis of variance (“ANOVA”) with
Hochberg’s procedure, ANOVA without Hochberg’s procedure, t-test with ~ Hochberg’s procedure, and t-test without Hochberg’s procedure.
It should also be appreciated that the IL-6 and ILL-6sR used as described in all of the below examples was the commercially available recombinant human IL- 6 and human IL-6sR purchased from R&D Systems, Minneapolis, Minnesota.
It should also be appreciated that prior to injection of MIA in Biological : Methods 1, 2, and 4 or IL-6 plus IL-6sR in Biological Method 5, rats were anesthetized with 5% volume/volume (“v/v”) isoflurane gas until knocked down and maintained with 2% v/v isoflurane. Rats became fully conscious about 5 minutes after isoflurane administration was discontinued.
It should also be appreciated that in Biological Method 5, the cytokine vehicle comprised 0.5% HPMC plus 0.2% Tween 80 in water (“HPMC/Tween 807).
It will be shown below in Biological Method 5 that administration of 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt will inhibit (IL-6 plus IL-6sR)-induced pain.
The newly discovered ability of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, to inhibit cartilage damage, alleviate pain, and treat osteoarthritis has been established in animal models as described below.
BIOLOGICAL METHOD 1
Monosodium Iodoacetate-induced Osteoarthritis in Rat Model of Cartilage
Damage (“MIA Rat™):
One end result of the induction of osteoarthritis in this model, as determined by histologic analysis, is the development of an osteoarthritic condition within the affected joint, as characterized by the loss of Toluidine blue staining and formation of osteophytes. Associated with the histologic changes is a concentration-dependent degradation of joint cartilage, as evidenced by affects on hind-paw weight distribution of the limb having the affected joint, the presence of increased amounts of proteoglycan or hydroxyproline in the joint upon biochemical analysis, or histopathological analysis of the osteoarthritic lesions.
The hind-paw weight distribution effects reported below, or the effects that would be expected to be observed, for the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, result from, or would result from, the ability of substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl . ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, to directly inhibit damage to articular cartilage.
Generally, In the MIA Rat model on Day 0, the hind-paw weight differential between the right arthritic joint and the left healthy joint of male
Wistar rats (150 g) are determined with an incapacitance tester, model 2KG (Linton Instrumentation, Norfolk, United Kingdom). The incapacitance tester has a chamber on top with an outwardly sloping front wall that supports a rat’s front limbs, and two weight sensing pads, one for each hind paw, that facilitates this determination. Then the rats are anesthetized with isofluorine, and the right, hind leg knee joint is injected with 1.0 mg of mono-iodoacetate (“MIA”) through the infrapatellar ligament. Injection of MIA into the joint results in the inhibition of glycolysis and eventual death of surrounding chondrocytes. The rats are further administered either an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, or vehicle (in the instant case, water) daily for 14 days or 28 days. The substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound useful in the invention method, or a pharmaceutically acceptable salt thereof, is typically administered at a dose of 30 mg of substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound useful in the invention method, or a pharmaceutically acceptable salt thereof, per kilogram of rat per day (30 mg/kg/day), but may be administered at other doses such as, for example, 10 mg/kg/day, 60 mg/kg/day, 90-mg/kg/day, or 100 mg/kg/day according to the requirements of the compound being studied. It is well within the level of ordinary skill in the pharmaceutical arts to determine a proper dosage of an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, in this model. Administration of the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound useful in the invention method, or a pharmaceutically acceptable salt thereof, in this model is optionally by oral administration or intravenous administration via an osmotic pump. After 7 and 14 days for a two week study, or 7, 14, and 28 days for a four week study, the hind-paw weight distribution is again determined. Typically, the animals administered vehicle alone place greater weight on their unaffected left hind paw than on their right hind paw, while animals administered an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, show a more normal (i.e., more like a healthy animal) weight distribution between their hind paws. This change in weight distribution is proportional to the degree of joint cartilage damage. Percent inhibition of a change in hind paw joint function is calculated as the percent change in hind-paw weight distribution for treated animals versus control animals.
For example, for a two week study,
Percent inhibition of a change in hind paw weight distribution (AW¢) wherein:
AW is the hind-paw weight differential between the healthy left limb and the arthritic limb of the control animal administered vehicle alone, as measured on
Day 14; and
AWG is the hind-paw weight differential between the healthy left limb and the arthritic limb of the animal administered an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, as measured on
Day 14.
In order to measure biochemical or histopathological end points in the
MIA Rat model, some of the animals in the above study may be sacrificed, and the amounts of free proteoglycan in both the osteoarthritic right knee joint and the contralateral left knee joint may be determined by biochemical analysis. The amount of free proteoglycan in the contralateral left knee joint provides a baseline value for the amount of free proteoglycan in a healthy joint. The amount of : proteoglycan in the osteoarthritic right knee joint in animals administered an active compound useful in the invention method, and the amount of proteoglycan in the osteoarthritic right knee joint in animals administered vehicle alone, are independently compared to the amount of proteoglycan in the contralateral left knee joint. The amounts of proteoglycan lost in the osteoarthritic right knee joints are expressed as percent loss of proteoglycan compared to the contralateral left knee joint control. The percent inhibition of proteoglycan loss, may be calculated as {1-[(proteoglycan loss from joint (%) with vehicle) - (proteoglycan loss from joint with substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound useful in the invention method)] + (proteoglycan loss from joint (%) with vehicle)} x 100.
The MIA Rat data that are expected from the analysis of proteoglycan loss would establish that substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, including a pharmaceutically acceptable salt thereof, including a compound named 6-(5-carboxy-5-methyl- hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, are effective for inhibiting cartilage damage, improving joint function, and treating osteoarthritis in mammalian patients, including human. The compound named 6-(5-carboxy-5- methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt was tested in MIA, and the results are described below in Biological Method 2.
BIOLOGICAL METHOD 2 6-(5-Carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt in
MIA:
In a particular experiment, monosodium iodoacetate (“MIA”) (1 mg/joint) was injected through the infrapatellar ligament of the right knee of anesthetized male, Wistar rats. The contralateral control knee was injected with 50 pL of physiologic saline. The change in hind paw weight distribution, as determined by use of an incapacitance tester, between the right (arthritic) and left (contralateral control) knees was utilized as an index of functional limitation in the arthritic knee. Limitations in joint function were determined on Days 7, 14, and 28 following induction of arthritis. Following sacrifice, erosion severity was determined on the tibial plateaus from the arthritic joint. Histological analysis was also conducted on these samples. The basis of the invention is derived from the ability of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, dosed orally two times per day (i.e., PO; BID), to significantly decrease cartilage erosion severity at 30-mg/kg and 10-mg/kg doses and by its ability to decrease joint function limitations as defined by a reduction in differential hind- limb weight bearing.
For oral administration, 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt, was dissolved in double distilled water (all calculations are based on the percent parent of the drug). Dose-response studies at doses of 3-, 10-, and 30-mg/kg [peroral (“PO”); twice a day (“BID”)] demonstrated that 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, at 4 weeks post-MIA, significantly decreased the degree of structural damage to the cartilage at the 30 mg/kg dose and significantly decreased joint pain.
The results of these studies with oral dosing are shown below in Table 1 in the columns labelled “UFL (%+/- SEM)”, wherein IJFL means Inhibition of Joint
Function Limitation and SEM means standard error of the mean; “SDCES”, wherein SDCES means Significant Decrease In Cartilage Erosion Severity, and “Decreased Erosion Size”, wherein Decreased Erosion Size means whether or not there was a statistically significant decrease in the size of the area of joint erosion.
Table 1. Four week study with oral administration of CI-1027, two times per day per dose:
Dose JFL Decreased (mg/kg) (%-+/- SEM) SDCES® Erosion Size 30 63 +/- 8? Yes No 10 36+/-9 Yes® Yes® 3 3+/- 156 Yes No 30 60 +/- 8% No No (a) p<0.05 versus vehicle (One-way Analysis of Variance (“One Way
ANOVA”; Dunnett’s Multiple Comparison Procedure); (b) p<0.05 versus vehicle (Ridit Analysis); (c) p<0.05 versus vehicle (One Way ANOVA), (d) actual p = 0.027; (e) ‘actual p = 0.001; (f) actual p =0.043. : (g) actual p =0.100
The ridit analysis was used to determine differences in overall erosion severity. This parameter takes into account both the erosion grade (0 =no erosion, I = erosion extending into the superficial or middle layers, or II = deep layer erosion), and area (small, medium and large, quantified by dividing the area : of the largest erosion in each score into thirds) simultaneously. The analysis recognizes that each unit of severity is different, but does not assume a mathematical relationship between units.
The MIA Rat data reported above in Table 1 establish that substituted dialkyl ether, substituted aryl-alky] ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, including a compound named 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, are effective at preventing or inhibiting cartilage damage, improving joint function, alleviating joint pain, and preventing or treating osteoarthritis.
The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt may also be administered subcutaneously via osmotic pumps.
Dosing may be carried out at, for example, 100-mg/kg/day, 90-mg/kg/day, 30- mg/kg/day, and 10-mg/kg/day dosing.
BIOLOGICAL METHOD 3
Induction of Experimental Osteoarthritis in Rabbit (“EOA in Rabbit”):
Normal rabbits are anaesthetized and anteromedial incisions of the right knees performed. The anterior cruciate ligaments are visualized and sectioned.
The wounds are closed and the animals are housed in individual cages, exercised, and fed ad libitum. Rabbits are given either vehicle (water) or 6-(5-carboxy-5- methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, or a pharmaceutically acceptable salt thereof, (10 rabbits per group). Each group is dosed three times per day with the 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, or a pharmaceutically acceptable salt thereof, group receiving 30-mg/kg/dose or 10-mg/kg/dose. The rabbits are euthanized 8 weeks after surgery and the proximal end of the tibia and the distal end of the femur are removed from each animal.
Macroscopic Grading
The cartilage changes on the femoral condyles and tibial plateaus are graded separately under a dissecting microscope (Stereozoom, Bausch & Lomb,
Rochester, NY). The depth of erosion is graded on a scale of O to 4 as follows: grade 0 = normal surface; Grade 1 = minimal fibrillation or a slight yellowish discoloration of the surface; Grade 2 = erosion extending into superficial or middle layers only; Grade 3 = erosion extending into deep layers; Grade 4 = erosion extending to subchondral bone. The surface area changes are measured and expressed in mm?2. Representative specimens may also be used for histologic grading (see below).
Histologic Grading
Histologic evaluation is performed on sagittal sections of cartilage from the lesional areas of the femoral condyle and tibial plateau. Serial sections (5 um) are prepared and stained with safranin-O. The severity of OA lesions is graded on a scale of 0 - 14 by two independent observers using the histologic-histochemical scale of Mankin et al. This scale evaluates the severity of OA lesions based on the loss of safranin-O staining (scale 0 - 4), cellular changes (scale 0 - 3), invasion of tidemark by blood vessels (scale 0 - 1) and structural changes (scale 0 - 6). On this latter scale, 0 indicates normal cartilage structure and 6 indicates erosion of the cartilage down to the subchondral bone. The scoring system is based on the most severe histologic changes in the multiple sections.
Representative specimens of synovial membrane from the medial and lateral knee compartments are dissected from underlying tissues. The specimens are fixed, embedded, and sectioned (5 um) as above, and stained with hematoxylin-eosin. For each compartment, two synovial membrane specimens are examined for scoring purposes and the highest score from each compartment is retained. The average score is calculated and considered as a unit for the whole knee. The severity of synovitis is graded on a scale of 0 to 10 by two independent observers, adding the scores of 3 histologic criteria: synovial lining cell hyperplasia (scale 0 - 2); villous hyperplasia (scale 0 - 3); and degree of cellular infiltration by mononuclear and polymorphonuclear cells (scale 0 - 5): 0 indicates normal structure.
Statistical Analysis
Mean values and SEM are calculated and statistical analysis is done using the Mann-Whitney U-test.
If these EOA studies were performed with a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, the results would show that the active compounds, or a pharmaceutically acceptable salt thereof, including a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, reduce the size of the lesion on the tibial plateaus, and perhaps the damage in the tibia or on the femoral condyles. In conclusion, the EOA results would show that substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, including a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, have significant inhibition effects on the damage to cartilage.
BIOLOGICAL METHOD 4
Monosodium iodoacetate (“MIA”)-induced osteoarthritis:
Male Wistar rats (175-200 g) were housed in solid bottom isolator cages, 2-4 rats per cage, with comcob bedding on a 12 hour:12 hour light:dark cycle. .
Animals were fed standard rat chow with water available ad libitum.
The rats were anesthetized with 5% volume/volume (“v/v”) isoflurane gas and maintained with 2% v/v isoflurane gas. The anesthetized rats were given a single intra-articular injection of 1 mg of MIA through the infrapatellar ligament of the right knee. MIA was dissolved in physiologic saline and administered in a volume of 50 PL. The contralateral control knee was injected with 50 puL of physiologic saline. Administration of isoflurane gas was discontinued, and the rats became fully conscious about 5 minutes later.
Shifts in hind paw weight distribution from the right to the left hind paws supporting the right (arthritic) and the left (contralateral control) hind leg knee joints were utilized as an index of joint pain and as a measure of compound efficacy. An incapacitance tester (Model 2KG, Linton Instrumentation, UK) was employed for determination of hind paw weight distribution. Each data point is the mean of three readings of 5 seconds duration.
CI-1027 (i.e., 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt) was dissolved in hydroxypropylmethylcellulose (“HPMC”) vehicle (0.05% HPMC + 0.2% Tween 80; compound amount was adjusted based on the percent of free acid, i.e., 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid).
Two dosing paradigms were used to test the effect of CI-1027 in this model: (1) A single (acute) dose was utilized to determine the pain alleviating effects of CI-1027 on joint pain following acute, single dose administration; and (2) Chronic (multiple day; b.i.d.) dosing was utilized to determine the inhibitory effect of CI-1027 on joint pain and/or cartilage damage. The acute dosing paradigm relates to osteoarthritis signs such as mobility and joint function and osteoarthritis symptoms such as joint pain. The chronic dosing paradigm identifies disease modifying osteoarthritis drugs (“DMOADs”).
For the acute (single) dose paradigm, changes in hind paw weight distribution were determined late on Day 13 or early on Day 14 post MIA injection, as described previously, to establish a baseline pain reading. Rats were then given a single, 10, 30, or 100 mg/kg, dose of CI-1027 via oral gavage (PO).
Changes in hind paw weight distribution were determined 2, 4 and 6 hours post- compound administration.
For the chronic (multiple) dosing paradigm, MIA and saline were injected on Day 0. CI-1027 was given PO 0.5 hour before MIA injection. CI-1027 (3,10, or 30 mg/kg) was then given approximately every 12 hours for 28 days. Changes in hind paw weight distribution were determined on Days 7, 14, and 28.
After administering CI-1027 b.i.d. for 4 weeks, the rats were euthanized by
CO, administration. The soft tissue was removed from the right (arthritic) leg, the joint was disarticulated, and the meniscus was carefully removed to expose the surface of the tibial plateau. The tibia was removed and placed in physiologic saline until erosion analysis was performed. Tibial plateau erosions were analyzed the same day as the sacrifice as follows. Each plateau was dipped in India ink for approximately 30 seconds to help define the erosions, rinsed in saline, and blotted on a paper towel. A stereomicroscope equipped with a digital camera was used to photograph each plateau. The tibial plateaus were photographed and graded separately by two ordinary skilled persons using the following system:
Grade 0 = no erosion; .
Grade I = erosion extending into the superficial or middle layers;
Grade II = deep layer erosion; no cartilage, sub-chondral bone exposed.
The photographs were transferred to a computer for image analysis using a
Zeiss KS 300 Image Analysis System to determine the total erosion area for each grade, expressed in square millimeters (“mm?”). A RIDIT analysis (see above) was used to determine differences in overall erosion severity. This analysis takes into account both the erosion grade and area (small, medium and large, quantified by dividing the area of the largest erosion in each score into thirds) simultaneously. The analysis recognizes that each unit of severity is different, but does not assume a mathematical relationship between units.
Results for joint pain alleviation following acute administration:
CI-1027 was tested in the rat MIA model in an acute dosing paradigm as described previously. MIA was injected into the right knee and saline into the left knee of all rats on Day 0. On Day 14 the rats were assessed on an incapacitance tester and then given CI-1027 (10, 30, or 100 mg/kg, PO). Two, four and six hours later, the rats were re-assessed. The results are graphically displayed in Figure 1, which is a dose response line graph that shows the change in rat hind paw weight distribution, expressed in grams. In Figure 1, administration of CI-1027 altered the shift in weight bearing potential (joint pain) in arthritic rats dosed with 100 mg/kg at 2, 4, and 6 hours post administration of CI-1027 in a statistically significant manner compared to pre-dose measurements. At the 30 mg/kg dose, only the change at the 4-hour post dose time point was statistically significant. Rats dosed with 10 mg/kg did not significantly alter their shift in weight bearing potential.
Statistically significant differences were determined by one-way ANOVA followed by Dunnett’s multiple comparisons procedure. Data are expressed as mean + SEM. N = 8 rats per group.
Results for joint pain alleviation following chronic administration of a single dose:
MIA and saline were injected on Day 0. CI-1027 (30 mg/kg) was given PO 0.5 hour before MIA injection. CI-1027 was then given b.i.d. for 28 days.
Changes in hind paw weight distribution were determined on Days 7,14, and 28.
The results are shown in Figure 2, which is a time course line graph that shows the change in rat hind paw weight distribution, expressed in grams. As shown in
Figure 2, CI-1027 decreased the change in hind paw weight distribution at all three time-points tested in a statistically significant manner (47+8%, 719%, and 60+8% inhibition at Days 7, 14 and 28, respectively; p < 0.05). Statistically significant differences were determined by One-Way ANOVA with the Dunnett’s multiple comparisons procedure (*p < 0.05). Data are expressed as mean + SEM.
N = 12 rats per group.
Results for joint pain alleviation following chronic administration for dose response:
A dose response for CI-1027 was also performed to look at joint pain as measured by changes in hind paw weight distribution after multiple doses. MIA and saline were injected on Day 0. CI-1027 (3, 10, or 30 mg/kg) was given PO OS hour before MIA injection. CI-1027 was then given b.i.d. for 28 days. Changes in hind paw weight distribution were determined on Days 7,14, and 28. The results are shown in Figure 3, which is a time course, dose response line graph that shows the change in rat hind paw weight distribution, expressed in grams. As shown in
Figure 3, consistent with the previous experiment, CI-1027 at 30 mg/kg decreased the change in hind paw weight distribution at Days 14 and 28 in a statistically significant manner (50+10% and 62+8% inhibition, respectively; p < 0.05). At
Day 7, however, the significant effect observed in the first experiment was not repeated (38+14% inhibition). There were no statistically significant changes in hind paw weight distribution at the 10 and 3 mg/kg doses at all three time-points tested. Statistically significant differences were determined by One-Way ANOVA with the Dunnett’s multiple comparisons procedure (*p < 0.05). Data are expressed as mean + SEM. N = 12 rats per group.
Results for inhibition of joint cartilage degradation following chronic administration: :
CI-1027 was tested for the ability to preserve cartilage structure in the rat
MIA model. Rats were dosed at 30 mg/kg, PO, b.i.d. for 28 days and sacrificed on
Day 28. The tibial plateaus were removed and analyzed as previously described in the methods. MIA and saline were injected on Day 0. CI-1027 (30 mg/kg) was given PO 0.5 hour before MIA injection and was then given b.i.d. for 28 days.
Erosion analysis was performed on Day 28. CI-1027 had no statistically significant effect on tibial plateau erosion severity when analyzed using the RIDIT test (p = 0.10). N = 12 rats per group. It should be appreciated that 2 of the 12 vehicle-treated rats had no erosions, which could partially account for the lack of statistical significance. Additionally, it should also be appreciated that 5 of the 12 rats treated with CI-1027 had no erosions.
The effect of CI-1027 on total erosion area (regardless of grade) was also determined. MIA and saline were injected on Day 0. CI-1027 (30 mg/kg) was given PO 0.5 hour before MIA injection and was then given b.i.d. for 28 days.
Erosion analysis was performed on Day 28. There were no statistically significant differences CI-1027 decreased the total erosion area by 43%. However, this reduction was not statistically significant (as determined by t-test; p=0.179; N = 12 rats per group), which again may be partially explained by the two vehicle rats with no erosions referenced above.
Results for inhibition of joint cartilage degradation following chronic administration for dose response:
Rats were dosed with 3, 10 or 30 mg/kg, PO, b.i.d. for 28 days, tibial plateaus were removed and analyzed using the RIDIT test as described above.
MIA and saline were injected on Day 0. CI-1027 (3, 10, or 30 mg/kg) was given
PO 0.5 hour before MIA injection and was then given b.i.d. for 28 days. Erosion analysis was performed on Day 28. All three doses were statistically significant as determined by RIDIT analysis (p < 0.05); N = 12 rats per group. The results are shown in Figure 4, which is a dose response bar graph that shows effects on (i) cartilage erosion severity, expressed as Grade O (no erosion), Grade I (erosion extending into the superficial or middle cartilage layers and further characterized by size small, medium, and large), or Grade II (deep layer erosion; no cartilage remaining in spots, subchondral bone exposed in spots, and further characterized by size small, medium, and large) and (ii) cartilage size, expressed as percent erosion distribution, relative to vehicle-injected control animals. As shown in
Figure 4, all three doses of CI-1027 had a statistically significant inhibitory effect on erosion severity. It should be appreciated that all vehicle-treated rats had erosions, as opposed to the previously described experiment.
The effect of CI-1027 (3, 10, and 30 mg/kg) on total erosion area (regardless of grade) was also determined. MIA and saline were injected on Day 0. CI-1027 (3, 10, or 30 mg/kg) was given PO 0.5 hour before MIA injection and was then given b.i.d. for 28 days. Erosion analysis was performed on Day 28.
Statistical significance was determined by One-Way ANOVA, Dunnett’s multiple comparisons procedure (p < 0.05; N = 12 rats per group). The results are shown in
Figure 5, which is a dose response bar graph that shows effects on total cartilage erosion area, expressed in square millimeters, regardless of cartilage erosion severity grade, relative to vehicle-injected control animals. As shown in Figure 5, a statistically significant decrease in total erosion area was noted only at the 10 mg/kg dose of CI-1027 (62.4%).
A single dose of CI-1027 at 30 or 100 mg/kg effectively alleviated joint pain in MIA-induced arthritic rats, demonstrating that CI-1027 and the other active compounds of this invention method have a direct antihyperalgesic effect on joint pain. CI-1027 also improved joint pain in the rat MIA model when administered chronically. CI-1027 administered at 30 mg/kg, PO, b.i.d. improved joint pain after 1-2 weeks of dosing with sustained effects out to 4 weeks. In addition, CI-1027 effectively decreased medial tibial plateau erosion size when administered at 3, 10 or 30 mg/kg, PO, b.i.d. for 28 days, demonstrating that CI- 1027 and the other active compounds of this invention method have a direct cartilage damage inhibiting effect in a joint undergoing cartilage damage.
BIOLOGICAL METHOD 5
Interleukin-6 (“IL-6"") with Interleukin-6 soluble receptor (“IL-6sR”) induced joint pain:
The IL-6/IL-6sR model relates to osteoarthritis pain.
Male Wistar rats (175-200 g) were housed in solid bottom isolator cages, 2-4 rats per cage, with corncob bedding on a 12 hour:12 hour light:dark cycle.
Animals were fed standard rat chow with water available ad libitum.
Human recombinant IL-6 (100 ng per rat; R&D Systems, Minneapolis,
Minnesota) was incubated at room temperature with human recombinant IL-6 soluble receptor (300 ng per rat; R&D Systems, Minneapolis, Minnesota) in phosphate buffered saline (“PBS”) for 15 minutes prior to injection. Rats were : anesthetized with 5% volume/volume (“v/v”) isoflurane gas and maintained with 2% vlv isoflurane gas. The anesthetized rats were given a single intra-articular injection of IL-6/IL-6sR through the infrapatellar ligament of the right knee in a . volume of 50 pL. The contralateral control knee was injected with 50 uL of PBS.
Administration of isoflurane gas was discontinued, and the rats became fully conscious about 5 minutes later.
Shifts in hind paw weight distribution from the ri ght (arthritic) to the left (contralateral control) paws were utilized as an index of joint pain and as a measure of compound efficacy. An incapacitance tester (Model 2KG, Linton
Instrumentation, UK) was employed for determination of hind paw weight distribution. Each data point is the mean of three, 5-second readings.
CI-1027 was dissolved in HPMC vehicle as described above. Baseline changes in hind paw weight distribution readings were determined one day prior to injection of IL-6/IL-6sR. On the day of the experiment (Day 0), a single dose of
CI-1027 (10, 30 or 100 mg/kg) was given via oral gavage 3 hours prior to injection of IL-6/IL-6sR (n = 10 rats per group). Changes in hind paw weight distribution were determined one, three, and six hours after injection of IL-6/IL- 6sR.
The effect of CI-1027 (10, 30, and 100 mg/kg) on joint pain was tested in the rat IL-6/IL-6sR model. Baseline incapacitance readings were taken on Day ~1.
JL-6/IL-6sR and PBS were injected on Day 0. CI-1027 (10, 30, or 100 mg/kg) was given PO 3 hours before IL-6/IL-6sR injection. Changes in hind paw weight distribution were determined 1, 3, and 6 hours post injection (4, 6, and 9 hours post CI-1027 dose). The results are shown in Figure 6, which is a time course, dose response line graph that shows the change in rat hind paw weight distribution, expressed in grams. As shown in Figure 6, all three doses of CI-1027 decreased the change in hind paw weight distribution at 1 hour post injection, 4 hours post CI-1027 administration in a statistically significant manner (5319%, 74+8%, and 57%15% inhibition at 10, 30 and 100 mg/kg, respectively. Statistically significant differences were determined by One-Way ANCOVA followed by the
Hochberg’s procedure (*p < 0.001). Data are expressed as mean + SEM. N = 10 rats per group. No significant effect was noted at 3 and 6 hours post injection (6, and 9 hours post CI-1027 administration).
The experiment described above was repeated with the following changes:
CI-1027 was tested only at 10 and 30 mg/kg and all incapacitance test readings were blinded. Baseline incapacitance readings were taken on Day —1. IL-6/IL-6sR and PBS were injected on Day 0. CI-1027 (10 or 30 mg/kg) was given PO 3 hours before IL-6/IL-6sR injection. Changes in hind paw weight distribution were determined 1, 3, and 6 hours post injection (4, 6, and 9 hours post CI-1027 dose).
Statistically significant differences were determined by One-Way ANCOVA followed by the Hochberg’s procedure (*p < 0.001). Data are expressed as mean +
SEM. N = 10 rats per group. The results are shown in Figure 7, which is a time course, dose response line graph that shows the change in rat hind paw weight distribution, expressed in grams. As shown in Figure 7 and as previously seen in the first experiment, both the 10 and the 30 mg/kg doses of CI-1027 decreased change in hind paw weight distribution as compared to the vehicle group in a statistically significant manner (63+6% and 71+10% inhibition at 10 and 30 mg/kg, respectively).
In the rat IL-6/IL-6sR knee injection model, CI-1027 significantly alleviated joint pain 1-hour post injection of the IL-6/IL-6sR, demonstrating that
CI-1027 and the other active compounds of this invention method have a direct antihyperalgesic effect on joint pain.
BIOLOGICAL METHOD 6
Carrageenan-induced thermal hyperalgesia:
Purpose: to screen compounds for potential hyperalgesia-based analgesic efficacy (i.e., alleviation of inflammatory pain such as rheumatoid arthritic pain).
Male Sprague Dawley rats (200-300g), obtained from Charles River, were housed in groups of 2 under a 12 hour light/ dark cycle with food and water ad libitum. Animals were allowed to acclimate to the test room one hour prior to testing.
Thermal hyperalgesia was assessed using the rat plantar test (apparatus from Univ. California, San Diego) following a modified method of Hargreaves et al., 1988. Rats were habituated to the apparatus, which consisted of three perspex boxes that individually housed 2 rats per box on an elevated glass table. A mobile radiant heat source (halogen lamp) was located under the glass table and focused onto the hind paw. Paw withdrawal latencies (PWL) were recorded in seconds (“s™). An automatic cut off point of 22.5s was set to prevent tissue damage. The mean of 2-3 PWL was taken at each time point for both hind paws of each animal.
The apparatus was calibrated to give a PWL of approximately 10s before carrageenan administration.
After basal PWL were determined, animals receive an intraplantar 100 pL. of 10 mg/mL) into the right hind paw. Lambda carrageenan (Sigma Chemical Co.) was dissolved in isotonic saline 5 minutes prior to injecting. PWL were reassessed following the same protocol 2 hours post carrageenan (this time point represented the start of peak hyperalgesia) to ascertain that hyperalgesia had developed. 6-(5- _ Carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt was then administered orally via oral dosing needles 2.5 hours post carrageenan injection,
and PWL were taken again at 30- or 60-minute intervals post drug administration for 6 hours.
Data consisted of the mean of 2-3 reads/paw for individual animals. Group data was the compiled individual means. Percent inhibition was calculated as follows for each time point: (mean drug treated - mean control) / (mean baseline - mean control) x 100.
The inhibition results were then statistically analyzed.
Resuits for use of CI-1027 for alleviating joint pain expressed as percent inhibition of a change in hind paw weight distribution (MIA and IL-6) or paw withdrawal latency (CITH) are shown below in Table 2.
Table 2. Alleviation of joint pain as measured by inhibition of a change in hind paw weight distribution (MIA and IL-6) or paw withdrawal latency (CITH) by one single oral dose of 30 mg/kg of 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt on Day 7 (MIA) or Day 1 (IL-6 and CITH) measured at 4 hours post dose:
Inhibition of
Pain (% versus
Model control)
IL WL
*n < 0.05.
The following substituted dialkyl ether compounds (reference numbers) and substituted alkyl compound (reference number) have been assayed for pain alleviation effects in at least one of the above methods selected from MIA, IL~ 6/TL-6sR, and CITH: 7,7 -0xybis(2,2-dimethylheptanoic acid) (Al); 5,5’-0xybis(2,2-dimethylpentanoic acid) (A2); 4,4’ -oxybis(2,2-dimethylbutanoic acid) (A3); and 2.2,12,12-tetramethyltridecanedioic acid (A4).
The data are shown below in Tables 3 to 5. In Table 3 below, data from the method of Biological Method 4 are expressed as a percent inhibition of a change in hind paw weight distribution * the standard error of the mean. The percents inhibition were calculated according to the formula recited above in Biological
Method 1.
Table 3. Following the method of Biological Method 4, alleviation of joint pain as measured by inhibition of a MIA-induced change in hind paw weight distribution by one single oral dose of 30 mg/kg of compound reference numbers Al to A4 on
Day 7 or Day 14 measured at 2, 4, or 6 hours post dose of compound, expressed as a percentage inhibition = the standard error of the mean, as shown below in the columns headed “Cpd. Ref. No.,” “Day 7 2 hr. (%+SEM),”“Day 7 4 hr. (%+SEM),” Day 7 6 hr. (%+SEM),”“Day 14 2 hr. (%+SEM),” “Day 14 4 hr. (%0+SEM),” and “Day 14 6 hr. (%+SEM),”, respectively:
Cpd. Day 7 Day 7 Day 7 Day 14 Day 14 Day 14
Ref. 2 hr. 4 hr. 6 hr. 2 hr. 4 hr. . 6hr
No. | (%+SEM) | (%+SEM) | (%+SEM) | (%xSEM) | (%+SEM) | (%+SEM)
N/d means no data available
In Table 4 below, data from the method of Biological Method 5 are expressed as a percent inhibition of a change in hind paw weight distribution + the standard error of the mean. The percents inhibition were calculated as follows.
Percent inhibition of a change in hind paw weight distribution _ i Ea | X 100 (AW¢) wherein: AW is the hind-paw weight differential between the healthy limb and the hrllL-6 + hrIL-6sR injected limb of the control animal group administered vehicle alone, as measured at time 1, 3, or 6 hours post injection; and
AWG is the hind-paw weight differential between the healthy limb and the hrIL-6 + hrIL-6sR injected limb of a treatment animal group as measured at time 1, 3, or 6 hours post injection.
Table 4. Following the method of Biological Method 5, alleviation of joint pain as measured by inhibition of a human recombinant (IL-6/IL-6sR)-induced change in hind paw weight distribution by one single oral dose of 30 mg/kg of compound reference number A4 on Day 1 measured at 1, 3, or 6 hours post injection of the
IL-6/TL-6sR, expressed as a percentage inhibition + the standard error of the mean, as shown below in the columns headed “Cpd. Ref. No.,” “1 hr. (%+SEM),” 3 hr. (%+SEM),” and “6 hr. (%+SEM),”, respectively:
Cpd.
Ref. 1 hr. 3 hr. 6 hr.
Table 5. Following the method of Biological Method 6, alleviation of pain as measured by paw withdrawal latency in CITH by one single oral dose of 30 mg/kg or 100 mg/kg of compound reference numbers Al to A4 on Day 1, expressed as a percentage inhibition, as shown below in the columns headed “Cpd. Ref. No.,” “Dose (mg/kg),” and “CITH (%),”, respectively:
Cpd Ref. | Dose | CITH
BIOLOGICAL METHOD 7
The method according to Biological Method 5, wherein the IL-6, IL-6sR, or IL-6 and IL-6sR is replaced by a protein or protein and its receptor,
respectively, selected from: oncostatin-M, oncostatin-M and oncostatin-M receptor, leukemia inhibitor factor (“LIF”), LIF and leukemia inhibitor factor receptor (“LIFR”), interleukin-11 (“IL-11"), and IL-11 and interleukin-11 receptor (“IL-11R™).
A method of assaying activity of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound in rheumatoid arthritis is described below in
Biological Method 8.
BIOLOGICAL METHOD 8
Monoclonal antibody-induced arthritis (“MAIA’’) Mouse Model:
Rapid induction of arthritis in mice in this model is made possible through the utilization of a commercially available arthritis-inducing monoclonal antibody cocktail. This cocktail contains four different monoclonal antibodies (“mAbs”) that were generated in DBA/1 (H-2% haplotype) mice with active collagen-induced arthritis (“CIA;” CIA may be induced in mice by intradermal immunization of susceptible animals with native bovine type II collagen in complete Freund’s adjuvant, but this typically takes 6-8 weeks and the incidence and severity of disease can be quite variable, requiring relatively large numbers of mice to achieve statistical significance). Three of the mAbs recognize autoantigenic epitopes clustered within an 84 amino acid residue fragment, LyC2 (smallest arthrogenic fragment of type II collagen) of CB11 and the fourth mAb reacts with
LyC2 (Terato, K., Harper, D., Griffiths, M., Hasty, D., Ye, J., Cremer, M. and J,
Seyer. Collagen-induced arthritis in mice: synergistic effect of Escherichia coli (“E. coli”) lipopolysaccharide bypasses epitopespecificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity. 22(3):137-147). More importantly, all four mAbs recognize epitopes of type II collagen that are conserved among many animal species and thus crossreact with both homologous and heterologous type II collagen.
One of the main benefits of the monoclonal antibody-induced arthritis protocol over a traditional CIA model is its ability to induce a CIA-like arthritis in strains of mice other than DBA/1. As most knockout mice are made in 129/SvJ,
BALB/c or C57BL/6 strains, and not DBA/1, it has been difficult to use
~ -90- knockouts to validate targets for rheumatoid arthritis. Researchers were forced to spend years backcrossing their knockout mice onto the DBA/1 background in order to test the effect of a genetic deficiency on the onset or severity of arthritis.
When the 129/SvJ, BALB/c, C3H/FeJ, and CS7TBL/6 strains were tested,
DBA/1 was found to be the most responsive, but BALB/c, C57BL/6, and 129/SvJ strains were only slightly less responsive than the DBA/1. The C3H/HeJ mice were relatively unresponsive. The response of the 129/SvJ mice to the combination of mAb and LPS was also low, but still statistically significantly higher than in 129/SvJ mice injected with LPS only.
One of the hallmarks of a good preclinical disease model is that agents that work to alleviate the human disease also work in the animal model. Methotrexate, cyclosporin A, and anti-TNF-a antibodies have all been used in the successful treatment of rheumatoid arthritis in a human. When tested in BALB/c mice using the monoclonal antibody-induced arthritis model, methotrexate (4 mg/kg) and anti-TNF-o antibody (83.33 ug) were both found to significantly inhibit footpad and ankle swelling throughout the course of the disease. Anti-TNF-o antibody (83.33 pg/animal) was administered i.p. one and five days after injection of
Arthrogen-CIA antibody. Cyclosporin A (25 mg/kg) demonstrated an early inhibition of the swelling response, but by Day 9 there was no difference from the vehicle control.
MAIA Protocol:
In a typical MAIA experiment, groups of four mice were injected intraperitoneally (“i.p.””) with 0.4 mL (BALB/c and DBA/1strains) or 0.8 mL (C57BL/6, 129X1/Sv], C3H/Hel, and C3H/FeJ strains) with a 10 mg/mL solution of Arthrogen-CIA Monoclonal Antibody Blend (Chemicon International, Inc.).
Two days later, the mice were injected i.p. with 0.2 mL of a 0.25 mg/mL solution of LPS (lipopolysaccharide form E. coli strain 0111B4) in PBS. Footpad and ankle size was assessed using a Dyer Digital Caliper (#655-030-4916) on the day of mAb injection, and every two days following LPS injection.
In experiments involving therapeutic agents, 30, 100, or 200 mg/kg of 6- (5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt were dosed orally 1 day prior to Arthrogen-CIA antibody and then daily thereafter.
The results for oral administration of vehicle or 30, 100, or 200 mg/kg of 6-(5-carboxy-S5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, are shown in Figure 8. In Figure 8, a time course, dose response line graph shows that the compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt when dosed at 200 mg/kg inhibits a change in mouse ankle joint and paw swelling, expressed in millimeters (“mm”), in a statistically significant manner (p < 0.05) as measured on Days 4, 7, and 9 and at 100 mg/kg on Day 7.
BIOLOGICAL METHOD 9
Pain-alleviating effect of a combination of a substituted dialkyl ether and a COX-2 inhibitor in MIA:
Results for joint pain alleviation following acute administration: 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt (“CI-1027"") and rofecoxib was tested in the rat MIA model in an acute dosing paradigm as described previously. MIA was injected into the right knee and saline into the left knee of all rats on Day 0. On Day 14 the rats were assessed on an incapacitance tester and then given 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt (10 mg/kg, PO) and rofecoxib (3 mg/kg,
PO). Two hours later, the rats were reassessed. The results for inhibition of pain, expressed as a percentage + standard error of the mean, are shown below in Table 5. The percent inhibition of pain was determined as described above in Biological
Method 1. In Table 5, administration of 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt and rofecoxib altered the shift in weight bearing potential (joint pain) in arthritic rats at 2 hours post administration of 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt and rofecoxib in a statistically significant manner compared to pre-dose measurements as well as compared to 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt or rofecoxib alone. Statistically significant differences were determined by one-way ANOVA followed by Dunnett’s multiple comparisons procedure and indicated in Table 5 with a “*.”” Data are expressed as mean % +
SEM. N = 8 rats per group.
Table 5.
CI-1027 (10 mg/kg) + lhe = (10 mg/kg) | G mg/kg) | (3 mg/kg)
Mean pain alleviation at 2 hours post administration (% + SEM) 2049 237 36x11* *P <0.05
The foregoing studies establish, or would establish, that substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, including a compound named 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, or a combination comprising such a compound and a COX-2 inhibitor, are effective for the prevention and inhibition of cartilage damage, improvement of joint function, alleviation of pain, including IL-6 induced joint pain, mechanical pain,
OA pain, inflammatory pain, RA pain, acute pain, chronic pain, alleviation of acute pain, alleviation of chronic pain, and the like, and prevention and treatment of osteoarthritis and rheumatoid arthritis in human, and other mammalian patients.
Such a treatment offers a distinct advantage over existing treatments that only modify pain and other secondary symptoms. The effectiveness of a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound useful in the invention method, or a pharmaceutically acceptable salt thereof, including a compound named 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, in the
MIA model indicate that substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, including a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-
dimethyl-hexanoic acid, calcium salt, will have clinically useful effects in preventing and/or treating cartilage damage, improving joint function, and alleviating pain.
Administration according to the invention method of an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, to a mammal to treat the diseases listed above may be, but is not necessarily, accomplished by administering the compound, or a salt thereof, in a pharmaceutical dosage form.
The substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, can be prepared and administered according to the invention method in a wide variety of oral and parenteral pharmaceutical dosage forms. Thus, the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, can be administered by inhalation, for example, intranasally. Additionally, the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active components either an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof. The active compounds generally are present in a concentration of about 5% to about 95% by weight of the formulation.
For preparing pharmaceutical compositions from the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, (i.e., the active components)
pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances that may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid that is in a mixture with the finely divided active component. Powders suitable for intravenous administration or administration by injection may be lyophilized.
In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The powders and tablets typically contain from about 5% to about 70%, total, of the active component. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration.
Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. -
The pharmaceutical preparation may optionally be in unit dosage form. In such form, the preparation is subdivided into unit doses having an appropriate quantity of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The quantity of active component in a unit dose preparation may be varied or adjusted from 0.01 to 1000 mg, including from 1 to S00 mg or from 10 to 250 mg, according to the particular application and the potency of the active components. The composition can, if desired, also contain other compatible therapeutic agents.
In therapeutic use as agents to treat the above-listed diseases, the substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, or a combination of the same with another therapeutic agent, are administered at a dose that is effective for improving at least one clinical measure, pathological hallmark, or symptom of the disease or disorder being treated. The initial dosage of about 1 mg/kg to about 30° 100 mg/kg daily of the active component will be effective. A daily dose range of about 25 mg/kg to about 75 mg/kg of the active component is typical. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the particular substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound useful in the invention method, or a pharmaceutically acceptable salt thereof, or combination being employed.
Determination of the proper dosage for a particular situation is within the skill of the art as described above. Typical dosages will be from about 0.1 mg/kg to about 500 mg/kg, and ideally about 25 mg/kg to about 250 mg/kg, such that it will be an amount that is effective to treat the particular disease or disorder being treated.
A typical composition for dogs comprises an ingestible liquid peroral dosage form selected from the group consisting of a solution, suspension, emulsion, inverse emulsion, elixir, extract, tincture and concentrate, optionally to be added to the drinking water of the dog being treated. Any of these liquid dosage forms, when formulated in accordance with methods well known in the art, can either be administered directly to the dog being treated, or may be added to the drinking water of the dog being treated. The concentrate liquid form, on the other hand, is formulated to be added first to a given amount of water, from which an aliquot amount may be withdrawn for administration directly to the dog or addition to the drinking water of the dog.
A composition can provide delayed-, sustained- and/or controlled-release of an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof. Such compositions include all such dosage forms which produce > 40% inhibition of cartilage degradation or pain, and result in a plasma concentration of the active component of, for example, at least 3 fold the active component’s EDj for at least 2 hours; for at least 4 hours; for at least 8 hours; for at least 12 hours; for at least 16 hours; for at least 20 hours; or for at least 24 hours. For example, there is included within the above-described dosage forms those which produce > 40% inhibition of cartilage degradation or pain, and result in a plasma concentration of the active component of at least 5 fold the active components EDyg for at least 2 hours, for at least 2 hours, for at least 8 hours, for at least 12 hours, for at least 20 hours and for at least 24 hours. Further, there is included the above-described dosage forms which produce > 50% inhibition of cartilage degradation or pain, and result in a plasma concentration of the active component of at least 5 fold the active component’s EDyy for at least 2 hours, for at least 4 hours, for at least 8 hours, for at least 12 hours, for at least 20 hours and for at least 24 hours.
The above formulation examples illustrate the invention pharmaceutical compositions having an effective amount of an active compound, an invention combination, or compositions having discrete formulations of the active components of the invention combination and a pharmaceutically acceptable carrier, diluent, or excipient and a pharmaceutically acceptable carrier, diluent, or excipient. The examples are representative only, and are not to be construed as limiting the invention in any respect.
While it may be desirable to formulate another therapeutic agent and 6~(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, or a pharmaceutically acceptable salt thereof, together in one capsule, tablet, ampoule, solution, and the like, for simultaneous administration, it is not necessary for the purposes of practicing the invention methods. For example, valdecoxib and a 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt, or a pharmaceutically acceptable salt thereof, of an invention combination alternatively can each be formulated independently in any form such as, those of any one Formulation Examples 1 to 16, and administered either simultaneously or at different times.
It should be appreciated that the invention methods comprising administering an invention combination to a mammal to treat diseases or disorders listed above may be used to treat different diseases simultaneously. For example, administration of valdecoxib in accordance with the invention combination may be carried out as described above to treat inflammation, arthritic pain, pain associated with menstrual cramping, and migraines, while an active compound useful in the invention method, or a pharmaceutically acceptable salt thereof, may be administered to treat osteoarthritis, rheumatoid arthritis, improve joint function, alleviate pain, or inhibit cartilage damage.
As shown above, the invention method offers a distinct advantage over existing treatments for diseases such as osteoarthritis that comprise cartilage damage, wherein the existing treatments modify pain or secondary symptoms, but do not show a disease modifying effect. Substituted dialkyl ether, substituted aryl- alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-
alkyl compounds useful in the invention method, or a pharmaceutically acceptable salt thereof, including a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, calcium salt, have been shown to be useful for inhibiting cartilage damage, preventing or treating rheumatoid arthritis, improving joint function, treating osteoarthritis or alleviating pain.
While the invention has been described and illustrated above with reference to certain particular aspects and embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. It is intended, therefore, that the invention be defined by the scope of the claims that follow and that such claims be interpreted as broadly as is reasonable.
All patents, patent applications, and publications, including patent application publications, cited herein are hereby incorporated by reference in their entirety for all purposes.
Having described invention methods, compositions, and combinations, various aspects and embodiments of the invention are hereupon initially claimed.
Claims (28)
1. Use of a substituted dialkyl ether of Formula I y! v2 Ri (CHO (CH (gs R? R3 I or a pharmaceutically acceptable salt thereof, wherein: n and m independently are integers of from 2 to 9; R!, RZ, R3, and R* independently are C,-C alkyl, C,-Cg4 alkenyl, or C,-C¢ alkynyl; or R! and R? together with the carbon atom to which they are attached, or R3 and R* together with the carbon atom to which they are attached, or R! and R? together with the carbon atom to which they are attached and R3 and R? together with the carbon atom to which they are attached, can complete a carbocyclic ring having from 3 to 6 carbons; Y! and Y2 independently are COOH, CHO, tetrazole, or COOR? , wherein RY is C,-Cg alkyl, C,-Cg4 alkenyl, or C,-Cg alkynyl; and wherein the alkyl, alkenyl, and alkynyl groups may be substituted with one or two groups selected from halo, hydroxy, C;-C¢ alkoxy, and phenyl in the manufacture of a medicament for treating an IL-6 mediated disease or disorder selected from arthritis, cartilage damage, joint pain, joint inflammation, systemic lupus erythematous, mixed connective tissue disease, and sepsis in a mammal.
2. Use according to Claim 1, wherein the arthritis is selected from osteoarthritis and rheumatoid arthritis. AMENDED SHEET
PCT/IB2003/003664
3. Use according to Claim 1, wherein the joint pain is selected from osteoarthritic joint pain, rheumatoid arthritic joint pain, and inflammatory joint pain.
4. Use according to Claim 1, wherein the joint pain is selected from acute joint pain and chronic joint pain.
5. Use according to Claim 1, wherein the joint inflammation is rheumatoid arthritic joint inflammation.
6. Use according to any one of Claims 1 to 5, wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2- dimethyl-hexanoic acid, or a pharmaceutically acceptable salt thereof.
7. Use according to Claim 6, wherein the substituted dialkyl ether is selected from: 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt hydrate; Crystal Form 1 of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt; and Crystal Form 2 of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt.
8. Use according to Claim 6, wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt.
9, A combination, comprising a COX-2 inhibitor selected from celecoxib and valdecoxib, or a pharmaceutically acceptable salt thereof, and a substituted dialkyl ether compound selected from compound named 6-(5- carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, or a pharmaceutically acceptable salt thereof. AMENDED SHEET
10. The combination according to Claim 9, wherein the substituted dialkyl ether is selected from: 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid calcium salt; 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt hydrate; Crystal Form 1 of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt; and Crystal Form 2 of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt.
11. A pharmaceutical composition comprising a.) a substituted dialkyl ether compound of Formula I Y! vy? RT (CH) o—CHy—f{~ rR? Rr? Rr I or a pharmaceutically acceptable salt thereof, wherein: n and m independently are integers of from 2 to 9; RY, R?% R®, and R* independently are C;-C alkyl, C,-Cs alkenyl, or C,-C alkynyl; or R! and R? together with the carbon atom to which they are attached, or R> and R* together with the carbon atom to which they are attached, or R' and R? together with the carbon atom to which they are attached and Rand R* together with the carbon atom to which they are attached, can complete a carbocyclic ring having from 3 to 6 carbons; Y! and Y? independently are COOH, CHO, tetrazole, or COOR’, wherein R® is C1-Cs alkyl, Co-Cs alkenyl, or C,-Cs alkynyl; and wherein the alkyl, alkenyl, and alkynyl groups may be substituted with one or two groups selected from halo, hydroxy, C;-C¢ alkoxy, and phenyl;
b.) aselective COX-2 inhibitor or a pharmaceutically acceptable salt thereof; and c.) a pharmaceutically acceptable carrier or diluent.
12. The pharmaceutical composition of Claim 11, wherein said COX-2 inhibitor is
1.AS-34475; UR-8880; ABT-963; valdecoxib; BMS-347070; celecoxib; tilacoxib; the compound of formula (B) F A 8) H,N—8=0 2’ \, CS-502, (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6- dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid; CV-24T7; 2(SH)-Furanone, 5,5-dimethyl-3-(1-methylethoxy)-4-{4- (methylsulfonyl)phenyl]- (“DFP”), carprofen; deracoxib; etoricoxib; GW-406381;
tiracoxib; meloxicam; nimesulide; 2-(Acetyloxy)benzoic acid, 3-[(nitrooxy)methyllphenyl ester; lumiracoxib; parecoxib; P54; rofecoxib; reviIMiD; 2,6-Bis(1,1-dimethylethyl)-4-[(E)-(2-ethyl-1,1-dioxo-5- isothiazolidinylidene)methyl]phenol; 5(R)-Thio-6-sulfonamide-3(2H)-benzofuranone; N-[3-(Formylamino)-4-ox0-6-phenox y-4H-1-benzopyran-7-yl]- methanesulfonamide; or a pharmaceutically acceptable salt thereof.
13. The pharmaceutical composition of Claim 11, wherein said dialkyl ether is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, or a pharmaceutically acceptable salt thereof.
14. The pharmaceutical composition of Claim 11, wherein said dialkyl ether is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt hydrate; 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt; Crystal Form 1 of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt; or Crystal Form 2 of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt.
15. The pharmaceutical composition of Claim 11, wherein said dialkyl ether is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium
PCT/IB2003/003664 salt and said COX-2 inhibitor is parecoxib, rofecoxib, valdecoxib, or celecoxib.
16. A substance or composition for use in a method of treating an IL-6 mediated disease or disorder selected from arthritis, cartilage damage, joint pain, joint inflammation, systemic lupus erythematous, mixed connective tissue disease, and sepsis in a mammal, said substance or composition comprising a substituted dialkyl ether of Formula I or a pharmaceutically acceptable salt thereof, as defined in Claim 1, and said method comprising administering to the mammal a therapeutically effective amount of said substance or composition.
17. A substance or composition for use in a method of treatment according to Claim 16, wherein the arthritis is selected from osteoarthritis and rheumatoid arthritis.
18. A substance or composition for use in a method of treatment or prevention according to Claim 16, wherein the joint pain is selected from osteoarthritic joint pain, rheumatoid arthritic joint pain, and inflammatory joint pain.
19. A substance or composition for use in a method of treatment according to Claim 16, wherein the joint pain is selected from acute joint pain and chronic joint pain.
20. A substance or composition for use in a method of treatment according to Claim 16, wherein the joint inflammation is rheumatoid arthritic joint inflammation.
21. A substance or composition for use in a method of treatment according to any one of Claims 16 to 20, wherein the substituted dialkyl ether is a AMENDED SHEET
PCT/1B2003/003664 compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, or a pharmaceutically acceptable salt thereof.
22. A substance or composition for use in a method of treatment according to Claim 21, wherein the substituted dialkyl ether is selected from: 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt hydrate; Crystal Form 1 of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt; and Crystal Form 2 of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl- hexanoic acid, calcium salt.
23. A substance or composition for use in a method of treatment according to Claim 21, wherein the substituted dialkyl ether is a compound named 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid, calcium salt.
24. Use according to any one of Claims 1 to 8, substantially as herein described and illustrated.
25. A combination according to any one of Claims 9 or 10, substantially as herein described and illustrated.
26. A composition according to any one of Claims 11 to 15, substantially as herein described and illustrated.
27. A substance or composition for use in a method of treatment according to any one of Claims 16 to 23, substantially as herein described and illustrated.
28. A new use of a compound as defined in any one of Claims 1 to 8, or a pharmaceutically acceptable salt thereof; a new combination; a new AMENDED SHEET
PCT/IB2003/003664 composition; or a substance or composition for a new use in a method of treatment; substantially as herein described.
AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40525002P | 2002-08-22 | 2002-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200501133B true ZA200501133B (en) | 2008-01-30 |
Family
ID=31946834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200501133A ZA200501133B (en) | 2002-08-22 | 2005-02-08 | Method of treating osteoarthritis |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1539127A1 (en) |
JP (1) | JP2006501238A (en) |
KR (1) | KR20050058454A (en) |
CN (1) | CN1678297A (en) |
AU (1) | AU2003255937A1 (en) |
BR (1) | BR0313883A (en) |
CA (1) | CA2494544A1 (en) |
IL (1) | IL166600A0 (en) |
MX (1) | MXPA05001254A (en) |
PL (1) | PL375742A1 (en) |
TW (1) | TW200410677A (en) |
WO (1) | WO2004017952A1 (en) |
ZA (1) | ZA200501133B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004105801A1 (en) * | 2003-05-30 | 2004-12-09 | Warner-Lambert Company Llc | Animal model for the alleviation of pain using il-6 |
WO2005002557A1 (en) * | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
DE102008000237A1 (en) | 2007-02-06 | 2008-08-07 | Basf Se | Mixtures, useful e.g. as an inhibitor or retarder for the stabilization of polymerizable compound, preferably swellable hydrogel-forming polymers, comprises a phenol imidazole derivative and a polymerizable compound |
IL181577A0 (en) * | 2007-02-26 | 2007-07-04 | Jacob Bar Tana | Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders |
US8530420B2 (en) * | 2008-12-16 | 2013-09-10 | Kaohsiung Medical University | Treatment of arthritis with parathyroid hormone |
TWI382841B (en) * | 2010-10-29 | 2013-01-21 | Univ China Medical | Pharmaceutical composition for inhibiting inflammation |
JP2020516622A (en) * | 2017-04-18 | 2020-06-11 | ジェムフィアー セラピューティクス インコーポレイテッド | Gemcavene, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof |
EP3867222A4 (en) * | 2018-10-18 | 2022-07-06 | Gemphire Therapeutics Inc. | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
CN114847223B (en) * | 2022-02-19 | 2023-11-07 | 昆明理工大学 | Method for establishing OA cynomolgus monkey model |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
EE200200404A (en) * | 2000-01-25 | 2003-10-15 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods for their preparation and treatment of vascular disease and diabetes |
US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
-
2003
- 2003-08-13 MX MXPA05001254A patent/MXPA05001254A/en unknown
- 2003-08-13 CN CNA038199513A patent/CN1678297A/en active Pending
- 2003-08-13 AU AU2003255937A patent/AU2003255937A1/en not_active Abandoned
- 2003-08-13 CA CA002494544A patent/CA2494544A1/en not_active Abandoned
- 2003-08-13 KR KR1020057003022A patent/KR20050058454A/en not_active Application Discontinuation
- 2003-08-13 WO PCT/IB2003/003664 patent/WO2004017952A1/en not_active Application Discontinuation
- 2003-08-13 EP EP03792585A patent/EP1539127A1/en not_active Ceased
- 2003-08-13 JP JP2004530464A patent/JP2006501238A/en not_active Withdrawn
- 2003-08-13 PL PL03375742A patent/PL375742A1/en not_active Application Discontinuation
- 2003-08-13 BR BR0313883-6A patent/BR0313883A/en not_active IP Right Cessation
- 2003-08-21 TW TW092123032A patent/TW200410677A/en unknown
-
2005
- 2005-01-31 IL IL16660005A patent/IL166600A0/en unknown
- 2005-02-08 ZA ZA200501133A patent/ZA200501133B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2006501238A (en) | 2006-01-12 |
CA2494544A1 (en) | 2004-03-04 |
WO2004017952A1 (en) | 2004-03-04 |
PL375742A1 (en) | 2005-12-12 |
CN1678297A (en) | 2005-10-05 |
AU2003255937A1 (en) | 2004-03-11 |
EP1539127A1 (en) | 2005-06-15 |
BR0313883A (en) | 2005-07-19 |
IL166600A0 (en) | 2006-01-15 |
KR20050058454A (en) | 2005-06-16 |
MXPA05001254A (en) | 2005-06-08 |
TW200410677A (en) | 2004-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200501133B (en) | Method of treating osteoarthritis | |
US20070203212A1 (en) | Method of treating osteoarthritis | |
EP1680125A1 (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
RU2286151C2 (en) | Combinations of alpha-2-delta-ligand with selective cycloixygenase-2 inhibitor | |
US20040019053A1 (en) | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | |
US20050026979A1 (en) | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | |
US20040034086A1 (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | |
US20040034085A1 (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | |
US20030166706A1 (en) | Method of treating osteoarthritis | |
US20040019054A1 (en) | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | |
US20050004196A1 (en) | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | |
CA2489722A1 (en) | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | |
JP2006502991A (en) | Combinations of allosteric alkyne inhibitors of matrix metalloproteinase-13 and selective inhibitors of cyclooxygenase-2 that are not celecoxib or valdecoxib |